|
Unidentified gut microbes |
Baicalin |
Herbal Substance |
Medicinal Herbal Compounds |
"Hydrolysis; deglycosylation" |
"Baicalein; oroxylin A" |
Increase Efficacy |
n.a. |
"Inflammation; diabetes mellitus; tumor" |
Increased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Olsalazine |
Therapeutic Substance |
Approved Drug |
Azo reduction |
5-aminosalicylclic acid |
"Increase Efficacy; Increase Toxicity" |
In vivo |
"Inflammatory diseases(ulcerative colitis; Crohn disease; rheumatoid arthritis)" |
Increased activity or causing side effects(anorexia and nausea) |
"PMID:26569070 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
N-oxide bond cleavage |
n.a. |
Decrease Efficacy |
In vivo |
Peptic ulcer disease |
Decreased intestinal absorption and systemic bioavailability |
"PMID:26569070 |
|
Unidentified gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
N-oxide bond cleavage |
n.a. |
Decrease Efficacy |
n.a. |
Peptic ulcer disease |
Decreased intestinal absorption and systemic bioavailability |
"PMID:26569070 |
|
Unidentified gut microbes |
Flucytosine |
Therapeutic Substance |
Approved Drug |
Deamination |
5-fluorouracil |
"Increase Efficacy; Increase Toxicity" |
In vivo |
n.a. |
Increased activity or toxicity |
"PMID:26569070 |
|
Unidentified anaerobic bacterium |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
Reduction |
"sulindac sulfide; sulinpyrzone sulfide" |
Increase Efficacy |
In vivo |
Irinotecan-induced diarrhea model |
Increased activity |
"PMID:26569070 |
|
Unidentified anaerobic bacterium |
Sulindac |
Therapeutic Substance |
Approved Drug |
Reduction |
"sulindac sulfide; sulinpyrzone sulfide" |
Increase Efficacy |
In vivo |
Irinotecan-induced diarrhea model |
Increased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Insulin human |
Therapeutic Substance |
Approved Drug |
Proteolysis |
Peptides |
Decrease Efficacy |
In vivo |
Health |
Decreased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Loperamide oxide |
Therapeutic Substance |
Investigational Drug |
Reduction |
Loperamide |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
7-aminonitrazepam |
Increase Toxicity |
In vivo |
Moderate to severe insomnia |
Inducing teratogenicity |
"PMID:26569070 |
|
Unidentified gut microbes |
Nitroglycerin |
Therapeutic Substance |
Approved Drug |
Denitration |
"Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate" |
Decrease Efficacy |
n.a. |
Angina pectoris |
Decreased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Dihydroxyphenylalanine (DOPA) |
Therapeutic Substance |
Approved Drug |
Dehydroxylation |
"m-tyramine; m-hydroxylphenylacetic acid" |
Increase Efficacy |
n.a. |
Parkinson disease (PD) |
Increased activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
Deconjugation |
n.a. |
"Decrease Efficacy; Increase Toxicity" |
n.a. |
n.a. |
"Decreased activity; increased side effects(diarrhea; anorexia; weight loss)" |
"PMID:26569070 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
"Hydrolysis; demethylation; hydroxylation/dehydroxylation; oxidation" |
"Lactic acid; 3-hydroxybutanoic acid; cyclohexanecarboxylic acid; 2-hydroxyvaleric acid" |
n.a. |
n.a. |
Cardiovascular disease |
Altering its lipid-lowering activity |
"PMID:26569070 |
|
Unidentified gut microbes |
Risperidone |
Therapeutic Substance |
Approved Drug |
"Ring cleavage; hydroxylation" |
"Benzisoxazole ring scission; Benzisoxazole ring hydroxylation" |
Increase Toxicity |
In vitro |
n.a. |
Inducting symptoms of Parkinson disease |
"PMID:26569070 |
|
Unidentified gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
"Amine formation; hydrolysis" |
p-aminphenyl-2-amino-13-propanediol |
Increase Toxicity |
n.a. |
n.a. |
Inducing bone marrow aplasia |
"PMID:26569070 |
|
Clostridium sp. |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
"Dihydrodaidzein; equol; O-desmethylanolensin(ODMAReduction; phenolic ring opening" |
n.a. |
n.a. |
n.a. |
PMID |
PMDBM2020051
|
|
anaerobic bacterium 'strain 7' |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
"Dihydrodaidzein; equol; O-desmethylanolensin(ODMAReduction; phenolic ring opening" |
n.a. |
n.a. |
n.a. |
PMID |
PMDBM2020049
|
|
Bacteroides uniformis |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
Hydrogenation |
Production of 5-hydroxyequol |
n.a. |
n.a. |
"Obesity; Type 2 diabetes" |
n.a. |
PMID:26569070 |
|
Bacteroides |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
Hydrolysis |
Compound K |
Increase Efficacy |
n.a. |
"Inflammation; tumor" |
Increased activity |
PMID:26569070 |
|
Bifidobacterium |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
Hydrolysis |
Compound K |
Increase Efficacy |
n.a. |
"Inflammation; tumor" |
Increased activity |
PMID:26569070 |
|
Eubacterium sp. GLH |
Glycyrrhizin |
Herbal Substance |
Medicinal Herbal Compounds |
Hydrolysis |
18-glycyrrhetinic acid |
Increase Efficacy |
n.a. |
Inflammation |
Increased activity |
PMID:26569070 |
|
Pseudocera |
Hesperidin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Deglycosylation |
Hesperetin |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Klebsiella pneumoniae |
Lactulose |
Therapeutic Substance |
Approved Drug |
Hydrolysis |
"Monosaccharides; lactate, acetate; butyrate" |
n.a. |
n.a. |
n.a. |
"Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" |
PMID:26569070 |
|
Enterococcus faecalis |
Lactulose |
Therapeutic Substance |
Approved Drug |
Hydrolysis |
"Monosaccharides; lactate, acetate; butyrate" |
n.a. |
n.a. |
n.a. |
"Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" |
PMID:26569070 |
|
Cronobacter sakazakii |
Lactulose |
Therapeutic Substance |
Approved Drug |
Hydrolysis |
"Monosaccharides; lactate, acetate; butyrate" |
n.a. |
n.a. |
n.a. |
"Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" |
PMID:26569070 |
|
Enterococcus casseliflavus |
Lactulose |
Therapeutic Substance |
Approved Drug |
Hydrolysis |
"Monosaccharides; lactate, acetate; butyrate" |
n.a. |
n.a. |
n.a. |
"Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" |
PMID:26569070 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Thiazole ring opening |
"levametabol-I; levametabol-II; levametabol-III" |
Increase Efficacy |
n.a. |
Colon cancer |
Increased activity |
PMID:26569070 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Thiazole ring opening |
"levametabol-I; levametabol-II; levametabol-III" |
Increase Efficacy |
n.a. |
Colon cancer |
Increased activity |
PMID:26569070 |
|
Clostridia |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
Demethylation |
"Amphetamine; norephedrine; an unknown metabolite" |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Enterococcus |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
Demethylation |
"Amphetamine; norephedrine; an unknown metabolite" |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Lactobacillus |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
Demethylation |
"Amphetamine; norephedrine; an unknown metabolite" |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Unidentified anaerobic bacterium |
Omeprazole |
Therapeutic Substance |
Approved Drug |
Reduction |
corresponding sulfide metabolites |
Decrease Efficacy |
n.a. |
Gastric ulcer |
Decreased activity |
PMID:26569070 |
|
Enterococcus casseliflavus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
Deglycosylation |
"Butyrate; acetate; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
"Cardiovascular disease; tumors" |
n.a. |
PMID:26569070 |
|
Eubacterium ramulus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
Deglycosylation |
"Butyrate; acetate; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
"Cardiovascular disease; tumors" |
n.a. |
PMID:26569070 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
"O-Sulfation; C-S cleavage of acetaminophen-3-cysteine" |
"acetaminophen sulfate; glucuronide" |
"Increase Efficacy; Decrease Toxicity" |
n.a. |
n.a. |
Altered activity or toxicity |
PMID:26569070 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Reduction |
"Dihydrodigoxin; dihydrodigoxigenin" |
Decrease Efficacy |
In vivo |
Heart disease |
Decreased cardiac activity |
PMID:26569070 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Dehydroxylation |
"m-tyrosine; m-tyramine; m-hydroxyphenylacetic acid" |
Decrease Efficacy |
n.a. |
Parkinson disease (PD) |
Decreased activity |
PMID:26569070 |
|
Unidentified gut microbes |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Reduction |
"N-(2-hydroxyethyl)-oxamic acid; acetamide" |
Increase Toxicity |
n.a. |
n.a. |
Probably increase its liver toxicity |
PMID:26569070 |
|
Bacteroides fragilis |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
Hydrolysis |
(E)-5-(2-bromovinyl) uracil |
Increase Toxicity |
n.a. |
n.a. |
Lead to lethal toxicity when co-administered with 5-fluorouracil |
"PMID:26569070 |
|
Bacteroides thetaiotaomicron |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
Hydrolysis |
(E)-5-(2-bromovinyl) uracil |
Increase Toxicity |
n.a. |
n.a. |
Lead to lethal toxicity when co-administered with 5-fluorouracil |
"PMID:26569070 |
|
Bacteroides uniformis |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
Hydrolysis |
(E)-5-(2-bromovinyl) uracil |
Increase Toxicity |
n.a. |
n.a. |
Lead to lethal toxicity when co-administered with 5-fluorouracil |
"PMID:26569070 |
|
Bacteroides vulgatus |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
Hydrolysis |
(E)-5-(2-bromovinyl) uracil |
Increase Toxicity |
n.a. |
n.a. |
Lead to lethal toxicity when co-administered with 5-fluorouracil |
"PMID:26569070 |
|
Bacteroides eggerthii |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
Hydrolysis |
(E)-5-(2-bromovinyl) uracil |
Increase Toxicity |
n.a. |
n.a. |
Lead to lethal toxicity when co-administered with 5-fluorouracil |
"PMID:26569070 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Differences in gut microbial metabolism contribute to variations in drug efficacy |
"PMID:11344150 |
|
Unidentified gut microbes |
Azo dyes |
Environmental Substance |
"Industrial Chemicals; Pollutants" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:26972811 |
|
Unidentified gut microbes |
Enrofloxacin |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Enrofloxacin-or vancomycin-treated |
"Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels" |
"PMID:18698804 |
|
Unidentified gut microbes |
Vancomycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
Enrofloxacin-or vancomycin-treated |
"Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels" |
"PMID:18698804 |
|
Unidentified gut microbes |
Pentobarbital |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Germ-free,colonized |
Germ-free animals are more efficient at metabolizing drug |
"PMID:19742318 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Treatment is positively associated with the production by the microbiota(lithocholic acid, taurolithocholic acid and glycolithocholic acid) |
"PMID:22022402 |
|
Unidentified gut microbes |
Oxaliplatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Induces apoptosis |
"PMID:24264989 |
|
Firmicutes |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Limit tumour growth |
"PMID:24264990 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin |
Decrease Efficacy |
n.a. |
n.a. |
n.a. |
"PMID:6836275 |
|
Unidentified gut microbes |
Heterocyclic amines |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Microbiota contribute to associations between the risk of CRC and the intake of heterocyclic amines |
"PMID:8055651 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Re-activate the drug causing increased toxicity(towards intestinal epithelial cells);exacerbate the diarrhoea" |
"PMID:8891470 |
|
Unidentified gut microbes |
7-ethyl-10-hydroxycamptothecin |
Therapeutic Substance |
Investigational Drug |
n.a. |
"SN-38G; ;cyanuric acid" |
Increase Toxicity |
In vivo |
Germ-free,colonized |
Metabolites are harmful to the host |
PMID:26972811 |
|
Fusobacteria |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI |
PMID:26972811 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI |
PMID:26972811 |
|
Bacteroidetes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI |
PMID:26972811 |
|
Actinobacteria |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI |
PMID:26972811 |
|
Bifidobacterium |
Anti-PD-L1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase the efficacy of PD-1 |
PMID:26972811 |
|
Staphylococcus |
Anti-TNF antibobies |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Therapy is accompanied by a substantial increase in the abundance of bacteria |
PMID:26972811 |
|
Proteobacteria |
Choline-containing compounds |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Associate with the risk of cardiovascular disease |
PMID:26972811 |
|
Firmicutes |
Choline-containing compounds |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Associate with the risk of cardiovascular disease |
PMID:26972811 |
|
Bacteroides fragilis |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Blockade immunotherapy |
PMID:26972811 |
|
Bacteroides thetaiotaomicron |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Blockade immunotherapy |
PMID:26972811 |
|
Enterococcus faecium |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Bifidobacterium sp. |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Lactobacillus mucosae |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Eggerthella sp. |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Gordonibacter |
Ellagic acid |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Metabolize ellagitannins |
PMID:26972811 |
|
Unidentified gut microbes |
Heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reactivate the compound |
PMID:26972811 |
|
Campylobacter |
Isoaminile |
Therapeutic Substance |
Approved Drug |
n.a. |
cyclohexylamine |
n.a. |
In vivo |
n.a. |
Exhibit toxicity |
PMID:26972811 |
|
Escherichia |
Isoaminile |
Therapeutic Substance |
Approved Drug |
n.a. |
cyclohexylamine |
n.a. |
In vivo |
n.a. |
Exhibit toxicity |
PMID:26972811 |
|
Enterococcus |
Isoaminile |
Therapeutic Substance |
Approved Drug |
n.a. |
cyclohexylamine |
n.a. |
In vivo |
n.a. |
Exhibit toxicity |
PMID:26972811 |
|
Clostridium |
Isoaminile |
Therapeutic Substance |
Approved Drug |
n.a. |
cyclohexylamine |
n.a. |
In vivo |
n.a. |
Exhibit toxicity |
PMID:26972811 |
|
Corynebacterium |
Isoaminile |
Therapeutic Substance |
Approved Drug |
n.a. |
cyclohexylamine |
n.a. |
In vivo |
n.a. |
Exhibit toxicity |
PMID:26972811 |
|
Firmicutes |
Lignans |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
May elicit protective effects against breast cancer |
PMID:26972811 |
|
Bacteroidetes |
Lignans |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
May elicit protective effects against breast cancer |
PMID:26972811 |
|
Actinobacteria |
Lignans |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
May elicit protective effects against breast cancer |
PMID:26972811 |
|
Unidentified gut microbes |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
In vivo |
Germ-free,colonized |
n.a. |
PMID:26972811 |
|
Unidentified gut microbes |
NSAIDs |
Therapeutic Substance |
Drug Class |
n.a. |
"SN-38G; ;cyanuric acid" |
Increase Toxicity |
In vivo |
Germ-free,colonized |
Metabolites are harmful to the host |
PMID:26972811 |
|
Unidentified gut microbes |
Phenoxyethanol |
Therapeutic Substance |
Approved Drug |
n.a. |
"SN-38G; ;cyanuric acid" |
Increase Toxicity |
In vivo |
Germ-free,colonized |
Metabolites are harmful to the host |
PMID:26972811 |
|
Raoultella terrigena |
Phenoxyethanol |
Therapeutic Substance |
Approved Drug |
n.a. |
cyanuric acid |
n.a. |
In vivo |
n.a. |
Lead to increased kidney damage |
PMID:26972811 |
|
Raoultella terrigena |
Phenoxyethanol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Lead to kidney stones |
PMID:26972811 |
|
Akkermansia muciniphila |
Polyphenols |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
Fed high-fat diets |
Limit the risk of systemic inflammation |
PMID:26972811 |
|
Clostridiales bacterium |
Saccharin |
"Therapeutic Substance; Dietary Substance; Herbal Substance" |
"Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms |
Increase the abundance of bacteria |
PMID:26972811 |
|
Unidentified gut microbes |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol,enterolactone |
n.a. |
n.a. |
n.a. |
Product the cancer-protective compounds |
PMID:26972811 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Bioavailability |
n.a. |
n.a. |
Contribute to?the absorption of simvastatin |
PMID:26972811 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
In vivo |
Germ-free,colonized |
Contribute to therapeutic concentrations |
PMID:26972811 |
|
Enterococcus faecalis |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
"Antibiotic-treated or germ-free;convention" |
Result in drug cleavage |
PMID:26972811 |
|
Lactobacillus sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
"Antibiotic-treated or germ-free;convention" |
Result in drug cleavage |
PMID:26972811 |
|
Bacteroides sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
"Antibiotic-treated or germ-free;convention" |
Result in drug cleavage |
PMID:26972811 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
In vivo |
Germ-free,colonized |
Contribute to therapeutic concentrations |
PMID:26972811 |
|
Faecalibacterium prausnitzii |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
Kidney transplant recipient |
The abundance of the gut bacterium has a positive correlation with an increase in tacrolimus dosing |
PMID:26972811 |
|
Unidentified gut microbes |
TMAO |
Environmental Substance |
Human Metabolite |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Bacteria provide a link for drugs |
PMID:26972811 |
|
Clostridiales bacterium |
Xylitol |
"Therapeutic Substance; Herbal Substance; Dietary Substance" |
"Approved Drug; Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms |
Increase the abundance of bacteria |
PMID:26972811 |
|
Bacteroidales |
Carboxymethylcellulose |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome |
PMID:26972811 |
|
[Ruminococcus] gnavus |
Carboxymethylcellulose |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome |
PMID:26972811 |
|
Bacteroidales |
Polysorbate 80 |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome |
PMID:26972811 |
|
[Ruminococcus] gnavus |
Polysorbate 81 |
Environmental Substance |
"Industrial Chemicals; Pollutants" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome |
PMID:26972811 |
|
Escherichia coli |
Glucuronidated compound |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
In vivo |
Convention, germ-free |
Reactivate the toxic compound and augment genotoxicity |
PMID:26972811 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
triamino benzene,sulfanilamide |
Increase Efficacy |
n.a. |
n.a. |
Activate drug |
PMID:26972811 |
|
Enterococcus faecalis |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
Eubacterium limosum |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
[Clostridium] scindens |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
Blautia producta |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
Eggerthella lenta |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
Lactonifactor longoviformis |
Secoisolariciresinol |
Therapeutic Substance |
Investigational Drug |
n.a. |
enterodiol and entero lactone |
Increase Efficacy |
In vivo |
Germ-free,or germ-free colonized with a bacterial consortium |
Protective effects against breast cancer |
PMID:26972811 |
|
Unidentified gut microbes |
Diclofenac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation |
PMID:26972811 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation |
PMID:26972811 |
|
Unidentified gut microbes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation |
PMID:26972811 |
|
Bacteroides |
Saccharin |
"Therapeutic Substance; Dietary Substance; Herbal Substance" |
"Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms |
Increase the abundance of bacteria |
PMID:26972811 |
|
Unidentified gut microbes |
Tempol |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Increase the abundance of Bacteroidetes;decrease the abundance of Firmicutes" |
PMID:26972811 |
|
Firmicutes |
Tempol |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce members of the genus Lactobacillus |
PMID:26972811 |
|
Bacteroides |
Xylitol |
"Therapeutic Substance; Herbal Substance; Dietary Substance" |
"Approved Drug; Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms |
Increase the abundance of bacteria |
PMID:26972811 |
|
Lactobacillus |
Amoxicillin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Nearly eradicated the lactobacilli |
PMID:26972811 |
|
Clostridioides difficile |
Amoxicillin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Promote colonization by opportunistic pathogens |
PMID:26972811 |
|
Candida albicans |
Amoxicillin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Promote colonization by opportunistic pathogens |
PMID:26972811 |
|
Clostridioides difficile |
Antibiotic |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death)" |
PMID:26972811 |
|
Candida albicans |
Cefoperazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Allergic-airways diease develops after challenge with mould spores |
PMID:26972811 |
|
Lactobacillus |
Cephalosporins |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase susceptibility to asthma |
PMID:26972811 |
|
Bifidobacterium |
Cephalosporins |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase susceptibility to asthma |
PMID:26972811 |
|
Candida albicans |
Cephalosporins |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase susceptibility to asthma |
PMID:26972811 |
|
Lactobacillus |
Kanamycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Clinical scores for atopic dermatitis are higher |
PMID:26972811 |
|
Bifidobacterium sp. |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
More bifidobacterium spp. |
PMID:26972811 |
|
Gram-negative bacterium B1G-1A |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce expression of the gene encoding REG3n.a. |
PMID:26972811 |
|
Gram-negative bacterium B1G-1A |
Neomycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce expression of the gene encoding REG3n.a. |
PMID:26972811 |
|
Salmonella enterica subsp. enterica serovar Typhimurium |
Streptomycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
Streptomycin treated |
Result in an increased inflammatory state |
PMID:26972811 |
|
Unidentified vaginal microbes |
Unspecified antibiotic |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Candida albicans |
Unspecified antibiotic |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26972811 |
|
Unidentified gut microbes |
Vancomycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Gram-negatinve populations are depleted(not being restricted by vancomycin) |
PMID:26972811 |
|
Gram-negative bacterium B1G-1A |
Vancomycin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce expression of the gene encoding REG3n.a. |
PMID:26972811 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
hydroxyiminonizatidine |
n.a. |
In vitro |
n.a. |
n.a. |
"PMID:27485182 |
|
Unidentified gut microbes |
Nabumetone |
Therapeutic Substance |
Approved Drug |
n.a. |
4-(6-methoxy-2-naphthyl)-butan-2-ol (reduced nabumetone) |
Decrease Efficacy |
"In vivo (Rat); In vitro (Human)" |
n.a. |
"Cause lower absorbtion of nabumetone and lower its bioavailability;[drug interaction:erythromycin and tetracycline suppresses the reduction of digoxin]" |
"PMID:23584048 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
a phosphorylated derivative and active 2-hydroxy lovastatic acid |
n.a. |
In vivo |
n.a. |
[drug interaction]:antibiotics decreases the bioavailability of the active metabolite |
"PMID:27485182 |
|
Unidentified gut microbes |
Lovastatin related compounds |
Therapeutic Substance |
n.a. |
n.a. |
a phosphorylated derivative and active 2-hydroxy lovastatic acid |
n.a. |
In vivo |
n.a. |
[drug interaction]:antibiotics decreases the bioavailability of the active metabolite |
"PMID:27485182 |
|
Unidentified gut microbes |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
"In vivo; In vitro" |
Ileostomy patients |
n.a. |
"PMID:3630204 |
|
Unidentified gut microbes |
Sulindac |
Therapeutic Substance |
Approved Drug |
n.a. |
sulindac sulfide |
n.a. |
"In vivo; In vitro" |
n.a. |
n.a. |
"PMID:3630204 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid (mesalazine)and sulfapyridine |
Decrease Toxicity |
In vivo |
Ulcerative colitis |
Lead to side effect |
"PMID:27485182 |
|
Unidentified gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
p-aminophenyl-2-amin-1,3-propanediol |
Increase Toxicity |
In vitro |
n.a. |
Produce toxic metabolite related to risk of marrow aplasia |
"PMID:27485182 |
|
Unidentified anaerobic bacterium |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
n.a. |
In vivo |
Conventional(CV), germ-free(GF) |
n.a. |
"PMID:27485182 |
|
Clostridium perfringens |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
n.a. |
In vivo |
Conventional(CV), germ-free(GF) |
n.a. |
"PMID:27485182 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
m-tyramine and m-hydroxyphenylacetic acid |
n.a. |
In vivo |
Conventional, in pathogen free |
Form the metabolites |
"PMID:4723308 |
|
Unidentified gut microbes |
Misonidazole |
Therapeutic Substance |
Investigational Drug |
n.a. |
amino derivative |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:6260109 |
|
Unidentified gut microbes |
Balsalazide |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
n.a. |
In vivo |
n.a. |
n.a. |
"PMID:27485182 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Germ-free and ex-germ-free |
n.a. |
"PMID:27485182 |
|
Unidentified gut microbes |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
dihydroxy-risperidone and hydroxyl-ke-to-risperidone |
n.a. |
In vivo |
n.a. |
[drug interaction]:(in the liver)antibiotics decrease the bioavailability of risperidone. |
"PMID:27485182 |
|
Unidentified gut microbes |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfide metabolites |
n.a. |
In vivo |
n.a. |
n.a. |
"PMID:27485182 |
|
Unidentified gut microbes |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
2-sulfamoylacetylphenol |
n.a. |
In vivo |
n.a. |
[drug interaction]:antibiotics inhibit the urinary and faecal excretion of metabolites |
"PMID:9231340 |
|
Unidentified gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin and dihydrodigoxigenin |
Decrease Efficacy |
In vivo |
Health |
Have lower cardiac activity |
"PMID:27485182 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:27485182 |
|
Unidentified gut microbes |
Sulfapyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:27485182 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
p-cresol sulfate and phenylacetylglutamine |
Increase Toxicity |
n.a. |
n.a. |
Increased toxicity |
PMID:27485182 |
|
Bacteroides |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose and galactose |
Increase Efficacy |
n.a. |
n.a. |
Lead to laxative effect of lactulose |
PMID:27485182 |
|
Lactobacillus |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose and galactose |
Increase Efficacy |
n.a. |
n.a. |
Lead to laxative effect of lactulose |
PMID:27485182 |
|
Escherichia coli |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose and galactose |
Increase Efficacy |
n.a. |
n.a. |
Lead to laxative effect of lactulose |
PMID:27485182 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I,levametabol-II,and levametabol-III |
Increase Efficacy |
n.a. |
n.a. |
"Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole" |
PMID:27485182 |
|
Bacteroidetes |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I,levametabol-II,and levametabol-III |
Increase Efficacy |
n.a. |
n.a. |
"Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole" |
PMID:27485182 |
|
Escherichia coli ATCC 25922 |
Nabumetone |
Therapeutic Substance |
Approved Drug |
n.a. |
a reduced pharmacologically inactive metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Cause lower absorbtion and lower bioavailability of the drug |
PMID:27485182 |
|
[Clostridium] leptum |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminonitrazepam |
n.a. |
In vivo |
n.a. |
Produce products with teratogenic effects |
PMID:27485182 |
|
Bacteroides sp. |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil |
n.a. |
n.a. |
n.a. |
[drug interaction]:metabolites cause toxic level of anticancer drug 5-fluorouracil |
PMID:27485182 |
|
Unidentified gut microbes |
Neoprontosil |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfanilamide |
Increase Efficacy |
n.a. |
n.a. |
"Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil" |
PMID:27485182 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
sulfanilamide |
Increase Efficacy |
n.a. |
n.a. |
"Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil" |
PMID:27485182 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
In vivo |
n.a. |
"Cause diarrhoea;[drug interaction]:(rat)ciprofloxacin and amoxapine can suppress diarrhoea" |
"PMID:21051639 |
|
Unidentified gut microbes |
CpG oligodeoxynucleotides |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
[drug interaction]:antibiotic or germ-free (sterile) status attenuates this response |
"PMID:24264989 |
|
Unidentified gut microbes |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide" |
"PMID:24264990 |
|
Unidentified gut microbes |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide" |
"PMID:24264990 |
|
Unidentified gut microbes |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Toxicity |
In vivo |
TLR2 knockout vs wildtype mice |
Bacteria regulate against chemotherapy-induced small bowel injury |
"PMID:25589072 |
|
Unidentified gut microbes |
Ginsenosides |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Metabolites have anti-proliferative effects in human colon cancer cells;[drug interaction]:co-treatment with 5-FU and its pro-drug intermediate 5?deoxy-5-fluorouridine,potentiate the anticancer effects" |
"PMID:25625815 |
|
Unidentified gut microbes |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
Specific pathogen-free,germ-free(GF) |
"MCA205 sarcoma progression is not controlled(in germ-free mice;or those treated with broad-spectrum antibiotics)" |
"PMID:26541610 |
|
Mycoplasma hyorhinis |
Floxuridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds |
PMID:28270698 |
|
Mycoplasma hyorhinis |
Trifluridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds |
PMID:28270698 |
|
Bifidobacterium sp. |
Anti-PD-L1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Combination of microbiota and anti-PD-L1 improve tumour control,inducte tumour-specific T?cells,increase T?cells in the tumour microenvironment |
PMID:28270698 |
|
Proteobacteria |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reducte bacteria that?limit inflammation,increase bacteria associated with colitis |
PMID:28270698 |
|
Firmicutes |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reducte bacteria that?limit inflammation,increase bacteria associated with colitis |
PMID:28270698 |
|
Actinobacteria |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reducte bacteria that?limit inflammation,increase bacteria associated with colitis |
PMID:28270698 |
|
Ruminococcus |
CpG oligodeoxynucleotides |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28270698 |
|
Alistipes |
CpG oligodeoxynucleotides |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28270698 |
|
Burkholderiales |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated?mice |
PMID:28270698 |
|
Bacteroidales |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated?mice |
PMID:28270698 |
|
Segmented filamentous bacteria |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Gram-positive commensals mediate accumulation of TH17 and TH1-cell response |
PMID:28270698 |
|
Lactobacillus |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Gram-positive commensals mediate accumulation of TH17 and TH1-cell response |
PMID:28270698 |
|
Pseudomonas aeruginosa |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides) |
Reduce incidence and severity of Pseudomonas aeruginosa translocation |
PMID:28270698 |
|
Enterococcus hirae |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
"Inoculated with MCA205 tumours;microbiota-depleted" |
n.a. |
PMID:28270698 |
|
Barnesiella intestinihominis |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
"Inoculated with MCA205 tumours;microbiota-depleted" |
n.a. |
PMID:28270698 |
|
Enterococcus hirae |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus murinus |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus johnsonii |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Enterococcus hirae |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus murinus |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus johnsonii |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Unidentified gut microbes |
Ellagic acid |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
urolithins |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28270698 |
|
Mycoplasma |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Have deleterious effects on its therapeutic efficacy |
PMID:28270698 |
|
Bacteroidetes |
Ipilimumab |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Bacteria is associated with increased risk of CTLA?4 blockade?induced colitis |
PMID:28270698 |
|
Enterobacteriaceae |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Cause diarrhoea;" |
PMID:28270698 |
|
Streptococcus thermophilus |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Clostridioides difficile |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Cause diarrhoea;" |
PMID:28270698 |
|
Lactobacillus acidophilus |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Lactobacillus plantarum |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Lactobacillus paracasei |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Bifidobacterium breve |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Bifidobacterium longum |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Lactobacillus delbrueckii subsp. bulgaricus |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Bifidobacterium longum subsp. infantis |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis |
PMID:28270698 |
|
Unidentified gut microbes |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea |
PMID:28270698 |
|
Unidentified gut microbes |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" |
PMID:28270698 |
|
Bacteroides |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea |
PMID:28270698 |
|
Bacteroides |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" |
PMID:28270698 |
|
Streptococcus |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea |
PMID:28270698 |
|
Streptococcus |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" |
PMID:28270698 |
|
Bacteroides fragilis |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil (BVU) |
n.a. |
n.a. |
n.a. |
[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients |
PMID:28270698 |
|
Bacteroides thetaiotaomicron |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil (BVU) |
n.a. |
n.a. |
n.a. |
[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients |
PMID:28270698 |
|
Bacteroides uniformis |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil (BVU) |
n.a. |
n.a. |
n.a. |
[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients |
PMID:28270698 |
|
Bacteroides vulgatus |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil (BVU) |
n.a. |
n.a. |
n.a. |
[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients |
PMID:28270698 |
|
Bacteroides eggerthii |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil (BVU) |
n.a. |
n.a. |
n.a. |
[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients |
PMID:28270698 |
|
Unidentified gut microbes |
Neoprontosil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Affect drug disposition and toxicity |
PMID:28270698 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Affect drug disposition and toxicity |
PMID:28270698 |
|
Bacteroides thetaiotaomicron |
Brivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
bromovinyluracil (BVU) |
Increase Toxicity |
In vivo |
Conventional(CV),germ-free(GF) |
"Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" |
PMID:30733391 |
|
Bacteroides ovatus |
Brivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
bromovinyluracil (BVU) |
Increase Toxicity |
n.a. |
n.a. |
"Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" |
PMID:30733391 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
aminoclonazepam (NH2-CLZ),aminohydroxyclonazepam (NH2OH-CLZ) |
Increase Toxicity |
In vivo |
Conventional(CV),germ-free(GF) |
Lead to toxicity |
PMID:30733391 |
|
Bacteroides thetaiotaomicron |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
bromovinyluracil (BVU) |
Increase Toxicity |
In vivo |
Conventional(CV), germ-free(GF) |
Metabolized by members of this genus |
PMID:30733391 |
|
Bacteroides ovatus |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
bromovinyluracil (BVU) |
Increase Toxicity |
n.a. |
n.a. |
Metabolized by members of this genus |
PMID:30733391 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
2-hydroxy lovastatic acid,2-hydroxy simvastatin acid |
Increase Efficacy |
In vivo |
n.a. |
"Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects" |
"PMID:9728898 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
2-hydroxy lovastatic acid,2-hydroxy simvastatin acid |
Increase Efficacy |
In vivo |
n.a. |
"Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects" |
"PMID:9728898 |
|
Clostridium perfringens |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
n.a. |
In vivo |
n.a. |
n.a. |
"PMID:231450 |
|
Streptococcus pyogenes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
sulfanilamide |
Increase Efficacy |
In vivo |
Streptococcus pyogenes systemic infection |
"Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion" |
"PMID:4405598 |
|
Unidentified gut microbes |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
calycosin |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics suppresses the transformation |
"PMID:9657051 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
In vivo |
Cancer |
"Causes diarrhea;drug interaction:coadministration of the poorly absorbed aminoglycoside antibiotic neomycin could be advantageous for diarrhea" |
"PMID:25926432 |
|
Unidentified gut microbes |
Sulindac sulfide |
"Therapeutic Substance; Environmental Substance" |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
|
Drug interaction:metronidazole decreases the formation of sulfides of sulindac ex vivo |
"PMID:3630204 |
|
Unidentified gut microbes |
Neoprontosil |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfanilamide |
Increase Efficacy |
In vivo |
n.a. |
"Product the pharmacologically active metabolite;drug interaction:antibiotics reduced the amount of sulfanilamide excreted in the urine after oral administration" |
"PMID:5173017 |
|
Unidentified gut microbes |
Misonidazole |
Therapeutic Substance |
Investigational Drug |
n.a. |
1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-ol |
Increase Toxicity |
In vivo |
Convention,germ-free |
Drug interaction:antibiotic inhibits misonidazole transformation and toxicity |
"PMID:6260109 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminoclonazepam |
n.a. |
In vivo |
Germ-free and exerm-free |
Drug interaction:antibiotic suppresses the reduction |
"PMID:6506755 |
|
Unidentified gut microbes |
Loperamide oxide |
Therapeutic Substance |
Investigational Drug |
n.a. |
loperamide |
n.a. |
In vivo |
n.a. |
Drug interaction:absorption of orally delivered loperamide oxide is lower when administered with cotrimoxazole |
"PMID:25926432 |
|
Unidentified gut microbes |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
daidzein,calycosin |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides |
"PMID:9657051 |
|
Unidentified gut microbes |
Puerarin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
daidzein,calycosin |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides |
"PMID:9657051 |
|
Unidentified gut microbes |
Fenfluramine |
Therapeutic Substance |
Approved Drug |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Hesperidin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Naringenin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Wognoside |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
"Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" |
"PMID:25926432 |
|
Unidentified gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin,dihydrodigoxigenin |
Decrease Efficacy |
In vivo |
Health |
"Convert to the inactive metabolites;attenuates the drug effects;drug interaction:antibiotics潒rythromycin and tetracycline〃locks the reduction of digoxin" |
"PMID:25926432 |
|
Unidentified gut microbes |
Sulindac |
Therapeutic Substance |
Approved Drug |
n.a. |
sulindac sulfide |
n.a. |
In vivo |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Affect the pharmacokinetics |
PMID:25926432 |
|
Lactococcus garvieae |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Adlercreutzia equolifaciens |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Slackia equolifaciens |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Slackia isoflavoniconvertens |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Lactococcus garvieae |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Adlercreutzia equolifaciens |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Slackia equolifaciens |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Slackia isoflavoniconvertens |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxy-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Ruminococcus sp. |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:antibiotics inhibits the metabolism |
PMID:25926432 |
|
Oscillibacter sp. |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:antibiotics inhibits the metabolism |
PMID:25926432 |
|
Sutterella sp. |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:antibiotics inhibits the metabolism |
PMID:25926432 |
|
Holdemania sp. |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) |
Increase Efficacy |
n.a. |
n.a. |
Drug interaction:antibiotics inhibits the metabolism |
PMID:25926432 |
|
Unidentified gut microbes |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Affect the pharmacokinetics |
PMID:25926432 |
|
Bacteroides |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose,galactose |
n.a. |
n.a. |
n.a. |
Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs |
PMID:25926432 |
|
Lactobacillus |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose,galactose |
n.a. |
n.a. |
n.a. |
Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs |
PMID:25926432 |
|
Escherichia coli |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
fructose,galactose |
n.a. |
n.a. |
n.a. |
Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs |
PMID:25926432 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I, levametabol-II, and levametabol-III |
n.a. |
n.a. |
n.a. |
Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect |
PMID:25926432 |
|
Bacteroides spp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I, levametabol-II, and levametabol-III |
n.a. |
n.a. |
n.a. |
Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect |
PMID:25926432 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Affect the pharmacokinetics |
PMID:25926432 |
|
Unidentified gut microbes |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Affect the pharmacokinetics |
PMID:25926432 |
|
[Eubacterium] rectale |
Picosulfuric acid |
Therapeutic Substance |
Approved Drug |
n.a. |
free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol] |
Increase Efficacy |
n.a. |
n.a. |
"Have a laxative effect;drug interaction:antibiotics inhibits the transformation" |
PMID:25926432 |
|
Unidentified gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Affect the pharmacokinetics |
PMID:25926432 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Efficacy |
n.a. |
n.a. |
Induces anti-inflammatory effects |
PMID:25926432 |
|
Unidentified gut microbes |
Epicatechin |
Therapeutic Substance |
Investigational Drug |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Anthocyanidins |
Herbal Substance |
Herbal Compounds |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Balsalazide |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
n.a. |
In vivo |
|
Drug interaction:antibiotic suppresses the metabolism,limit its effectiveness |
PMID:25926432 |
|
Unidentified gut microbes |
Cianidanol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
phenolic acids |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Flucytosine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-fluorouracil |
n.a. |
n.a. |
n.a. |
Drug interaction:antimicrobial agents may reduce the antifungal effect of flucytosine |
PMID:25926432 |
|
Unidentified gut microbes |
Glycyrrhizic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
18b-glycyrrhetic acid |
n.a. |
In vivo |
Germ-free |
Drug interaction:antibiotics(amoxicillin and metronidazole)suppresses the conversion |
PMID:25926432 |
|
Unidentified gut microbes |
Hesperidin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
hesperetin |
n.a. |
In vivo |
n.a. |
"Suppress gut bacterial glycosidase activities;drug interaction:Antibiotic inhibits the metabolism " |
PMID:25926432 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
tyramine,m-hydroxyphenylacetic acid |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics(vancomycin)inhibits the dehydroxylation of bile acid by the gut microbiota |
PMID:25926432 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-amino-nitrazepam |
Increase Toxicity |
In vivo |
n.a. |
"Affect the pharmacokinetics,product an active teratogenic substance;drug interaction: antibiotic reduced nitrazepam-induced teratogenicity" |
PMID:25926432 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
hydroxyiminonizatidine |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
hydroxyiminoranitidine |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics(rifampicin)decreases the absorption of ranitidine |
PMID:25926432 |
|
Unidentified gut microbes |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
dihydroxy-risperidone,hydroxy-keto-risperidone |
n.a. |
In vivo |
n.a. |
Drug interaction:Antibiotics(rifampin)inhibit the bioavailability of risperidone in the liver |
PMID:25926432 |
|
Unidentified gut microbes |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
oroxylin A |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Sennosides |
Therapeutic Substance |
Investigational Drug |
n.a. |
rheinanthrone |
Increase Efficacy |
n.a. |
n.a. |
"Product a purgative compound;drug interaction:antibiotics潏hloramphenicol, streptomycin, and rifampicin”nhibits the biotransformation" |
PMID:25926432 |
|
Unidentified gut microbes |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfinpyrazone sulfide |
n.a. |
In vivo |
n.a. |
Drug interaction:Metronidazole decreases the extent of sulfinpyrazone reduction in rabbits in vivo |
PMID:25926432 |
|
Unidentified gut microbes |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
2-sulfamoyacetylphenol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25926432 |
|
Unidentified gut microbes |
Hydrazine |
Environmental Substance |
"Industrial Chemicals; Medicinal chemicals" |
n.a. |
n.a. |
Decrease Toxicity |
In vivo |
n.a. |
n.a. |
"PMID:19396371 |
|
Unidentified anaerobic bacterium |
Fostamatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Health |
n.a. |
"PMID:26261284 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
In vivo |
n.a. |
Result in diarrhea |
"PMID:26261284 |
|
Unidentified gut microbes |
BILR355 |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:(with ritonavir)bacterial mediated reactions predominate |
"PMID:26261284 |
|
Unidentified gut microbes |
2-chloro-5-nitro-N-phenylbenzamide |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter its mutagenicity |
"PMID:26261284 |
|
Unidentified gut microbes |
Antiobiotics |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics effect the functional activity of bacteria |
"PMID:26261284 |
|
Unidentified gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics effect the functional activity of bacteria |
"PMID:26261284 |
|
Unidentified gut microbes |
Phenacetin |
Therapeutic Substance |
Approved Drug (Withdrawn) |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics effect the functional activity of bacteria |
"PMID:26261284 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics effect the functional activity of bacteria |
"PMID:26261284 |
|
Unidentified gut microbes |
Arsenic |
Environmental Substance |
"Heavy Metals; Toxic Agents" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Alter the gut microbiota |
"PMID:26261284 |
|
Unidentified gut microbes |
Phenoxyethanol |
Therapeutic Substance |
Approved Drug |
n.a. |
cyanuric acid |
Increase Toxicity |
n.a. |
n.a. |
Lead to toxicity |
"PMID:26261284 |
|
Faecalibacterium prausnitzii |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter the pharmacokinetics of tacrolimus |
"PMID:26261284 |
|
Unidentified gut microbes |
Astragali radix |
Herbal Substance |
Medicinal Herb |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) |
"PMID:26261284 |
|
Unidentified gut microbes |
Calycosin-7-O-b-D-glucoside |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) |
"PMID:26261284 |
|
Unidentified gut microbes |
Epimedium grandiflorum top (flavonoids) |
Herbal Substance |
Medicinal Herb |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
[disease]osteoporosis may modulate the metabolism of Epimedii and may affect its bioavailability and efficacy |
"PMID:26135008 |
|
Unidentified gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Microbial (p-cresol) may compete for a host enzyme (SULT1A1) |
PMID:26261284 |
|
Desulfovibrio desulfuricans |
Arsenic |
Environmental Substance |
"Heavy Metals; Toxic Agents" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Product a more toxic form of arsenic |
PMID:26261284 |
|
Firmicutes |
Butyric Acid |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Limit the growth of pathogenic microorganisms |
PMID:26261284 |
|
Faecalibacterium prausnitzii |
Butyric Acid |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Limit the growth of pathogenic microorganisms |
PMID:26261284 |
|
Escherichia coli |
Curcumin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
tetrahydrocurcumin |
Increase Efficacy |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Drug is inactivated |
PMID:26261284 |
|
Helicobacter pylori |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reactivated by microbially expressed enzymes |
PMID:26261284 |
|
Escherichia coli |
Nitrobenzodiazepine |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Micrococcus luteus |
Polyaromatic compounds |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
hydroxyl metabolites |
n.a. |
n.a. |
n.a. |
Exhibit estrogenic activities |
PMID:26261284 |
|
Clostridioides difficile |
PPIs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug is associated with Clostridium difficule infections |
PMID:26261284 |
|
Unidentified gut microbes |
Resveratrol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Enterobacter |
Tretazicar |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Staphylococcus |
Tretazicar |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Escherichia coli |
Tretazicar |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Mycobacterium |
Tretazicar |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Bacillus |
Tretazicar |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Unidentified gut microbes |
Sulfadiazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-amino 5-salicylic acid |
Increase Efficacy |
n.a. |
n.a. |
n.a. |
PMID:26261284 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
In vivo |
n.a. |
"Lead to the severe intestinal side effect of diarrhea;[drug interaction:Antibiotic/a potent inhibitor of glucuronidase can reduce intestinal side effect]" |
"PMID:26569070 |
|
Unidentified gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Show low postdose acetaminophen sulfate to acetaminophen glucuronide;alter the bioavailability;lead to hepatotoxicity;[drug interaction]:(rat)antibiotic lead to higher level of acetaminophen glutathione conjugates" |
"PMID:26569070 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Secondary bile acids can predict effect of simvastatin |
"PMID:26569070 |
|
Firmicutes |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Alter the composition of gut microbiota;induce the translocation(Gram positive bacteria)into secondary lymphoid organs" |
PMID:26569070 |
|
Unidentified anaerobic bacterium |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfide metabolites |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
Acetaminophen sulfate and glucuronide |
"Decrease Efficacy; Increase Toxicity" |
n.a. |
n.a. |
Decrease activity,or increase cellular toxicity |
PMID:26569070 |
|
Unidentified gut microbes |
CpG-oligonucleotide immunotherapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
Germ free,orantibiotic-treated |
Microbiota impairs the therapeutic responses of tumors |
PMID:26569070 |
|
Unidentified anaerobic bacterium |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Clostridium sp. HGH 136 |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin |
Decrease Efficacy |
n.a. |
n.a. |
Produce inactive metabolite |
PMID:26569070 |
|
Bacteroides uniformis |
Genistein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
5-hydroxyequol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26569070 |
|
Bacteroides |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
Compound K |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Bifidobacterium |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
Compound K |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Eubacterium sp. GLH |
Glycyrrhizic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
18-glycyrrhetinic acid |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Klebsiella pneumoniae |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
Monosaccharides |
n.a. |
n.a. |
n.a. |
Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) |
PMID:26569070 |
|
Enterococcus faecalis |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
Monosaccharides |
n.a. |
n.a. |
n.a. |
Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) |
PMID:26569070 |
|
Cronobacter sakazakii |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
Monosaccharides |
n.a. |
n.a. |
n.a. |
Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) |
PMID:26569070 |
|
Enterococcus casseliflavus |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
Monosaccharides |
n.a. |
n.a. |
n.a. |
Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) |
PMID:26569070 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I, II and III |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I, II and III |
Increase Efficacy |
n.a. |
n.a. |
Increased activity |
PMID:26569070 |
|
Clostridia |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
n.a. |
Amphetamine, norephedrine and an unknown metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Enterococcus |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
n.a. |
Amphetamine, norephedrine and an unknown metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Lactobacillus |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
n.a. |
Amphetamine, norephedrine and an unknown metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Decreased activity |
PMID:26569070 |
|
Unidentified gut microbes |
Platinum chemotherapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
Germ free,orantibiotic-treated |
Microbiota impairs the therapeutic responses of tumors |
PMID:26569070 |
|
Enterococcus casseliflavus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26569070 |
|
Eubacterium ramulus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:26569070 |
|
Escherichia coli |
Diclofenac |
Therapeutic Substance |
Approved Drug |
Hydrolysis to diclofenac |
Diclofenac glucuronide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Escherichia coli |
Flucytosine |
Therapeutic Substance |
Approved Drug |
Deamination |
5-fluorouracil |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified anaerobic bacterium |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Double bond reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:6836275 |
|
Clostridioides difficile |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Double bond reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:6836275 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Double bond reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:6836275 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Double bond reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:6836275 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Pseudomonas aeruginosa |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Citrobacter freundii |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Klebsiella oxytoca |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Klebsiella pneumoniae subsp. ozaenae |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Morganella morganii |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Serratia marcescens |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Shigella flexneri |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Vibrio cholerae |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Plesiomonas shigelloides |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Citrobacter amalonaticus |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Klebsiella pneumoniae subsp. rhinoscleromatis |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Citrobacter farmeri |
Mesalazine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl-5-aminosalicylic acid |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:1425876 |
|
Clostridium sporogenes |
Zonisamide |
Therapeutic Substance |
Approved Drug |
Benzisoxazole ring reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
N-oxide reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
N-oxide reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Thiazole ring opening |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Thiazole ring opening |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified anaerobic bacterium |
Fostamatinib |
Therapeutic Substance |
Approved Drug |
O-Demethylation |
metabolite R529 |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified gut microbes |
Sulfapyridine |
Therapeutic Substance |
Approved Drug |
Acetylation |
N-acetyl sulfapyridine |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified anaerobic bacterium |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
Sulfoxide reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Unidentified anaerobic bacterium |
Sulindac |
Therapeutic Substance |
Approved Drug |
Sulfoxide reduction |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:27591027 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
SN-38 glucuronide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:16437251 |
|
Bacteroides fragilis |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
SN-38 glucuronide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:16437251 |
|
Streptococcus agalactiae |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
SN-38 glucuronide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:16437251 |
|
Clostridium perfringens |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
SN-38 glucuronide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:16437251 |
|
Unidentified gut microbes |
3,4-Dihydro-5-Methyl-Isoquinolinone |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Convention and germ-free |
DHQ production was dependent on bacteria |
"PMID:27782392 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug modulate or interact with the microbiota |
"PMID:21060933 |
|
Unidentified gut microbes |
Hippuric acid |
Environmental Substance |
"Industrial Chemicals; Pollutants; Toxic Agents" |
n.a. |
n.a. |
Increase Efficacy |
In vivo |
Germ-free,or with antibiotics |
Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics |
"PMID:27782392 |
|
Unidentified gut microbes |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Contribute to metformin therapy |
"PMID:25038099 |
|
Unidentified gut microbes |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug modulate or interact with the microbiota |
"PMID:25038099 |
|
Unidentified gut microbes |
Levocarnitine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
TMA, TMAO |
n.a. |
n.a. |
n.a. |
Decrease AGE levels |
"PMID:25636076 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Cause gut inflammation and irritation;drug interaction:irinotecan with a glucuronidase inhibitor decreases harmful metabolites and alleviates the gastrointestinal inflammation" |
"PMID:27782392 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
m-tyramine |
n.a. |
In vivo |
Germ-free |
(GF mice)reduce metabolism of L-DOPA,prolong L-DOPA half-life and hence activity |
"PMID:4974346 |
|
Escherichia sp. |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Result in an increase of gas metabolism pathways(side effect of metformin) |
PMID:27782392 |
|
Pseudomonas aeruginosa |
2,8-DHQ (including 2,4-DHQ) |
Environmental Substance |
Human Metabolite |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Drug is involved in the pathogenicity of bacteria |
PMID:27782392 |
|
Enterobacteriaceae |
Aspartame |
"Therapeutic Substance; Dietary Substance; Herbal Substance" |
"Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" |
n.a. |
SCFA(propionate) |
n.a. |
In vivo |
n.a. |
Aspartame increased total bacteria |
PMID:27782392 |
|
[Clostridium] leptum |
Aspartame |
"Therapeutic Substance; Dietary Substance; Herbal Substance" |
"Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" |
n.a. |
SCFA(propionate) |
n.a. |
In vivo |
n.a. |
Aspartame increased total bacteria |
PMID:27782392 |
|
Bifidobacterium |
B-GOSr (prebiotic oligosaccharide) |
Therapeutic Substance |
n.a. |
n.a. |
SCFA(acetate) |
n.a. |
n.a. |
n.a. |
Bacteria populations increases acetate |
PMID:27782392 |
|
Clostridia |
Choline |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
trimethylamine (TMA) |
n.a. |
n.a. |
n.a. |
Have a direct relationship to cardiovascular disease and atherosclerosis |
PMID:27782392 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin |
Decrease Efficacy |
n.a. |
n.a. |
Lack cardiac activity |
PMID:27782392 |
|
Bacteroides |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
lactic acid,acetic acid |
Increase Efficacy |
n.a. |
n.a. |
Produce its therapeutic metabolites |
PMID:27782392 |
|
Bifidobacterium |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
lactic acid,acetic acid |
Increase Efficacy |
n.a. |
n.a. |
Produce its therapeutic metabolites |
PMID:27782392 |
|
Unidentified gut microbes |
3,3-dimethyl-1-butanol |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
TMA, TMAO |
n.a. |
In vivo |
n.a. |
Drug interaction:inhibition of TMA lyase inhibits microbial production of TMA, reducing TMAO levels |
PMID:27782392 |
|
Unidentified gut microbes |
Arabinoxylan-oligosaccharides |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
"SCFA; phenol, pcresol" |
n.a. |
n.a. |
n.a. |
AXOS supplementation has a long-term effect on colonic microbe community |
PMID:27782392 |
|
Unidentified gut microbes |
Aryl hydrocarbon receptor activator |
Environmental Substance |
"Industrial Chemicals; Pollutants; Toxic Agents" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter the gut microbiota community its metabolic function |
PMID:27782392 |
|
Unidentified gut microbes |
Ellagic acid |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter the gut microbiota community its metabolic function |
PMID:27782392 |
|
Unidentified gut microbes |
Arsenic |
Environmental Substance |
"Heavy Metals; Toxic Agents" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter the gut microbiota community its metabolic function |
PMID:27782392 |
|
Escherichia coli |
NSAIDs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Yield harmful metabolites,cause the formation of ulcers in the gut;" |
PMID:27782392 |
|
Unidentified gut microbes |
Persistent organic pollutant |
Environmental Substance |
"Industrial Chemicals; Pollutants" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Alter the gut microbiota community its metabolic function |
PMID:27782392 |
|
Unidentified gut microbes |
Rifaximin |
Therapeutic Substance |
Approved Drug |
n.a. |
Hippuric acid |
n.a. |
In vivo |
n.a. |
Drug interaction:antibiotic(rifaximin)decreases microbial metabolites(hippuric acid) |
PMID:27782392 |
|
Lactobacillus |
Tempol |
Therapeutic Substance |
Investigational Drug |
n.a. |
T灏綧CA |
n.a. |
In vivo |
n.a. |
Tempol reduces BSH activity of bacteria and produces antiobesity effects |
PMID:27782392 |
|
Unidentified gut microbes |
Oxaliplatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Mediated by TLR4 and reactive oxygen species production by myeloid cells |
"PMID:18555978 |
|
Mycoplasma |
Floxuridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity |
PMID:28270698 |
|
Mycoplasma |
Trifluridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity |
PMID:28270698 |
|
Bifidobacterium |
Anti-PD-L1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Tumour?specific T?cell induction;increase T?cells in?tumour microenvironment" |
PMID:28270698 |
|
Proteobacteria |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis |
PMID:28270698 |
|
Firmicutes |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis |
PMID:28270698 |
|
Actinobacteria |
Carmustine, Etoposide, Cytarabine and melphalan combination |
Therapeutic Substance |
Drug Combination |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis |
PMID:28270698 |
|
Ruminococcus |
CpG oligodeoxynucleotides |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Priming of tumour?associated myeloid inflammatory responses |
PMID:28270698 |
|
Alistipes |
CpG oligodeoxynucleotides |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Priming of tumour?associated myeloid inflammatory responses |
PMID:28270698 |
|
Bacteroidales |
CTLA-4 blockade |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Decreased activation of splenic effector CD4 + T?cells and?tumour?infiltrating lymphocytes |
PMID:28270698 |
|
Segmented filamentous bacteria |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Gram?positive commensals mediate accumulation of TH 17 and TH 1?cell response |
PMID:28270698 |
|
Lactobacillus |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Gram?positive commensals mediate accumulation of TH 17 and TH 1?cell response |
PMID:28270698 |
|
Enterococcus hirae |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus murinus |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus johnsonii |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Enterococcus hirae |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus murinus |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Lactobacillus johnsonii |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs |
PMID:28270698 |
|
Mycoplasma |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity |
PMID:28270698 |
|
Bacteroidetes |
Ipilimumab |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of?CTLA?4 blockade?induced colitis |
PMID:28270698 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
"Increase Efficacy; Increase Toxicity" |
n.a. |
n.a. |
Bacterial glucuronidase cleaves glucuronide from inactive metabolite, releasing active metabolite (SN?38) in the gut |
PMID:28270698 |
|
Bacteroides |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduced diversity and shifts in relative abundance associated with chemotherapy?induced diarrhoea |
PMID:28270698 |
|
Streptococcus |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduced diversity and shifts in relative abundance associated with chemotherapy?induced diarrhoea |
PMID:28270698 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Yield a inactive metabolite |
"PMID:11344150 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
"sulfapyridine;5-ASA;N-acetyl 5-ASA" |
Decrease Efficacy |
n.a. |
n.a. |
Lack anti-inflammatory |
"PMID:1425876 |
|
Unidentified gut microbes |
Ginsenosides |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Inhibit cytochrome P-450s;affect host xenobiotic metabolism" |
"PMID:16547074 |
|
Unidentified gut microbes |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"antioxidant indole-3-propionic acid;the neurotransmitter tryptamine;indole" |
Increase Toxicity |
n.a. |
n.a. |
Generate the uremic toxin indoxyl sulfate |
"PMID:17146590 |
|
Unidentified gut microbes |
Cysteine-S-conjugates of xenobiotics |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
thiol metabolites |
n.a. |
n.a. |
n.a. |
Serve as a sole nitrogen,a potential role in nutrient acquisition |
"PMID:20306345 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Cause intestinal damage and severe diarrhea;drug interaction:inhibitors" |
"PMID:21051639 |
|
Unidentified gut microbes |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
n.a. |
Increase Bioavailability |
n.a. |
n.a. |
Allow intestinal absorption |
"PMID:26174047 |
|
Unidentified gut microbes |
Sulfoxide |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:3630204 |
|
Unidentified gut microbes |
Azo dyes |
Environmental Substance |
"Industrial Chemicals; Pollutants" |
n.a. |
mutagenic bis-aniline benzidine |
Increase Toxicity |
In vivo |
n.a. |
Increase carcinogen exposure |
"PMID:3726894 |
|
Unidentified gut microbes |
Methylmercury |
Environmental Substance |
"Industrial Chemicals; Pollutants; Toxic Agents" |
n.a. |
inorganic mercury |
Decrease Toxicity |
In vivo |
n.a. |
Lead to less toxicity,facilitate mercury excretion |
"PMID:626001 |
|
Unidentified gut microbes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
"Medicinal Herbal Compounds; Dietary Compounds" |
n.a. |
mandelonitrile |
Increase Toxicity |
n.a. |
n.a. |
Produce benzaldehydy and toxic cyanide |
"PMID:7362642 |
|
Unidentified gut microbes |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:7628301 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28642381 |
|
Escherichia coli |
Anticancer drugs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase or decrease the efficacy of drug |
PMID:28642381 |
|
Listeria welshimeri |
Anticancer drugs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase or decrease the efficacy of drug |
PMID:28642381 |
|
Escherichia coli |
CB954 |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28642381 |
|
Escherichia coli |
Fludarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28642381 |
|
Escherichia coli |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:28642381 |
|
Lactobacillus brevis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
mtyramine |
n.a. |
n.a. |
n.a. |
Contribute to the substantial variation |
PMID:28642381 |
|
Klebsiella |
Phenoxyethanol |
Therapeutic Substance |
Approved Drug |
n.a. |
cyanuric acid |
Increase Toxicity |
In vivo |
n.a. |
Lead to renal toxicity |
PMID:28642381 |
|
Unidentified gut microbes |
Thiazolidinediones |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
In vivo |
Diet-induced obesity |
Indirectlyaffect gut bacteria(HFD leads to an increase in the relative abundance of Proteobacteria) |
"PMID:27751827 |
|
Unidentified gut microbes |
Acarbose |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
Hyperlipidemia or T2D |
"Enhance starch-fermenting and butyrate-producing bacteria;inhibit starch use by propionate-producing bacteria;increase Lactobacillus,Bifidobacterium and other SCFA-producing bacteria;associated with a diminution of Enterobacteriaceae,Bacteroidaceae and lecithinase positive Clostridum in human feces" |
PMID:28973971 |
|
Escherichia coli |
Acarbose |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Block the growth of E.coli |
PMID:28973971 |
|
SCFA-producing bacteria |
Antidiabetic drugs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Positively influence the bacteria |
PMID:28973971 |
|
Unidentified gut microbes |
Incretin |
Environmental Substance |
Human Metabolite |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Influence incretin secretion |
PMID:28973971 |
|
Unidentified gut microbes |
Liraglutide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
High-fat diet(HFD),HF-fed,diabetes-induced |
"Enrich Firmicutes;deplete Bacteroidetes,Proteobacteria and Actinobacteria phyla;enrich 13 phylotypes(Allobaculum,Turicibacter,Anaerostipes,Blautia,Lactobacillus,Butyricimonas,Desulfovibrio);decrease 20 phylotypes in the orders Clostridiales and Bacteroidales" |
PMID:28973971 |
|
Escherichia |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Influence the side-effects of drug |
PMID:28973971 |
|
Bacteroides |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Enric the bacteria |
PMID:28973971 |
|
Lactobacillus |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Positive effects |
PMID:28973971 |
|
Phascolarctobacterium |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Enric the bacteria |
PMID:28973971 |
|
Blautia |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Enric the bacteria |
PMID:28973971 |
|
Butyricicoccus |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Enric the bacteria |
PMID:28973971 |
|
Bacteroidetes |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
High-fat diet (HFD) |
Decrease bacterial diversity |
PMID:28973971 |
|
Proteobacteria |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Positive effects |
PMID:28973971 |
|
Firmicutes |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
High-fat diet (HFD) |
Decrease bacterial diversity |
PMID:28973971 |
|
Verrucomicrobia |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
High-fat diet (HFD) |
Increase the relative abundance of bacteria |
PMID:28973971 |
|
Bifidobacterium adolescentis |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Contribute to the glucose-lowering effect |
PMID:28973971 |
|
Allobaculum |
Metformin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Positive effects |
PMID:28973971 |
|
Coriobacteriaceae |
Miglitol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
A high fat and high glucose diet |
Reverse the increase of bacteria |
PMID:28973971 |
|
Erysipelotrichaceae |
Miglitol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
A high fat and high glucose diet |
Reverse the increase of bacteria |
PMID:28973971 |
|
SCFA-producing bacteria |
Physical activity |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Positively influence the bacteria |
PMID:28973971 |
|
Proteobacteria |
Pioglitazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
High-fat diet (HFD) |
Reduce the abundance of bacteria |
PMID:28973971 |
|
Unidentified gut microbes |
Saxagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
HF-fed,diabetic-induced |
"Enrich Firmicutes,mainly the genera Lactobacillus,Allobaculum and Turicibacter;contain less Bacteroides and Prevotella;decrease the phylum Bacteroidetes" |
PMID:28973971 |
|
Unidentified gut microbes |
Sitagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Diabetes |
"Increase in the relative abundance of Bacteroidetes and Proteobacteria;decrease Firmicute;influence SCFA-producing bacteria;Lactobacillus and Bifidobacterium are depleted in feces" |
PMID:28973971 |
|
Unidentified gut microbes |
Voglibose |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Decrease the Firmicutes to Bacteroidetes ratio and higher the abundance in Verrucomicrobia |
PMID:28973971 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
acetylated 5-aminosalicylic acid |
Increase Efficacy |
n.a. |
n.a. |
Exert physiopathological effects,increase activity |
"PMID:11344150 |
|
Unidentified gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Lead to poor bioavailability of ranitidine |
"PMID:11564550 |
|
Unidentified gut microbes |
Morphine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Increase drug toxicity |
"PMID:1185599 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Decrease activity |
"PMID:30227749 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8) |
n.a. |
In vitro |
n.a. |
Produce four metabolites |
"PMID:30227749 |
|
Unidentified gut microbes |
Deleobuvir |
Therapeutic Substance |
Investigational Drug |
n.a. |
CD 6168 |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:30227749 |
|
Unidentified gut microbes |
Amlodipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Increase activity |
"PMID:30227749 |
|
Unidentified gut microbes |
Epacadostat |
Therapeutic Substance |
Investigational Drug |
n.a. |
Amidine metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Decrease activity |
"PMID:30227749 |
|
Unidentified gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
n.a. |
"PMID:30227749 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
"PMID:5173017 |
|
Unidentified gut microbes |
Sulfonamide antibiotics |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:5173017 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminoclonazepam |
Increase Toxicity |
n.a. |
n.a. |
n.a. |
"PMID:6506755 |
|
Unidentified gut microbes |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Decrease activity |
"PMID:7512019 |
|
Unidentified gut microbes |
Loperamide oxide |
Therapeutic Substance |
Investigational Drug |
n.a. |
active drug loperamide |
Increase Efficacy |
n.a. |
n.a. |
Make the metabolism and increase activity of loperamide oxide |
"PMID:7628301 |
|
Unidentified gut microbes |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
No alteration of pharmacokinetics |
"PMID:7629748 |
|
Unidentified gut microbes |
Calcitonin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase large-intestinal absorption,decrease activity |
"PMID:30227749 |
|
Unidentified gut microbes |
Insulin human |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase large-intestinal absorption,decrease activity |
"PMID:30227749 |
|
Unidentified gut microbes |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Influence drug delivery and absorption |
PMID:30227749 |
|
Unidentified gut microbes |
Famotidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Influence drug delivery and absorption |
PMID:30227749 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Influence drug delivery and absorption |
PMID:30227749 |
|
Bacteroides |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl)uracil |
Decrease Efficacy |
n.a. |
n.a. |
Reduce activity |
PMID:30227749 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
"Decrease Efficacy; Increase Toxicity" |
n.a. |
n.a. |
"Reduce activity;delay the metabolism of drug in the human body and increase risk of hepatotoxicity" |
PMID:30227749 |
|
Enterobacteriales |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
"Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" |
PMID:30227749 |
|
Enterococcus |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
"Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" |
PMID:30227749 |
|
Lactobacillus |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
"Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" |
PMID:30227749 |
|
Escherichia coli Nissle 1917 |
Amiodarone |
Therapeutic Substance |
Approved Drug |
n.a. |
DEA |
"Increase Efficacy; Increase Bioavailability" |
In vivo |
n.a. |
Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C |
PMID:30227749 |
|
Clostridium sp. |
Balsalazide |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
digoxigenin,or dihydrodigoxin |
Decrease Efficacy |
In vitro |
n.a. |
"Produce inactive metabolites;[interaction]:(gnotobiotic mice)dietary protein reduces microbial metabolism of digoxin(vivo) and changes drug concentration(in the serum and urine);[drug interaction]:antibiotics(tetracycline or erythromycin) increase plasma concentration of digoxin" |
PMID:30227749 |
|
Bacteroides |
Glucuronides |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
diclofenac,ketoprofen,indomethacin |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Clostridium |
Glucuronides |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
diclofenac,ketoprofen,indomethacin |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Bifidobacterium sp. |
Glucuronides |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
diclofenac,ketoprofen,indomethacin |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Bacteroides vulgatus |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Erysipelatoclostridium ramosum |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Bacteroides |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
lactic and acetic acidsactive metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Reduce activity |
PMID:30227749 |
|
Clostridium |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
lactic and acetic acidsactive metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Reduce activity |
PMID:30227749 |
|
Lactobacillus |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
lactic and acetic acidsactive metabolite |
Decrease Efficacy |
n.a. |
n.a. |
Reduce activity |
PMID:30227749 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Increase activity |
PMID:30227749 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Increase activity |
PMID:30227749 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Helicobacter pylori |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Bioavailability |
In vivo |
Parkinson disease (PD) |
"Reduce acute L-dopa absorption;reduce L-dopa onset time, ON duration, motor severity, and quality of life parameters" |
PMID:30227749 |
|
Clostridium perfringens |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
Decrease Efficacy |
n.a. |
n.a. |
Reduce activity |
PMID:30227749 |
|
[Clostridium] leptum |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-acetylaminonitrazepam |
Decrease Toxicity |
n.a. |
n.a. |
Produce teratogenic activity metabolites,Induce teratogenicity |
PMID:30227749 |
|
Clostridium sp. |
Olsalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Lactobacillus |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Affect the pharmacokinetics and pharmacodynamics;increase the risk of myopathy" |
PMID:30227749 |
|
Clostridium sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Clostridium sporogenes |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
2-sulphamoylacetylphenol |
Increase Efficacy |
n.a. |
n.a. |
Increase activity |
PMID:30227749 |
|
Pseudomonas fluorescens |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Escherichia coli |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Bacteroides vulgatus |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Enterococcus faecalis |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Clostridium sporogenes |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Bifidobacterium bifidum |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Lactobacillus rhamnosus |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Salmonella enterica subsp. enterica serovar Typhimurium |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30227749 |
|
Eubacterium sp. |
Balsalazide |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Unidentified gut microbes |
Diclofenac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce intestinal tract toxicity |
PMID:30227749 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce intestinal tract toxicity |
PMID:30227749 |
|
Unidentified gut microbes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce intestinal tract toxicity |
PMID:30227749 |
|
Eubacterium sp. |
Olsalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Eubacterium sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-aminosalicylic acid |
Increase Toxicity |
n.a. |
n.a. |
Increase toxicity |
PMID:30227749 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Acetylating to acid |
"PMID:11344150 |
|
Unidentified gut microbes |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:30338735 |
|
Unidentified gut microbes |
Sulfonamide antibiotics |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Activation of prodrug to 5-aminosalicylic acid |
"PMID:30338735 |
|
Clostridium perfringens |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduction to acetamide |
"PMID:30338735 |
|
Bacterium DZY-HS11 |
Arsenic |
Environmental Substance |
"Heavy Metals; Toxic Agents" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
n.a. |
"PMID:30338735 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics can reduce the biotransformation |
"PMID:30338735 |
|
Unidentified gut microbes |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Hydrolysis of glucuronide |
"PMID:28922 |
|
Unidentified gut microbes |
Nifedipine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
n.a. |
"PMID:30338735 |
|
Unidentified gut microbes |
Nifedipine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
Hypoxic conditions at high altitudes |
Increase the bioavailability of drug |
"PMID:30338735 |
|
Unidentified gut microbes |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Result in increased toxicity |
"PMID:30338735 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfapyridine and 5-ASA |
Decrease Efficacy |
n.a. |
n.a. |
Lose activity |
"PMID:30338735 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Increase the drug |
"PMID:30338735 |
|
Unidentified gut microbes |
Dihydroxyphenylalanine (DOPA) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Direct dopa to alternative metabolic pathways |
"PMID:4723308 |
|
Unidentified gut microbes |
Plant-derived glycosides(amygdalin) |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:7362642 |
|
Unidentified gut microbes |
Loperamide oxide |
Therapeutic Substance |
Investigational Drug |
n.a. |
loperamide |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:30338735 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-acetylaminonitrazepam |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:30338735 |
|
Clostridium |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
p-cresol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Enterobacteriales |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics can potentiate the therapeutic potency |
PMID:30338735 |
|
Enterococcus |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics can potentiate the therapeutic potency |
PMID:30338735 |
|
Lactobacillus |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics can potentiate the therapeutic potency |
PMID:30338735 |
|
Unidentified gut microbes |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
calycosin |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxigenin,dihydrodigoxin |
Decrease Efficacy |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Escherichia |
Diosmin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Enterococcus |
Diosmin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Clostridium |
Diosmin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Lactobacillus |
Diosmin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bifidobacterium |
Diosmin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bacteroides |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
n.a. |
n.a. |
n.a. |
Leads to GI toxicity |
PMID:30338735 |
|
Clostridium |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
n.a. |
n.a. |
n.a. |
Leads to GI toxicity |
PMID:30338735 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Enhance the irinotecan toxicity |
PMID:30338735 |
|
Bacteroides vulgatus |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Enhance the irinotecan toxicity |
PMID:30338735 |
|
Erysipelatoclostridium ramosum |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Enhance the irinotecan toxicity |
PMID:30338735 |
|
Bifidobacterium sp. |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
n.a. |
n.a. |
n.a. |
Leads to GI toxicity |
PMID:30338735 |
|
Bacteroides |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
acetic lactic,acids active |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Clostridium |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
acetic lactic,acids active |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Lactobacillus |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
acetic lactic,acids active |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I,levametabol-III |
Increase Efficacy |
n.a. |
n.a. |
Generate active metabolites |
PMID:30338735 |
|
Clostridium sp. |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
levametabol-I,levametabol-III |
Increase Efficacy |
n.a. |
n.a. |
Generate active metabolites |
PMID:30338735 |
|
[Eubacterium] rectale |
Puerarin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
daidzein |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bacteroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Clostridium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Lactobacillus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Eubacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bifidobacterium sp. |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Escherichia |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Streptococcus |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Lactobacillus |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Eubacterium |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Bifidobacterium sp. |
Scutellaria baicalensis root |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Lactobacillus |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Increase the risk of myopathy |
PMID:30338735 |
|
Bacteroides |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
(E)-5-(2-bromovinyl) uracil |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Gardnerella |
Tenofovir |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Clostridium |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
2-sulphamoylacetylphenol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Unidentified gut microbes |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
Calycosin |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30338735 |
|
Faecalibacterium prausnitzii |
Anti?PD?1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
Metastatic melanoma |
"Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum" |
PMID:30530851 |
|
Bifidobacterium longum |
Anti?PD?1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
Metastatic melanoma |
"Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum" |
PMID:30530851 |
|
Akkermansia muciniphila |
Anti?PD?1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
Non-small cell lung cancer |
Increased relative abundance of bacteria in PD-1 R |
PMID:30530851 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Efficacy |
In vivo |
n.a. |
221% increase in simvastatin AUC for homozygotes |
"PMID:19833260 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Lactone ring reduction |
n.a. |
Increase Toxicity |
In vivo |
n.a. |
"Decreased AUC; narrow therapeutic window" |
"PMID:24637603 |
|
Unidentified gut microbes |
Warfarin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Altered activity of drug |
"PMID:22380001 |
|
Unidentified gut microbes |
Bromazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Amino-metabolite generation, Inactivation |
"PMID:27591027 |
|
Unidentified gut microbes |
Bromazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Change to inactive metabolite |
"PMID:27591027 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Amino-metabolite generation, Inactivation |
"PMID:27591027 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Change to inactive metabolite |
"PMID:27591027 |
|
Unidentified gut microbes |
Diclofenac |
Therapeutic Substance |
Approved Drug |
Deglucuronidation |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" |
"PMID:27591027 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
Deglucuronidation |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" |
"PMID:27591027 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Deglucuronidation |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" |
"PMID:27591027 |
|
Unidentified gut microbes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Deglucuronidation |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" |
"PMID:27591027 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Amino-metabolite generation, Inactivation |
"PMID:27591027 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
Nitroreduction |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Change to inactive metabolite |
"PMID:27591027 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
Deglucuronidation |
SN-38G metabolite |
In vitro |
Human |
n.a. |
PMID |
|
|
Unidentified gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Sulfonation |
n.a. |
Decrease Toxicity |
In vitro |
n.a. |
"Increased rate of glucuronidation; decreased risk of liver failure" |
"PMID:23408116 |
|
Unidentified gut microbes |
Brivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
additional bromovinyluracil |
Increase Toxicity |
In vitro |
n.a. |
"Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU" |
"PMID:9690942 |
|
Unidentified gut microbes |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
n.a. |
additional bromovinyluracil |
Increase Toxicity |
n.a. |
n.a. |
"Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU" |
"PMID:9690942 |
|
Unidentified gut microbes |
Balsalazide |
Therapeutic Substance |
Approved Drug |
Azoreduction |
local 5-ASA |
Increase Efficacy |
In vivo |
Ulcerative colitis |
Prodrug activation: local 5-ASA release |
"PMID:27591027 |
|
Unidentified gut microbes |
Calcitonin |
Therapeutic Substance |
Approved Drug |
Proteolysis |
n.a. |
Decrease Efficacy |
In vitro |
n.a. |
Breakdown of therapeutic protein |
"PMID:27591027 |
|
Unidentified gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Nitroreduction |
p-aminophenyl-2-amino-1,3-propanediol |
Increase Toxicity |
n.a. |
n.a. |
Bone marrow toxicity |
"PMID:27591027 |
|
Unidentified gut microbes |
Insulin human |
Therapeutic Substance |
Approved Drug |
Proteolysis |
n.a. |
Decrease Efficacy |
In vitro |
n.a. |
Breakdown of therapeutic protein |
"PMID:27591027 |
|
Unidentified gut microbes |
Ipsalazide |
Therapeutic Substance |
Approved Drug |
Azoreduction |
local 5-ASA |
Increase Efficacy |
In vivo |
Ulcerative colitis |
Prodrug activation: local 5-ASA release |
"PMID:27591027 |
|
Unidentified gut microbes |
Neoprontosil |
Therapeutic Substance |
Approved Drug |
Azoreduction |
n.a. |
Increase Efficacy |
In vitro |
n.a. |
Antibiotic activation |
"PMID:27591027 |
|
Unidentified gut microbes |
Olsalazine |
Therapeutic Substance |
Approved Drug |
Azoreduction |
local 5-ASA |
Increase Efficacy |
In vivo |
Ulcerative colitis |
Prodrug activation: local 5-ASA release |
"PMID:27591027 |
|
Unidentified gut microbes |
Picosulfuric acid |
Therapeutic Substance |
Approved Drug |
Desulfation |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Solubility increase |
"PMID:27591027 |
|
Unidentified gut microbes |
Prontosil |
Therapeutic Substance |
Approved Drug |
Azoreduction |
n.a. |
Increase Efficacy |
In vivo |
n.a. |
Antibiotic activation |
"PMID:27591027 |
|
Unidentified gut microbes |
Sulfadiazine |
Therapeutic Substance |
Approved Drug |
Azoreduction |
local 5-ASA |
Increase Efficacy |
n.a. |
n.a. |
Prodrug activation: local 5-ASA release |
"PMID:27591027 |
|
Unidentified gut microbes |
Mesalazine |
Therapeutic Substance |
Approved Drug |
N-Acetylation |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
"Less efficacy; possible pancreatic toxicity" |
"PMID:30227749 |
|
Unidentified gut microbes |
Amiodarone |
Therapeutic Substance |
Approved Drug |
N-dealkylation |
n.a. |
Increase Efficacy |
In vivo |
EcN-treated rats |
Increased bioavailability of active metabolite |
"PMID:30227749 |
|
Unidentified gut microbes |
Codeine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Deglucuronidation |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Reformation of active metabolite |
"PMID:30227749 |
|
Unidentified gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Lactone ring reduction |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Change to inactive metabolite |
"PMID:30227749 |
|
Unidentified gut microbes |
Metamfetamine |
Therapeutic Substance |
Approved Drug |
N-Demethylation |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Change to inactive metabolite |
"PMID:30227749 |
|
Unidentified gut microbes |
Morphine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Deglucuronidation |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Reformation of active metabolite |
"PMID:30227749 |
|
Unidentified gut microbes |
Brivudine |
Therapeutic Substance |
Approved Drug |
N-Dealkylation |
n.a. |
Increase Toxicity |
In vitro |
n.a. |
"Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation" |
"PMID:30733391 |
|
Unidentified gut microbes |
Sorivudine |
Therapeutic Substance |
Investigational Drug |
N-Dealkylation |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation" |
"PMID:30733391 |
|
Helicobacter pylori |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
P-Dehydroxylation |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Decrease in L-dopa absorption |
PMID:31171383 |
|
Pseudomonas aeruginosa |
Morphine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
Deglucuronidation |
morphine-glucuronide metabolite |
n.a. |
n.a. |
n.a. |
"Decreased clearance of morphine; Induces virulence in some strains of Pseudomonas aeruginosa" |
PMID:31171383 |
|
Unidentified gut microbes |
Estradiol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Increase Bioavailability |
In vitro |
n.a. |
"Greater absroption of estrogens;develop estrogen-driven cancer" |
"PMID:27107051 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
In vivo |
Health |
PMID |
|
|
Unidentified gut microbes |
Taurine conjugated bile acid |
Environmental Substance |
Human Metabolite |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Contribute to the etiology of cancer |
"PMID:27003186 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
"Lead to inactivation and decreased bioavailability;drug substructure similarity:cardenolides(great),progesterone閵嗕恭ortisone(bad);" |
PMID:31184303 |
|
Unidentified gut microbes |
Altretamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Cause diarrhea and kidney damage;interaction:tamoxifen閵嗕龚iphenhydramine閵嗕辜heobromine" |
PMID:31184303 |
|
Pseudomonas putida |
Altretamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
"Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence)" |
PMID:31184303 |
|
Styrax aureus |
Hypochlorite |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
cutaneous T cell lymphoma |
Reduce the amount of bacteria |
"PMID:18835065 |
|
Unidentified probiotic |
Common azole treatment |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Reduce the amount of azoleresistant fungal strains |
"PMID:25362524 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Result in side effects( stage 4 diarrhea and gastrointestinal damage) |
"PMID:31186074 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
m-tyramine, m-hydroxyphenylacetic acid (m-HPAA) |
Decrease Efficacy |
In vivo |
n.a. |
Decrease L-DOPA half-life and efficacy |
"PMID:4723308 |
|
Unidentified gut microbes |
Lactulose |
Therapeutic Substance |
Approved Drug |
n.a. |
acetic,lactic acid |
Increase Efficacy |
n.a. |
n.a. |
Product therapeutic metabolites |
"PMID:6804597 |
|
Unidentified gut microbes |
Antibiotic (extensive treatment) |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Lead to intestinal complications(antibiotic-associated diarrhea and colitis);drug interaction: C. difficile can be treated with vancomycin and metronidazole" |
PMID:31186074 |
|
Unidentified gut microbes |
Bromazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:2893665 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine |
n.a. |
n.a. |
n.a. |
n.a. |
"PMID:2893665 |
|
Unidentified gut microbes |
Potassium oxonate |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
cyanuric acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:10997934 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
N-acetyl sulfapyridine,N-acetyl-5-aminosalicylic acid |
n.a. |
In vitro |
n.a. |
n.a. |
PMID:1425876 |
|
Unidentified gut microbes |
Picosulfuric acid |
Therapeutic Substance |
Approved Drug |
n.a. |
4,40-dihydroxydiphenyl-(2 pyridyl)-methane |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:1507649 |
|
Unidentified gut microbes |
Phosphate or sulfate ester prodrugs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:1507649 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-amino 5-salicylic acid |
Increase Efficacy |
n.a. |
n.a. |
"Convert to its pharmacologically active form;enhance drug distribution閿涙lsalazine閵嗕攻alsalazide潟nflammatory bowel disease鈧柡鈧攰ntroduction of azo bonds" |
PMID:18305431 |
|
Unidentified gut microbes |
Antibiotic |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Lead to alteration in coagulation status |
PMID:18841274 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminonitrazepam,7-acetylaminonitrazepam |
Increase Toxicity |
In vivo |
Pregnant |
"Lead to nitrazepam-related teratogenicity;drug interaction:antibiotic reduced metabolites" |
PMID:1925980 |
|
Unidentified gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
N-acetyl p-benzoquuinone imine |
Increase Toxicity |
In vivo |
Health |
Impede the ability for the liver to detoxify |
"PMID:19667173 |
|
Unidentified anaerobic bacterium |
Fostamatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:20371637 |
|
Unidentified gut microbes |
Rosuvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Toxicity |
n.a. |
n.a. |
Cause side effect on fish odor syndrom |
PMID:21422137 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Alterations in bacteria(expansion of proinflammatory bacteria) |
PMID:22328575 |
|
Unidentified gut microbes |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
1-(2-aminoimidazol-1-yl)-3 methoxypropanol-2-ol and acetamide |
n.a. |
In vivo |
n.a. |
Lead to rat carcinogen |
PMID:231450 |
|
Unidentified gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Microbial inactivation |
PMID:23869020 |
|
Unidentified gut microbes |
CpG-oligonucleotide immunotherapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Stimulate the immune system to attack cancer cells |
PMID:24264989 |
|
Unidentified gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Drug interaction:long-term antibiotic treatment might lead to a failure to control serum cholesterol levels |
PMID:24947972 |
|
Unidentified gut microbes |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
n.a. |
n.a. |
Lead to activation of drug |
PMID:25091594 |
|
Unidentified gut microbes |
Eltrombopag |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25581726 |
|
Unidentified gut microbes |
Levosimendan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:25581726 |
|
Unidentified gut microbes |
Indole |
"Therapeutic Substance; Herbal Substance" |
Investigational Drug |
n.a. |
indole-3-propionic acid |
n.a. |
n.a. |
n.a. |
Provide ligands for the aryl hydrocarbon receptor |
PMID:26041783 |
|
Unidentified gut microbes |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
indole-3-propionic acid |
n.a. |
n.a. |
n.a. |
Provide ligands for the aryl hydrocarbon receptor |
PMID:26041783 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Lead to severe diarrhea;drug interaction:antibiotic mixtures(streptomycin,penicillin or neomycin and bacitracin)eliminated fecal b-glucuronidase activity; TJ-14 administration moderate weight loss and delay the drug-associated diarrhea; the P-glycoprotein and (cMOA T/MRP2) inhibitor of cyclosporin A or (UDP)-glucuronosyltransferase inhibitor valproic acid increased intestinal toxicity" |
PMID:26518357 |
|
Unidentified gut microbes |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase Efficacy |
In vivo |
n.a. |
Enhance pharmacological effect |
PMID:26701907 |
|
Unidentified oral microbes |
PPIs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Species of bacteria were seen to be over-represented in the fecal microbiome |
PMID:26719299 |
|
Unidentified gut microbes |
PPIs |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Predispose PPI-treated subjects to C. difficile infection;[drug interaction]:frequent use of PPIs can exacerbate NSAID-induced small intestinal injury;[probiotics]prevent NSAID-induced damage in patients receiving PPI and NSAIDs" |
PMID:26923470 |
|
Unidentified gut microbes |
Rosuvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
With rosuvastatin |
Contribute to the composition of gut microbiota |
PMID:28209601 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease Toxicity |
n.a. |
n.a. |
Causes toxic side effects |
PMID:29104759 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dopamine |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:30659181 |
|
Escherichia coli |
Flucytosine |
Therapeutic Substance |
Approved Drug |
n.a. |
5-FU |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:3729334 |
|
Unidentified gut microbes |
2-amino-3,6-dihydro-3H-imidazo[4,5-f]quinoline |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
7-hydroxy metabolite |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:3821779 |
|
Unidentified gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:4418213 |
|
Unidentified gut microbes |
Phenacetin |
Therapeutic Substance |
Approved Drug (Withdrawn) |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:4418213 |
|
Unidentified gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
m-hydroxyphenylacetic acid |
n.a. |
In vivo |
n.a. |
Reduce the exposure of the drug in the brain |
PMID:5343357 |
|
Unidentified gut microbes |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Normal |
n.a. |
PMID:5345205 |
|
Unidentified gut microbes |
Radiation sensitizer misonidazole |
Therapeutic Substance |
n.a. |
n.a. |
l-(2-l-(2-aminoimidazol-l-yl)-3-methoxypropan-2-ol |
n.a. |
In vivo |
Normal,germ-free(GF) |
Drug interaction:penicillin increased drug exposure and decreased neurotoxicity |
PMID:6260109 |
|
Unidentified gut microbes |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
n.a. |
PMID:7512019 |
|
Unidentified gut microbes |
Calcitonin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
"Drug is rapidly degraded;more prone to proteolysis;drug interaction:protease inhibitors(camostat/aprotinin) improve the stability and bioavailability of these peptides" |
PMID:7550138 |
|
Unidentified gut microbes |
Loperamide oxide |
Therapeutic Substance |
Investigational Drug |
n.a. |
loperamide,the ranitidine,nitazidine |
n.a. |
In vivo |
n.a. |
n.a. |
PMID:7628301 |
|
Unidentified gut microbes |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
sulfide metabolite |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:7629748 |
|
Unidentified anaerobic bacterium |
Azetirelin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Drug interaction:concentrations of the drug were maintained after the administration of antibiotic |
PMID:9279880 |
|
Bacteroides |
1-b-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil |
Environmental Substance |
Unclassified Environmental Substances |
n.a. |
BVU |
n.a. |
In vivo |
n.a. |
Drug interaction: the drug with the anticancer drug 5-FU or prodrugs tegafur,5-FU accumulate(increase toxicity, including death) |
PMID:9808711 |
|
Unidentified gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
molecule sulfanilamide |
Increase Efficacy |
n.a. |
n.a. |
Generate the active form of the drug |
PMID:31235939 |
|
Bacteroides thetaiotaomicron |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Germ-free(GF) |
n.a. |
PMID:31235939 |
|
Faecalibacterium |
Anti?PD?1 therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
n.a. |
n.a. |
melanoma |
Prolong progession-free survival |
PMID:31462078 |
|
Bacteroidetes |
Checkpoint inhibitor therapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Decrease Toxicity |
n.a. |
n.a. |
Decrease occrrence of side effect |
PMID:31462078 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
dihydrodigoxin |
Decrease Bioavailability |
n.a. |
n.a. |
"Convert to the inactive microbial metabolite;limit absorbtion;drug interaction:antibiotics,arginine-rich diet(impair this reaction)" |
PMID:31462078 |
|
Unidentified gut microbes |
Rosuvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Hyperlipidemia |
Phyla Firmicutes閵嗕笚usobacteria潱egatively associated with LDL-C levelsCyanobacteria閵嗕俯entisphaerae(positively) |
PMID:31462078 |
|
Firmicutes |
Rosuvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Hyperlipidemia |
Reduce LDL-C levels |
PMID:31462078 |
|
Lactobacillus reuteri |
Rosuvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Hyperlipidemia |
Reduce LDL-C levels |
PMID:31462078 |
|
Unidentified gut microbes |
Irinotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
SN-38 |
Increase Toxicity |
n.a. |
n.a. |
"Sever diarrhea;drug interaction(mice:oral administration of a specific inhibitor of the glucuronidase enzyme,reduce irinotecan-induced toxicity)" |
PMID:31462078 |
|
Unidentified gut microbes |
Levocarnitine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
trimethylamine-N-oxide(TMAO) |
Increase Toxicity |
n.a. |
n.a. |
Interfer with drug pharmacokinetics and pharmacodynamics |
PMID:31462078 |
|
Unidentified gut microbes |
Acetylsalicylic acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Damage the mucosa of the upper GI tract;be able to distinguish aspirin users:(Prevotella species, Bacteroides species, a member of the Ruminococaceae family, and Barnesiella species" |
PMID:31462078 |
|
Unidentified gut microbes |
Amlodipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
"Decreased amount of active drug reaching target tissues;its major metabolite increased;drug interaction:rat(pretreated with ampicillin),enhance amlodipine's absorption;" |
PMID:31462078 |
|
Unidentified gut microbes |
Atorvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
n.a. |
"High-fat diet (Rat); Hypercholesterolemia (Human)" |
Increase abundance of putative anti-inflammatory species |
PMID:31462078 |
|
Unidentified gut microbes |
Captopril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vivo |
Hypertensive |
Reverse the dysbiotic state |
PMID:31462078 |
|
Unidentified gut microbes |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-aminoclonazapam |
n.a. |
n.a. |
n.a. |
Drug interaction:antibiotics(inhibit) |
PMID:31462078 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
Decrease Efficacy |
n.a. |
n.a. |
Decreased amount of drug reaching target tissues |
PMID:31462078 |
|
Unidentified gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vivo |
n.a. |
Predict the magnitude of LDL-C lowering |
PMID:31462078 |
|
Unidentified gut microbes |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
7-amino-nitrazepam |
Increase Toxicity |
n.a. |
n.a. |
"Produce a teratogenic metabolite;drug interaction:antibiotics(inhibit)" |
PMID:31462078 |
|
Bacteroides dorei DSM17855 |
Alfuzosin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Alprenolol |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Benzbromarone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Clostridium difficile 120 |
Camylofine dihydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Capecitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Clemizole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Diphenylpyraline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Ethoxzolamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Irsogladine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Lofexidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Metitepine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Orphenadrine citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Oxcarbazepine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Papaverine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sp. |
Paroxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Rizatriptan benzoate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Sulpiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Trimetazidine dihydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Verapamil |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Zidovudine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Acecainide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Acecainide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Anastrozole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium sp. |
Anastrozole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Benzthiazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Clostridium sp. |
Benzthiazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Bicalutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Bicalutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Bupropion |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Bupropion |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Celecoxib |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Celecoxib |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Cyclobenzaprine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Clostridium sp. |
Cyclobenzaprine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Anaerostipes sp. |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Memantine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Memantine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Clostridium sp. |
Methsuximide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Methsuximide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Methysergide maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Methysergide maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Metoprolol tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Metoprolol tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Naftopidil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Naftopidil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Nevirapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sp. |
Nevirapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Thiothixene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Clostridium sp. |
Thiothixene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Tranilast |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Tranilast |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Vinpocetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Clostridium sp. |
Vinpocetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Dipyridamole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Clostridium sp. |
Dipyridamole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Dipyridamole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Doxazosin mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Clostridium sp. |
Doxazosin mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Doxazosin mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Enalapril maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Enalapril maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Enalapril maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Fluvoxamine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Clostridium sp. |
Fluvoxamine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Fluvoxamine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Sildenafil citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium sp. |
Sildenafil citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium difficile 120 |
Sildenafil citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Sumatriptan succinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Sumatriptan succinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Sumatriptan succinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Warfarin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Warfarin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Warfarin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Ziprasidone mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ziprasidone mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Ziprasidone mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Amantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Amantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Amantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Amantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Ergotamine tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Ergotamine tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Ergotamine tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ergotamine tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Mefloquine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Mefloquine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Mefloquine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Mefloquine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium sp. |
Penbutolol sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Penbutolol sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Penbutolol sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Penbutolol sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Clostridium sp. |
Pimozide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Pimozide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Pimozide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Pimozide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Tadalafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Tadalafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Tadalafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Tadalafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Biperiden |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Clostridium sp. |
Biperiden |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Biperiden |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Biperiden |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Methylphenidate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sp. |
Methylphenidate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Methylphenidate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Methylphenidate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Ethopropazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium sp. |
Ethopropazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ethopropazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ethopropazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Odoribacter splanchnius |
Ethopropazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Phenytoin sodium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Phenytoin sodium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Phenytoin sodium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Phenytoin sodium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Phenytoin sodium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Clostridium sp. |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Clostridium sp. |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Odoribacter splanchnius |
Nafronyl oxalate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Odoribacter splanchnius |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Clostridium sp. |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Odoribacter splanchnius |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Odoribacter splanchnius |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Bezafibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sp. |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Odoribacter splanchnius |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Carbetapentane citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Clostridium sp. |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Chlormezanone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium difficile 120 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Fenofibrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Clostridium sp. |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Odoribacter splanchnius |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Clostridium sp. |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Clostridium difficile 120 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Nicergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Ooscapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sp. |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.328 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Oorgestimate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium sp. |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Odoribacter splanchnius |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sp. |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Odoribacter splanchnius |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Pericyazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Clostridium difficile 120 |
Primaquine phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Odoribacter splanchnius |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Anaerostipes sp. |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.751 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Clostridium sp. |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Ketorolac tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Odoribacter splanchnius |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Oxybutynin chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.572 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Odoribacter splanchnius |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.509 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.36 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Odoribacter splanchnius |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Clostridium sp. |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Clostridium sp. |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Odoribacter splanchnius |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Odoribacter splanchnius |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Gliclazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Rebamipide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Odoribacter splanchnius |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Odoribacter splanchnius |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.67 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Galantamine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.721 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Griseofulvin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Clostridium sp. |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.722 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.98 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.708 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Naloxone |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Odoribacter splanchnius |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Naproxen(+) |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Neostigmine bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Odoribacter splanchnius |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Odoribacter splanchnius |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Colchicine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Clostridium sp. |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.677 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.654 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.964 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Clostridium difficile 120 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.601 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Ergonovine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.655 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Odoribacter splanchnius |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.63 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Losartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Odoribacter splanchnius |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.727 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Odoribacter splanchnius |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.427 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Clostridium sp. |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Odoribacter splanchnius |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.484 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.78 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Clostridium sp. |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Betamethasone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium sp. |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.334 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Odoribacter splanchnius |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.997 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.922 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.225 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.632 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.426 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.691 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.975 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.243 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.653 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.566 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.604 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.092 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.46 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.656 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.322 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.428 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Odoribacter splanchnius |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.6 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.215 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.342 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.623 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.764 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.722 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.787 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Odoribacter splanchnius |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.253 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.544 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.018 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.902 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Linagliptin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.569 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Clostridium sp. |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.768 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.603 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Odoribacter splanchnius |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.013 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.989 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.126 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.052 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Odoribacter splanchnius |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.833 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Mevastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.747 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.816 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.922 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Fenspiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium sp. |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.542 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.829 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Procarbazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.969 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.908 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.867 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.66 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Odoribacter splanchnius |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.637 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.825 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Odoribacter splanchnius |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Valsartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium sp. |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.83 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Odoribacter splanchnius |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Betamethasone valerate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Clostridium sp. |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Cyproterone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.146 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.011 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Odoribacter splanchnius |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Methoxsalen |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.93 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Odoribacter splanchnius |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sp. |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.703 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Odoribacter splanchnius |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.481 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.604 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Odoribacter splanchnius |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Clostridium sp. |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.864 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Odoribacter splanchnius |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.752 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.802 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.104 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.963 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.777 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.94 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.231 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.171 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.133 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.821 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.3 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium sp. |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.178 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.591 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.84 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.965 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.01 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Pidotimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.072 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.771 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Odoribacter splanchnius |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Clostridium sp. |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Carisoprodol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.86 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.468 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.607 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.393 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.631 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Odoribacter splanchnius |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.562 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.725 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Famprofazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Clostridium sp. |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.96 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.876 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.089 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Odoribacter splanchnius |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.988 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Idebenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.179 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.096 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.183 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.351 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Odoribacter splanchnius |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium difficile 120 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.697 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.777 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Loperamide |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.024 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Odoribacter splanchnius |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Megestrol acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Clostridium sp. |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.579 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.565 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.571 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.148 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Odoribacter splanchnius |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.605 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.846 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Clostridium sp. |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.323 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.794 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Odoribacter splanchnius |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.6 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.395 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Clostridium sp. |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.575 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Odoribacter splanchnius |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Clemastine fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.55 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sp. |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.44 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.987 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.86 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.05 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.045 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.149 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.351 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Diflorasone diacetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.421 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Clostridium sp. |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Digitoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium sp. |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Odoribacter splanchnius |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.979 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Trimebutine maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.368 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.416 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Clopidogrel sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.972 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.822 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Clostridium sp. |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.801 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.463 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.672 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.051 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Odoribacter splanchnius |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.451 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.964 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Clostridium difficile 120 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.019 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.11 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sp. |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.076 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.041 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.931 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.884 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.5 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.94 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Clostridium sp. |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Odoribacter splanchnius |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Pranoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sp. |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Odoribacter splanchnius |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.766 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.957 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.811 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.687 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.737 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.699 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.23 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.9 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.675 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.287 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.602 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.304 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.4 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.075 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.163 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.091 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.049 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.485 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.018 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.449 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.025 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.714 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.525 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.985 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.198 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.726 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Vilazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.194 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.667 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Clostridium sp. |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.773 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.084 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.485 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.916 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.073 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.272 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.27 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Odoribacter splanchnius |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.231 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.913 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.389 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.315 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.262 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.852 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.786 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.797 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Deflazacort |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.926 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.603 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.022 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.84 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.199 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.744 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.635 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.919 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.957 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.857 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.998 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.783 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.331 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.225 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Odoribacter splanchnius |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.791 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.383 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.95 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.474 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.096 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.639 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.397 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.783 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.554 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.872 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.353 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.818 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.942 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.097 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.061 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.639 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.062 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.698 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.746 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.948 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sp. |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.002 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Odoribacter splanchnius |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.418 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.849 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.03 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.342 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sp. |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.806 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.949 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.962 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.505 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.892 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.178 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.073 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.515 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.735 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.054 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.949 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Odoribacter splanchnius |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.898 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.549 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.476 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.901 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.134 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium difficile 120 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.091 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.015 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.202 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.39 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sp. |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.132 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.233 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.672 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.38 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.826 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.316 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.305 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.537 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.273 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.14 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Odoribacter splanchnius |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.875 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.369 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.404 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.04 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.159 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.859 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.981 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.76 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.89 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.799 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.489 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.91 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Oorethindrone acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.97 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.794 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.298 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.488 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.93 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.33 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.418 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.144 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.766 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.133 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.491 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.607 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.133 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.876 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.379 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.033 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Odoribacter splanchnius |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.37 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.251 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.435 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.493 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.811 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.766 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.382 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.362 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.313 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.428 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.922 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.831 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.629 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Roxatidine acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.419 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.071 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.164 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Clostridium sp. |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.959 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.801 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.567 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.715 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.804 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.556 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.672 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.664 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.684 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.066 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.333 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.515 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.664 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.527 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Odoribacter splanchnius |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.612 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.566 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.885 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.039 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Clostridium difficile 120 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.853 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.728 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.386 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.23 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.706 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.426 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.312 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Racecadotril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.694 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.254 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.057 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.932 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.366 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.939 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.431 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.026 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.139 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.106 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Anaerostipes sp. |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.671 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.049] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.818 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.556 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.06 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.205 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.869 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.613 [FDR-adjusted p-Value=0.047] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.21 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.262 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.105 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Odoribacter splanchnius |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.253 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium difficile 120 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.293 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.344 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.166 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.92 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.756 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Olmesartan medoxomil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.731 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.875 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sp. |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.567 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.984 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.155 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.718 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.824 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Clostridium difficile 120 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.123 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.017 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.606 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.215 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.38 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.666 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.764 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.178 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium sp. |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.136 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.872 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.961 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.886 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.983 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.213 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.715 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.719 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.471 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Anaerostipes sp. |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.21 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.719 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.711 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.977 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.813 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.98 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.047 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.105 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.52 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.531 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.243 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.536 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.164 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.581 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.825 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.806 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.878 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Odoribacter splanchnius |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.017 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.086 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.613 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.071 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.578 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.856 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.69 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.729 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium difficile 120 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.792 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.153 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.225 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.878 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.966 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.11 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.19 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.103 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.037 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Phenazopyridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.173 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.479 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.222 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.514 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.516 [FDR-adjusted p-Value=0.044] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.868 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sp. |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.937 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.569 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.556 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.631 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.073 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.095 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.385 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.858 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.938 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.443 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.168 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerostipes sp. |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.237 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.484 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.786 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.982 [FDR-adjusted p-Value=0.033] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.999 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.666 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.08 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.384 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.432 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.272 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.037 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.551 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.975 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.045 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.736 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.463 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.258 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.846 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.876 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Odoribacter splanchnius |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.669 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.286 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.928 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.836 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.663 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.509 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.279 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.725 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Clostridium difficile 120 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.322 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.234 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.631 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.224 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.648 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.056 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.351 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.911 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.167 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.405 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.389 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Nitrendipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.722 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.247 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.046 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.59 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.234 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.08 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.639 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.631 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.502 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.242 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.629 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.679 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.826 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.064 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.088 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.113 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.256 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Anaerostipes sp. |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.337 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.522 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.071 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.478 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.296 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.007 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.693 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.184 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.182 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.031 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.585 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.384 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.184 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.663 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.888 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.605 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.916 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Odoribacter splanchnius |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.892 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.002 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.854 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.072 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.61 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.01 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.927 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium difficile 120 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.039 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.303 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.844 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.252 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.327 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.522 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.398 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.576 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.641 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.756 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.211 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.21 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.326 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium sp. |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.625 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.355 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.221 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.879 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.51 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.402 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.773 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.078 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.163 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.325 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.75 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerostipes sp. |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.885 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.333 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.896 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.977 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.401 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.688 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.251 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.946 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.152 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.03 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.863 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.098 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.082 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.527 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.682 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.753 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.781 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.021 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.284 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.676 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.668 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.134 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Odoribacter splanchnius |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.536 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.592 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.624 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.053 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.387 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.609 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.603 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.448 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.943 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.845 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium difficile 120 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.338 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.31 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.418 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.685 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.839 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.07 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.71 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.543 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.994 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.098 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.89 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sp. |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.657 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerostipes sp. |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.043] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.462 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.353 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.799 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.044 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.3 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.877 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.781 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.034] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.223 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.079 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.675 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium difficile 120 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.175 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.665 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Mycophenolate mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.242 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.889 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.164 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.789 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium sp. |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.977 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.348 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.02 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.327 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.993 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Anaerostipes sp. |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.64 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.046] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.364 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.13 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.272 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.023 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.911 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.097 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.343 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.933 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.361 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.127 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Odoribacter splanchnius |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.976 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.921 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.925 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.718 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.102 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.548 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium difficile 120 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.563 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.05] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.157 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.198 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.066 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.099 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Bromocriptine mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.539 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.594 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.053 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.579 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.15 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium sp. |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.246 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.121 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.363 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.878 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.194 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.106 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.731 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.636 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.532 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.365 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.004 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.445 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Anaerostipes sp. |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.862 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.171 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.7 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.008 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.342 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.631 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.282 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.099 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.865 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.119 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.964 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.665 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.393 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.315 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.548 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.281 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.034 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.254 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.375 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.213 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Odoribacter splanchnius |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.255 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.258 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.842 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.076 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.063 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.104 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.135 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium difficile 120 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.42 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.58 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.77 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.83 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.775 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.56 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.334 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.788 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.839 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.877 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.29 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.012 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.172 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium sp. |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.539 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.805 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.544 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.099 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.901 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.527 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.834 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.318 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.254 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.623 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.624 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.772 [FDR-adjusted p-Value=0.028] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.139 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Anaerostipes sp. |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.848 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.913 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.237 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.912 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.35 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.388 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.995 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.165 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.826 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.035 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.009 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.493 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.68 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.212 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.48 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.371 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.315 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.112 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.335 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.617 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.285 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.181 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.454 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Odoribacter splanchnius |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.594 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.994 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.247 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.43 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.818 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.465 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.732 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium difficile 120 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.789 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.135 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.187 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.772 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.917 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.995 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.67 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.352 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.655 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Danazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.937 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.763 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.675 [FDR-adjusted p-Value=0.037] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.823 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Clostridium sp. |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.724 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.867 [FDR-adjusted p-Value=0.022] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.32 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.068 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.1 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.523 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.841 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.955 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.708 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.407 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.848 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.248 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.84 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.048 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.744 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.042 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.687 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.783 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.833 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.968 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.611 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.32 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.227 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.44 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.804 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.024 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.912 [FDR-adjusted p-Value=0.026] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.086 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.877 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.491 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.817 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.831 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.717 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.158 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.367 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Odoribacter splanchnius |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.638 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.433 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.12 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.345 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.595 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.46 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.291 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.178 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.41 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.138 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium difficile 120 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.67 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.406 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.404 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.57 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.716 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.131 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.916 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.244 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.117 [FDR-adjusted p-Value=0.048] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.334 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.709 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Tenatoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.928 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.109 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.531 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.103 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.76 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.572 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.686 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.301 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.649 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.671 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.733 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.947 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.983 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.5 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.028 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.156 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerostipes sp. |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.414 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.609 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.062 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.408 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.373 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.668 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.97 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.147 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.801 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.671 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.378 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.635 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.38 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.096 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.521 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.22 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.556 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.423 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.089 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.92 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.898 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.645 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.042] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.183 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Odoribacter splanchnius |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.166 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.863 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.529 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.676 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.927 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.216 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.259 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.117 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.366 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.709 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium difficile 120 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.065 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.642 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.583 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.576 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.595 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.215 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.392 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.268 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.246 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Diacetamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.28 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.156 [FDR-adjusted p-Value=0.038] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.966 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.873 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.453 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.013 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.812 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Clostridium sp. |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.563 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.397 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.517 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.289 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.345 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.183 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.458 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.355 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.371 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.558 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.065 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.334 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.464 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Anaerostipes sp. |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.374 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.584 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.412 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.3 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.385 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.391 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.844 [FDR-adjusted p-Value=0.02] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.526 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.901 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.173 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.316 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.874 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.784 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.195 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.467 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.27 [FDR-adjusted p-Value=0.018] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.311 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.146 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.006 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.571 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.505 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.849 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.645 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.733 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Odoribacter splanchnius |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.445 [FDR-adjusted p-Value=0.025] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.543 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.581 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.699 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.776 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.296 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.344 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.443 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium difficile 120 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.615 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.786 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.363 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.249 [FDR-adjusted p-Value=0.029] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.861 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.686 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.601 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.731 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.281 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Artemisinin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.742 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.148 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.706 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.802 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.855 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.448 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.162 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Clostridium sp. |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.005 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.718 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.153 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.851 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.201 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.659 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.61 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.892 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.492 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.986 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.578 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.773 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.513 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.681 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Anaerostipes sp. |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.467 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.362 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.316 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.65 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.463 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.2 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.436 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.415 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.097 [FDR-adjusted p-Value=0.039] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.775 [FDR-adjusted p-Value=0.036] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.071 [FDR-adjusted p-Value=0.023] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.503 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.67 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.396 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.628 [FDR-adjusted p-Value=0.035] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.499 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.014 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.563 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.246 [FDR-adjusted p-Value=0.041] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.067 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.804 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.496 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.786 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.449 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.045 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.212 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.419 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.679 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.287 [FDR-adjusted p-Value=0.045] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.319 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.391 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.987 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.875 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.814 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.944 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Clostridium difficile 120 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.527 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.421 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.418 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.794 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.716 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.222 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.207 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.66 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.531 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.654 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.87 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.612 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.102 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.027 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.233 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.813 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.878 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.22 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.378 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.752 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.091 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.989 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-12.105 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.313 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.466 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.173 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.431 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.122 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.718 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.5 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.186 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Anaerostipes sp. |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.204 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.255 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.885 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.422 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.311 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.728 [FDR-adjusted p-Value=0.031] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.452 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.686 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.712 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.324 [FDR-adjusted p-Value=0.032] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.654 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.456 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.716 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.49 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.584 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.081 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.328 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.122 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.549 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.863 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.547 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.23 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.41 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.369 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.192 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.472 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.201 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.266 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.587 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Odoribacter splanchnius |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.678 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.639 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.854 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.863 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.33 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.0 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.708 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.324 [FDR-adjusted p-Value=0.027] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.482 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.339 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.438 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.176 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium difficile 120 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.146 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.462 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.412 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.394 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.531 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.5 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.735 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.213 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.349 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.329 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.467 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.69 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.127 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.295 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.788 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.796 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.658 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.571 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.068 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sp. |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.955 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.441 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.52 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.869 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.412 [FDR-adjusted p-Value=0.015] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.969 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.142 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.785 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.529 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.657 [FDR-adjusted p-Value=0.019] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.488 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.949 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.2 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Anaerostipes sp. |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.127 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.673 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.432 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.41 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.326 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.147 [FDR-adjusted p-Value=0.011] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.965 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.968 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.823 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.304 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.47 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.297 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.973 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.704 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.711 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.726 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.622 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.618 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.254 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.301 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.758 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.454 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.289 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.754 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.645 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.417 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.905 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Odoribacter splanchnius |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.588 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.235 [FDR-adjusted p-Value=0.014] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.954 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.768 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.734 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.71 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.074 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.528 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.385 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.445 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.393 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium difficile 120 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.216 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.383 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.233 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.234 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.345 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.014 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.95 [FDR-adjusted p-Value=0.009] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.492 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.196 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.862 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.808 [FDR-adjusted p-Value=0.013] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Melphalan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.753 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides caccae ATCC43185 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.773 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Escherichia coli BW25113 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.945 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium ramosum DSM1402 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.55 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bifidobacterium adolescentis ATCC 15703 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.373 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides eggerthii DSM20697 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.959 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Blautia hansenii DSM20583 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.119 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Clostridium sp. |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.079 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Ruminococcus gnavus ATCC29149 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.484 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides dorei DSM17855 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.711 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides cellulosilyticus DSM14838 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.503 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides vulgatus ATCC8482 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.705 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Collinsella aerofaciens ATCC25986 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.12 [FDR-adjusted p-Value=0.016] |
PMID:31158845 |
|
Clostridium hathewayi DSM13479 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.579 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Anaerococcus hydrogenalis DSM7454 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.747 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium scindens ATCC35704 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.42 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Anaerotruncus colihominis DSM17241 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.17 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Clostridium bolteae ATCCBAA-613 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.643 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium symbiosum ATCC14940 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.399 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides finegoldii DSM17565 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.707 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Parabacteroides johnsonii DSM18315 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.462 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Anaerostipes sp. |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.543 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Eubacterium ventriosum ATCC27560 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Ruminococcus lactaris ATCC29176 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.181 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Proteus penneri ATCC35198 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.443 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Edwardsiella tarda ATCC23685 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.542 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Dorea formicigenerans ATCC27755 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Enterobacter cancerogenus ATCC35316 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Providencia stuartii ATCC25827 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.09 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Clostridium spiroforme DSM1552 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.853 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides intestinalis DSM17393 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.116 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Parabacteroides distasonis ATCC8503 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.99 [FDR-adjusted p-Value=0.012] |
PMID:31158845 |
|
Bacteroides pectinophilus ATCC43243 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.76 [FDR-adjusted p-Value=0.03] |
PMID:31158845 |
|
Pretovella copri DSM18205 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.312 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium asparagiforme DSM15981 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.948 [FDR-adjusted p-Value=0.017] |
PMID:31158845 |
|
Bifidobacterium breve DSM20213 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.484 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Coprococcus comes ATCC27758 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.892 [FDR-adjusted p-Value=0.021] |
PMID:31158845 |
|
Eubacterium hallii DSM3353 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Bifidobacterium longum subsp. Infantis CCUG52486 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.468 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Ruminococcus torques ATCC27756 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Bacteroides fragilis NCTC 9343 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.307 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides xylanisolvens DSM18836 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.779 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Lactobacillus reuteri CF48-3A BEI HM-102 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.879 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides uniformis ATCC8492 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.232 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides stercoris ATCC43183 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bifidobacterium ruminatum |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.706 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Akkermansia muciniphila ATCC BAA-835 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Providencia alcalifaciens DSM30120 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.112 [FDR-adjusted p-Value=0.04] |
PMID:31158845 |
|
Providencia rettgeri DSM1131 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.788 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Collinsella intestinalis DSM13280 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.406 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Blautia luti DSM14534 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.642 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Roseburia intestinalis L1-82 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.147 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Odoribacter splanchnius |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.449 [FDR-adjusted p-Value=0.002] |
PMID:31158845 |
|
Bacteroides ovatus ATCC8483 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.952 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Parabacteroides merdae ATCC43184 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.709 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides coprophilus DSM18228 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides WH2 WH2 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.006] |
PMID:31158845 |
|
Eubacterium rectale ATCC33656 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.421 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Subdoligranulum variabile DSM15176 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.337 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Clostridium sporogenes ATCC15579 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.01] |
PMID:31158845 |
|
Enterococcus faecalis V583 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.065 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bryantia formatexigens DSM 14469 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.008] |
PMID:31158845 |
|
Alistipes indistinctus DSM 22520 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.689 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Eubacterium biforme DSM3989 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.387 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Clostridium difficile 120 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.87 [FDR-adjusted p-Value=0.007] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron VPI-5482 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.729 [FDR-adjusted p-Value=0.005] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 3731 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.835 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides thetaiotaomicron 7330 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.624 [FDR-adjusted p-Value=0.004] |
PMID:31158845 |
|
Bacteroides fragilis 3397 T10 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.695 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Salmonella typhimurium LT2 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.086 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Eggerthella lenta ATCC25559 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.188 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Victivallis vadensis ATCC BAA-548 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.024] |
PMID:31158845 |
|
Bacteroides fragilis T(B)9 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.069 [FDR-adjusted p-Value=0.001] |
PMID:31158845 |
|
Bacteroides fragilis DS-208 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Bacteroides fragilis HMW610 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.267 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis HMW615 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.621 [FDR-adjusted p-Value=0.003] |
PMID:31158845 |
|
Bacteroides fragilis ATCC43859 |
Pantoprazole |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
n.a. |
n.a. |
In vitro |
n.a. |
Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.158 [FDR-adjusted p-Value=0.0] |
PMID:31158845 |
|
Gordonibacter urolithinfaciens sp. nov |
Pedunculagin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Ellagic acid; urolithin A, B, C and D" |
n.a. |
n.a. |
n.a. |
n.a. |
"DOI: 10.1016/j.foodres.2011.04.027; PMID:24744017 |
|
Chaetomium spp. |
Baicalin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"4?5,6,7-tetrahydroxyflavone; 5,7-dihydroxy-6-methoxxyflavone" |
n.a. |
n.a. |
n.a. |
n.a. |
"; DOI: 10.1016/j.molcatb.2007.08.009"
|
|
Bacteroides fragilis subspp. Thetaotus |
Shikonin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Anhydroalkannin; deoxyshikonin; cycloshikonin; metaboshikonin I; metaboshikonin II; shikometabolins A; B, C, D and E" |
n.a. |
n.a. |
n.a. |
n.a. |
"; DOI: 10.1016/S0040-4020(01)81108-X"
|
|
Bacteroides thetaiotaomicron |
Pectin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Nogalacturonic acid; SCFAs" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:10742206 |
|
Eubacterium spp. SDG-2 |
Secoisolariciresinol diglucoside |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11086885 |
|
Peptostreptococcus spp. SDG-1 |
Secoisolariciresinol diglucoside |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11086885 |
|
Eubacterium spp. SDG-2 |
Caffeic acid |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Dihydrocaffeic acid; m-hydroxyphenylpropionic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11767089 |
|
Bacteroides spp. |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11824558 |
|
Bifidobacterium spp. |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11824558 |
|
Eubacterium spp. |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11824558 |
|
Clostridium butyricum |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Bifidobacterium adolescentis |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Bacteroides fragilis subspp. Thetaotus |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Clostridium innocuum ES 24-06 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Fusobacterium nucleatum G-470 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Peptostreptococcus anaerobius 0240 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Peptostreptococcus intermedius EBF 77/25 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Proteus mirabillis S2 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Ruminococcus spp. P01-3 |
Phorbol |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Isophorbol; deoxyphorbol; 4920-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 49a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 49a,20-trihydroxy-14(13?2)-abeo12aH-1,6-tigliadiene-3,13-dione" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:11848202 |
|
Butyrivibrio fibrisolvens |
Linoleic acid |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:17644775 |
|
Butyrivibrio proteoclasticus |
Linoleic acid |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:17644775 |
|
Bacteroides intestinalis AM-1 |
Chenodeoxycholic acid |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
7-oxo-lithocholic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:19243441 |
|
Bacteroides intestinalis AM-1 |
Cholic acid |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
7-oxo-deoxycholic acid |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:19243441 |
|
Eggerthella sp. Julong732 |
Dihydrodaidzein |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
(3S)-equol |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:19304836 |
|
Bacteroides fragilis |
Geniposide |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Genipin |
Increase Toxicity |
n.a. |
n.a. |
n.a. |
PMID:22553067 |
|
Bifidobacterium longum HY8001 |
Geniposide |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Genipin |
Increase Toxicity |
n.a. |
n.a. |
n.a. |
PMID:22553067 |
|
Enterobacter cloacae |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Dihydroberberine |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:26174047 |
|
Escherichia coli |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Dihydroberberine |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:26174047 |
|
Staphylococcus aureus |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Dihydroberberine |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:26174047 |
|
Enterococcus faecalis |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Dihydroberberine |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:26174047 |
|
Enterococcus faecium |
Berberine |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
Dihydroberberine |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:26174047 |
|
Bacteroides JY-6 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium longum H-1 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium breve K-110 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium K-506 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Prevotella oris |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium longum H-1 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium breve K-110 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium K-506 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Prevotella oris |
Ginsenoside Rb2 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium longum H-1 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium breve K-110 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium K-506 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Prevotella oris |
Ginsenoside Rc |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside compound K |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Re |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides stercoris HJ-15 |
Ginsenoside Re |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Re |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Re |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rf |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides stercoris HJ-15 |
Ginsenoside Rf |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rf |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rf |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rg1 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides stercoris HJ-15 |
Ginsenoside Rg1 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rg1 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rg1 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"protopanaxatriol; ginsenoside F1; ginsenoside Rh1" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium longum H-1 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium breve K-110 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium K-506 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Prevotella oris |
Ginsenoside Rg3 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh2 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides JY-6 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium longum H-1 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium breve K-110 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bifidobacterium K-506 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Eubacterium A-44 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Fusobacterium K-60 |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Prevotella oris |
Ginsenoside Rg5 |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
ginsenoside Rh3 |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Bacteroides spp. |
Ginsenosides |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Lactobacillus spp. |
Ginsenosides |
Therapeutic Substance |
Investigational Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:29983606 |
|
Lacrimispora sphenoides |
Sennoside A |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"8-glucosylrheinanthrone; rheinanthrone; sennidin" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:3368516 |
|
[Eubacterium] rectale |
Sennoside A |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"8-glucosylrheinanthrone; rheinanthrone; sennidin" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:3368516 |
|
Eubacterium spp. |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
Dihydrodigoxin |
Decrease Toxicity |
n.a. |
n.a. |
n.a. |
PMID:7266632 |
|
Streptococcus S-2 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
Increase Bioavailability |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Bacteroides J-37 |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
"Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Eubacterium A-44 |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
"Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Fusobacterium K-60 |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Investigational Drug; Medicinal Herbal Compounds" |
n.a. |
"Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Bacteroides JY-6 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Eubacterium YK-4 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Feptostreptoccous YK-10 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Fusobacterium K-60 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Lactobacillus L-2 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Streptococcus S-2 |
Naringin |
Herbal Substance |
Medicinal Herbal Compounds |
n.a. |
"Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Bacteroides JY-6 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Bifidobacterium B-9 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Eubacterium YK-4 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Fusobacterium K-60 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Lactobacillus L-2 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
"Approved Drug; Medicinal Herbal Compounds" |
n.a. |
"Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" |
n.a. |
n.a. |
n.a. |
n.a. |
PMID:9875509 |
|
Absiella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella dolichum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella innocuum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000163515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Absiella sp000165065 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp003447295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066365 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetatifactor sp900066565 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetivibri A ethanolgignens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetomicrobium hydrogeniformans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetomicrobium hydrogeniformans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetomicrobium hydrogeniformans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acetomicrobium hydrogeniformans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Achromobacter xylosoxidans |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcaceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus fermentans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus fermentans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus fermentans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus fermentans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus intestini |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus intestini |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus intestini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus intestini |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp000437815 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp000437815 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp000437815 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp000437815 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp900291475 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp900291475 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp900291475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus sp900291475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidaminococcus timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D sp000302535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acidovorax D temperans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter baumannii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter fasciculus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter johnsonii |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter johnsonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter johnsonii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter johnsonii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter junii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter nosocomialis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter pittii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter radioresistens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp000369785 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter sp002934695 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acinetobacter ursingii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobacteria |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinobaculum massiliense |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces graevenitzii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces graevenitzii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces sp900323545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces urogenitalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomyces viscosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Actinomycetaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000432995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter sp000435395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacter timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Acutalibacteraceae |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Adlercreutzia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Adlercreutzia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Adlercreutzia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Adlercreutzia equolifaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromicrobium A massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas caviae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas dhakensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas hydrophila |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas rivipollensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aeromonas veronii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Afipia broomeae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter faecis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter rectalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobacter sp000434275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum butyriciproducens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum desmolans |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum desmolans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum desmolans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum desmolans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Agathobaculum sp900291975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aggregatibacter segnis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila |
Abiraterone |
Therapeutic Substance |
prostate cancer |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia muciniphila C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Akkermansia sp001580195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aliarcobacter butzleri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aliarcobacter butzleri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A ihumii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A indistinctus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes A sp900240235 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes finegoldii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes obesi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes onderdonkii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulfapyridine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes putredinis |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes shahii |
CpG oligodeoxynucleotides |
Therapeutic Substance |
oligodeoxynucleotides |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp000434235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp001941065 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002161445 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp002358415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900021155 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900083545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes sp900290115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alistipes timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Allisonella histaminiformans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloprevotella tannerae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloprevotella tannerae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloprevotella tannerae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloprevotella tannerae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloprevotella tannerae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Alloscardovia omnicolens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobic |
Sulphinpyrazone |
Therapeutic Substance |
anti-inflammatory |
n.a. |
Sulphide formation |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobic |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
Sulphide formation |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobic |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobic Bacterium(Mt1B8) |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
Dihydrodaidzein, equol |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
anaerobic cecal florn |
Misonidazole |
Therapeutic Substance |
Tumor Hypoxia |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerobiospirillum succiniciproducens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus vaginalis B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus hydrogenalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus lactolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus lactolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus obesiensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus obesiensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus obesiensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus obesiensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus obesiensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus octavius |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus octavius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus octavius |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus octavius |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus octavius |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus prevotii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus rubeinfantis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp001182725 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp002359915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerococcus sp900258475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerocolumna aminovalerica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis stercorihominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis stercorihominis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis stercorihominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerofustis stercorihominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus geminatus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus massiliensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus micronuciformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus micronuciformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus micronuciformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus micronuciformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus sp900240295 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus sp900240295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeroglobus sp900240295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp001305115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp002159845 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp002159845 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp002159845 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp002159845 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaeromassilibacillus sp002159845 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosalibacter A massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporobacter mobilis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporomusa |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporomusa |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporomusa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerosporomusa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes caccae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes hadrus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp000508985 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerostipes sp900066705 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum lactatifermentans |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum lactatifermentans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum lactatifermentans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum lactatifermentans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum lactatifermentans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp000436415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp000436415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp000436415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp000436415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotignum sp001304995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus colihominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus rubiinfantis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus sp900199635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus sp900199635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus sp900199635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus sp900199635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerotruncus sp900199635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovibrio |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovibrio |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovibrio |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovibrio |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Anaerovoracaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aneurinibacillus aneurinilyticus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aneurinibacillus aneurinilyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aneurinibacillus aneurinilyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Aneurinibacillus aneurinilyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Angelakisella sp003453215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arabia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Arcanobacterium A urinimassiliense |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atlantibacter hermannii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobiaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Atopobium minutum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A cereus AD |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A sp001884105 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A thuringiensis S |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A thuringiensis S |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A thuringiensis S |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A thuringiensis S |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A thuringiensis S |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus A wiedmannii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AC sp900199695 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD massilioanorexius |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD massilioanorexius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD massilioanorexius |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD massilioanorexius |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD testis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD testis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD testis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus AD testis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BD tuaregi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BE massilionigeriensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BE massilionigeriensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BE massilionigeriensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus BE massilionigeriensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus D sp000821085 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus E coagulans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus E coagulans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus E coagulans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus E coagulans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus E coagulans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus J andreraoultii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus K alcalophilus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus licheniformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus O smithii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus O smithii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus O smithii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus O smithii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus O smithii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus paralicheniformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus Q timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sonorensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus sp. 5-2 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus subtilis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus V massiliosenegalensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus V massiliosenegalensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus V massiliosenegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus V massiliosenegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus V massiliosenegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W jeddahensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W rubiinfantis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W rubiinfantis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W rubiinfantis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus W rubiinfantis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus X simplex |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus X simplex |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus X simplex |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacillus X simplex |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriodes uniformans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
quercetin-aglycone and polyphenols |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) |
Therapeutic substance |
negative regulators of T cell proliferation and functions |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Nitrazepam |
Therapeutic Substance |
anticonvulsant and hypnotic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Omeprazole |
Therapeutic Substance |
gastric acid-related disorders |
n.a. |
Production of corresponding sulfide metabolites |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
bacteroides |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
lactic and acetic acids |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
(E)-5-(2-bromovinyl)uracil |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Glucuronides |
Environmental Chemicals |
Environmental Substance |
n.a. |
diclofenac,ketoprofen,indomethacin |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron E50,VPI 5482,DSM 2079,ATCC 29148,NCTC 10582 |
Rosiglitazone |
Therapeutic substance |
Anti-diabetics |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron E50,VPI 5482,DSM 2079,ATCC 29148,NCTC 10582 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis CL03T00C23,HM-715 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis CL03T00C23,HM-715 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis CL03T12C37,HM-716 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A barnesiae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprocola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A coprophilus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A ilei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A mediterraneensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A plebeius A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A salanitronis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000432735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000434735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp000436795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161565 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp002161765 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides A sp900066455 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides acidifaciens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B dorei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sartorii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides B sp002493165 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides bouchesdurhonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulfapyridine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides caccae |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cellulosilyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides clarus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides congonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides cutis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Genistin |
Therapeutic substance |
Anti-cancer, estrogenic and antiatherosclerotic |
n.a. |
genistein |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides eggerthii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides F pectinophilus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides F pectinophilus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides F pectinophilus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Naringin |
Therapeutic Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides faecis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides finegoldii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fluxus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
antibiotic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Ipilimumab |
Therapeutic Substance |
a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis |
Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) |
Therapeutic substance |
negative regulators of T cell proliferation and functions |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides fragilis A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides gallinarum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides graminisolvens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides intestinalis |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ndongoniae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides neonati |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides nordii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides oleiciplenus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides ovatus |
Brivudine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
bromovinyluracil (BVU) |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides plebeius |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides plebeius |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides plebeius |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides plebeius |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides pyogenes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides salyersiae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp.22 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp002491635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides sp003545565 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercorirosoris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides stercoris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Ipilimumab |
Therapeutic Substance |
a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) |
Therapeutic substance |
negative regulators of T cell proliferation and functions |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Brivudine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
bromovinyluracil (BVU) |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides thetaiotaomicron |
Thiopurines |
Therapeutic substance |
compound |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides togonis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Genistein |
"Therapeutic Substance; Herbal Substance" |
antineoplastic and antitumor |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
(E)-5-(2-bromovinyl)uracil |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Vorinostat |
Therapeutic substance |
Anti-cancer |
n.a. |
vorinostat-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides uniformis |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides vulgatus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides vulgatus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroides xylanisolvens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidetes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidetes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidetes |
Ipilimumab |
Therapeutic Substance |
a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteroidetes |
Checkpoint inhibitor therapy |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bariatricus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella intestinihominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp002159975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiella sp003150885 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Barnesiellaceae |
Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) |
Therapeutic substance |
negative regulators of T cell proliferation and functions |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Beduini massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
bifidobacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
PD-1 inhibitors |
Therapeutic substance |
unknown |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) |
Therapeutic substance |
immune checkpoint repressing T cell response |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
lactic acid,acetic acid |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium |
Glucuronides |
Environmental Chemicals |
Environmental Substance |
n.a. |
diclofenac,ketoprofen,indomethacin |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis subsp.lactis BI-07 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis subsp.lactis BI-07 |
Rosiglitazone |
Therapeutic substance |
Anti-diabetics |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis subsp.lactis BI-07 |
Ezetimibe |
Therapeutic Substance |
Lipid modifying agents |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis subsp.lactis BI-07 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium longum subsp. infantis S12,DSM 20088,ATCC 15697,NCTC 11817 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium adolescentis |
Vorinostat |
Therapeutic substance |
Anti-cancer |
n.a. |
vorinostat-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium angulatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium animalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium bifidum |
Gliadin |
Therapeutic substance |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium bifidum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium bifidum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium breve |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium catenulatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium dentium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallicum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium gallinarum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium infantis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium lacrimalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium lacrimalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium lacrimalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudocatenulatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pseudolongum A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium pullorum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium ruminantium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium scardovii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium sp002742445 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium thermacidophilum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale E |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale F |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale G |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale G |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bifidobacterium vaginale G |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bilophila |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bilophila |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bilophila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bilophila |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bilophila wadsworthia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bittarella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blastococcus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hansenii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia hominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia producta |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000432195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp000436935 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp001304935 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp002161285 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp003287895 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia sp900120295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A hydrogenotrophica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A hydrogenotrophica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A hydrogenotrophica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A hydrogenotrophica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BlautiaA hydrogenotrophica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A obeum B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000285855 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp000433815 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066145 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066165 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066205 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900066505 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A sp900120195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Blautia A wexlerae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Caulobacteraceae g BOG-935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira pilosicoli |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brachyspira sp000431595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp000015165 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bradyrhizobium sp003020075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
BrevibacilluC massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Brevibacterium senegalense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Burkholderia cepacia |
Ipilimumab |
Therapeutic Substance |
a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butrivibrio sp. |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
quercetin-aglycone and polyphenols |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus A sp002395695 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricicoccus pullicaecorum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp002161485 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900184685 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900184685 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900184685 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900184685 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas sp900258545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas synergistica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyricimonas virosa |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A crossotus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A crossotus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A crossotus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A sp000431815 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Butyrivibrio A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g C941 s C941 sp900321725 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caecibacter massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae g CAG-115 s CAG-115 sp000432175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g CAG-1427 s CAG-1427 sp000436075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f DTU072 g CAG-1782 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-279 s CAG-279 sp000437795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp000431795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp000431795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-354 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-417 s CAG-417 sp000432835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-417 s CAG-417 sp000432835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-433 s CAG-433 sp000433675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-433 s CAG-433 sp000433675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-451 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-451 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-451 s CAG-451 sp000438295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-451 s CAG-451 sp000438295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000438075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000438075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp000437495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp001701295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002361235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp002491165 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-485 s CAG-485 sp900321585 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-533 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-533 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacilli o RF39 f CAG-1000 g CAG-582 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacilli o RF39 f CAG-1000 g CAG-582 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-582 s CAG-582 sp000435515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-582 s CAG-582 sp000435515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-594 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-594 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-594 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-594 s CAG-594 sp000434835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-433 g CAG-594 s CAG-594 sp000434835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-628 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-628 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-628 s CAG-628 sp003524085 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-628 s CAG-628 sp003524085 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-762 s CAG-762 sp000432575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g CAG-762 s CAG-762 sp000432575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 s CAG-776 sp000438195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g CAG-776 s CAG-776 sp000438195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae g CAG-81 s CAG-81 sp900066535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp001701165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp001701165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp001701165 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp001701165 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp001701165 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g CAG-873 s CAG-873 sp002493945 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-878 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-878 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g CAG-964 A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter fetus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter hyointestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus F |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus G |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus I |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus K |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus L |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus P |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus Q |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus R |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A concisus W |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter A curvus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter B ureolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D coli |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D coli A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D coli B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Campylobacter D jejuni |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Capnocytophaga ochracea |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cardiobacterium valvarum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catabacter hongkongensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium mitsuokai |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Catenibacterium sp000437715 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Caulobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Bacteriovoracia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cedecea davisae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulomonas timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cellulosilyticum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Centipeda artemidis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Centipeda artemidis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Centipeda artemidis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Centipeda artemidis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Centipeda artemidis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cetobacterium A somerae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella minuta |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella sp001678845 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenella A timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Christensenellales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium gambrini |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Chryseobacterium B bovis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter braakii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter europaeus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter freundii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter pasteurii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter portucalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter werkmanii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A amalonaticus D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter A farmeri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Citrobacter B koseri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus evryensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cloacibacillus porcorum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
Amphetamine, norephedrine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Balsalazide |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Ipsalazide |
Therapeutic Substance |
unknown |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridia |
Olsalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridiaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Antibiotic |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridioides difficile A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Nitrazepam |
Therapeutic Substance |
anticonvulsant and hypnotic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
Amphetamine, norephedrine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Balsalazide |
Therapeutic Substance |
anti-inflammatory |
n.a. |
5-aminosalicylic acid |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Olsalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium |
Glucuronides |
Environmental Chemicals |
Environmental Substance |
n.a. |
diclofenac,ketoprofen,indomethacin |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium bolteae WAL 16351,DSM 15670,ATCC BAA-613,CCUG 46953 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium bolteae WAL 16351,DSM 15670,ATCC BAA-613,CCUG 46953 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium ramosum 113-I,VPI 0427,DSM 1402,ATCC 25582,NCIB 10673 |
Rosiglitazone |
Therapeutic substance |
Anti-diabetics |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium baratii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium bolteae |
Hydrocortisone acetate |
Therapeutic Substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
hydrocortisone |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium bolteae |
Dasatinib |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium butyricum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium celatum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium difficile |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium difficile |
Paracetamol |
Therapeutic substance |
first-line therapy in pain |
n.a. |
Acetaminophen sulfate |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium disporicum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium leptum |
Nitrazepam |
Therapeutic Substance |
anticonvulsant and hypnotic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium leptum |
Clonazepam |
Therapeutic Substance |
Central nervous system agents |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium neonatale |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium nigeriense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium paraputrificum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium perfringens |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
antibiotic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium perfringens |
Misonidazole |
Therapeutic Substance |
Tumor Hypoxia |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium ramosum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium saudiense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium scindens |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium scindens |
Dexamethasone |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium septicum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
Dihydrodaidzein, equol |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp.HGH 136 |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
Dihydrodaidzein, equol |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp000435835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp001916075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp001916075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp001916075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sp001916075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium sporogenes |
Zonisamide |
Therapeutic Substance |
anticonvulsant |
n.a. |
2-sulfamoyalcetylphenol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium tertium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium A leptum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium AA polynesiense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B tyrobutyricum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B tyrobutyricum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B tyrobutyricum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium B tyrobutyricum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E jeddahense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E merdae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium E sporosphaeroides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum A |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F botulinum A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F niameyense |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F niameyense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F niameyense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F niameyense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F tepidum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F tepidum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F tepidum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium F tepidum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G cochlearium |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G cochlearium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G cochlearium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G cochlearium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G tetani |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G tetani |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G tetani |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G tetani |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium G tetani |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium H massiliodielmoense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium H massiliodielmoense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium H massiliodielmoense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium H massiliodielmoense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J ihumii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J ihumii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J ihumii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J ihumii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J ihumii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J senegalense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium J sp000821305 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium L amazonitimonense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M asparagiforme |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M bolteae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M citroniae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M clostridioforme A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M lavalense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000155435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp000431375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium M sp001517625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P mediterraneense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P perfringens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P sp001403635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P ventriculi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P ventriculi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P ventriculi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P ventriculi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium P ventriculi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q saccharolyticum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q saccharolyticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q saccharolyticum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q saccharolyticum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q saccharolyticum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp000435655 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp003024715 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp003024715 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp003024715 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q sp003024715 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q symbiosum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q symbiosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q symbiosum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q symbiosum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium Q symbiosum |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U hiranonis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U hiranonis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U hiranonis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium U hiranonis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X cadaveris |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X cadaveris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X cadaveris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X cadaveris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Clostridium X cadaveris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mahellia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g COE1 sp001916965 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cohnella sp900169535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens F |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella aerofaciens |
Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) |
Therapeutic substance |
immune checkpoint repressing T cell response |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella bouchesdurhonensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella bouchesdurhonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella bouchesdurhonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella bouchesdurhonensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella ihuae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella intestinalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella phocaeensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella provencensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000434535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp000763055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002232035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp002391315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella sp003487125 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella stercoris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella tanakaei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Collinsella vaginalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic agent |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
5-fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
5-fluorouridine monophospate |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Camptothecin |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Etoposide |
"Therapeutic Substance; Herbal Substance" |
Therapeutic Substance |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Methotrexate |
Therapeutic Substance |
chemotherapeutic |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Temozolomide |
Therapeutic Substance |
antitumor |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
5-fluoro-2'-deoxyuridine |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Neocarzinostatin |
Therapeutic substance |
compound |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Sunitinib |
Therapeutic substance |
multi-targeted receptor tyrosine kinase (RTK) inhibitor |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas |
Tamoxifen |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas kerstersii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas kerstersii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Comamonas kerstersii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacillus cateniformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter fastidiosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprobacter secundus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A catus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A catus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A catus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A catus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus A catus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus B comes |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus comes VPI CI-38,ATCC 27758 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus eutactus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000154245 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp000433075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coprococcus sp900066115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Coriobacteriales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium afermentans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium ammoniagenes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium amycolatum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium aurimucosum E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium bouchesdurhonense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium glucuronolyticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kefirresidentii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kroppenstedtii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kroppenstedtii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium kroppenstedtii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium phoceense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium propinquum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium provencense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium simulans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp000755185 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium sp900169525 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Corynebacterium striatum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Criibacterium bergeronii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter malonaticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
Monosaccharides |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cronobacter sakazakii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cupriavidus metallidurans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium acnes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium avidum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium granulosum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium granulosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium granulosum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Cutibacterium granulosum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g D5 s D5 sp900113995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g D5 s D5 sp900113995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g D5 s D5 sp900113995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g D5 s D5 sp900113995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dakarella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dechloromonas |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dechloromonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dechloromonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dechloromonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dermabacter hominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfitobacterium hafniense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans A |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Arsenic |
Environmental Chemicals |
Environmental Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio desulfuricans |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio fairfieldensis |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio piger A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio sp002159665 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio sp002159665 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio sp900319575 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio sp900319575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Desulfovibrio sp900319575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister invisus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister invisus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp000434475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp000434475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp002320515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp002320515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp900343095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister sp900343095 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister succinatiphilus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister succinatiphilus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister A pneumosintes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dialister A pneumosintes |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma fastidiosa |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma fastidiosa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma fastidiosa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma fastidiosa |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma fastidiosa |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dielma sp001305055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
digoxin |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea faecis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea formicigenerans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea formicigenerans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea formicigenerans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea formicigenerans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea formicigenerans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea hylemonae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea longicatena B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea phocaeense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea scindens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000433535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp000765215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp001185345 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900066765 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900086625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900240315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dorea sp900312975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Saccharofermentanales f DTU023 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g DTU089 A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
DTU089 A sp002440045 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Firmicutes G c SHA-98 o DTUO25 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Firmicutes G c SHA-98 o DTUO25 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001689425 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duncaniella sp001701225 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Duodenibacillus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas capnocytophagoides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas gadei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas mossii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Dysgonomonas sp900079735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Edwardsiella tarda |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella lenta |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella lenta |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella lenta |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella lenta |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthella lenta |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eggerthellaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eikenella corrodens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella sp900066775 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eisenbergiella tayi |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Elusimicrobiaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia sp900066695 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia sp900066695 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia sp900066695 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia sp900066695 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Emergencia timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enorma massiliensis A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter bugandensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cancerogenus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae H |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter cloacae K |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter himalayensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter kobei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter ludwigii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter mori |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter nimipressuralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter sesami |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter A timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacter D kobei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacteriaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterobacteriales |
Acetylsalicylic acid |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A avium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A devriesei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A gilvus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A pallens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A raffinosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus A sp002140655 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B durans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B faecium B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B hirae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B pernyi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B pernyi |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B pernyi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B pernyi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus B pernyi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C asini |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C dispar |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus C massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D casseliflavus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D gallinarum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus D sp002850555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus G italicus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
Amphetamine, norephedrine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
compound |
n.a. |
3,4-dihydroxyphenylacetic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus |
Chloroacetic acid |
Therapeutic substance |
Antioxidant |
n.a. |
haloacetic-acids |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus |
Acetylsalicylic acid |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus caccae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus casseliflavus |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
Monosaccharides |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus casseliflavus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
Monosaccharides |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecalis |
Thiopurines |
Therapeutic substance |
compound |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus faecium |
Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) |
Therapeutic substance |
immune checkpoint repressing T cell response |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterococcus hirae |
Cyclophosphamide |
Therapeutic Substance |
lymphoma and leukemia |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enterolignans |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
Dihydrodaidzein, equol |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enteroscipio rubneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enteroscipio rubneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Enteroscipio rubneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp000765235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp000765235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp003522105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp003522105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp003522105 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp003522105 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp003522105 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp900317525 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp900317525 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp900317525 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp900317525 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g ER4 s ER4 sp900317525 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium ramosum |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium saccharogumia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp000752095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp000752095 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp000752095 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp002160495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp003024675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium sp003024675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelatoclostridium spiroforme |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Erysipelotrichaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia albertii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
lactic and acetic acids |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
bacteriostatic |
n.a. |
toxic-metabolites |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
trifluorothymine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Doxifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
5-fluorouracil |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Tretazicar(CB1954) |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Metformin |
"Therapeutic Substance; Herbal Substance" |
Cardiac drugs |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
NSAIDs |
Therapeutic Substance |
compound |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Paclitaxel |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic agent |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
5-fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
5-fluorouridine monophospate |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
5-fluoro-2'-deoxyuridine |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Camptothecin |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Cladribine |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Etoposide |
"Therapeutic Substance; Herbal Substance" |
Therapeutic Substance |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
5-fluorocytosine |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
AQ4N |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Tretazicar |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Daunorubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Fludarabine de phosphate |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Idarubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Menadione |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Mitoxantrone |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Tegafur |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Vidarabine |
Therapeutic substance |
antiviral |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Methotrexate |
Therapeutic Substance |
chemotherapeutic |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Temozolomide |
Therapeutic Substance |
antitumor |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Neocarzinostatin |
Therapeutic substance |
compound |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Sunitinib |
Therapeutic substance |
multi-targeted receptor tyrosine kinase (RTK) inhibitor |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli |
Tamoxifen |
Therapeutic substance |
Therapeutic Substance |
n.a. |
n.a. |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli IAI1 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli IAI1 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli ATCC25922 |
Nabumetone |
Therapeutic Substance |
NSAID |
n.a. |
4-(6-methoxy-2-naphthyl)-butan-2-ol |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Amiodarone |
Therapeutic Substance |
anti-arrhythmic |
n.a. |
desethylamiodarone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Tegafur |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Fludarabine de phosphate |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
5-fluorocytosine |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
6-Mercaptopurine-2deoxyriboside |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Banoxantrone(AQ4N) |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Tretazicar(CB1954) |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Cladribine |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
chlorinated purine base |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Vidarabine |
Therapeutic substance |
antiviral |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Daunorubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Idarubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Etoposide phosphate |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Mitoxantrone |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
betaLapachone |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli Nissle 1917 |
Menadione |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia coli D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia fergusonii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia marmotae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Escherichia sp000208585 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacteria |
Balsalazide |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacteria |
Ipsalazide |
Therapeutic Substance |
unknown |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacteria |
Olsalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium |
Nitrazepam |
Therapeutic Substance |
anticonvulsant and hypnotic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium |
Glycyrrhizin |
Herbal Substance |
hepatoprotective |
n.a. |
18-beta-glycyrrhetinic acid |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium |
Balsalazide |
Therapeutic Substance |
anti-inflammatory |
n.a. |
5-aminosalicylic acid |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium |
Olsalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium rectale A1-86,DSM 17629,NCIMB 14373 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium callanderi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium lentum |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium limosum A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium ramulus |
Genistein |
"Therapeutic Substance; Herbal Substance" |
antineoplastic and antitumor |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium ramulus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium ramulus |
Quercetin-3-glucoside |
"Herbal Substance; Dietary Substance" |
compound |
n.a. |
3,4-dihydroxyphenylacetic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium ramulus |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium rectale |
Picosulfuric acid |
Therapeutic Substance |
compound |
n.a. |
free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol] |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium sp. Strain GLH |
Glycyrrhizin |
Herbal Substance |
hepatoprotective |
n.a. |
18-beta-glycyrrhetinic-acid |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium. sp.strain GLH57 |
Glycyrrhizin |
Herbal Substance |
hepatoprotective |
n.a. |
18-beta-glycyrrhetinic acid |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E hallii A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium E sp002161065 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000433735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp000434115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium F sp003491505 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000432355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000434315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G sp000435815 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium G ventriosum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I ramulus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium I sp900066595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium J |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium M |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium M |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium M |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R coprostanoligenes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000431535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000433975 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000434995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp000436835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp002493325 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Eubacterium R sp003526845 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Exiguobacterium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella coagulans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ezakiella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An172 s An172 sp002160515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g An200 s An200 sp003268275 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g 43-108 s 43-108 sp001915545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g An181 s An181 sp002160325 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Megasphaeraceae g 28L s 28L sp000177555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Megasphaeraceae g 28L s 28L sp000177555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Megasphaeraceae g 28L s 28L sp000177555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Synergistaceae g An23 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Synergistaceae g An23 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Synergistaceae g An23 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Synergistaceae g An23 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp000318095 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp000318095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp000318095 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp000318095 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp000318095 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp900095835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp900095835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp900095835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp900095835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g F0040 s F0040 sp900095835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Veillonellaceae g F0422 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Veillonellaceae g F0422 s F0422 sp001553345 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f F082 g F082 s F082 sp002633315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Tacrolimus |
"Therapeutic Substance; Herbal Substance" |
reduce the activity of the patient's immune system |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Clonazepam |
Therapeutic Substance |
Central nervous system agents |
n.a. |
clonazepam-M1 |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Vorinostat |
Therapeutic substance |
Anti-cancer |
n.a. |
vorinostat-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii F |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii G |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii H |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii I |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii J |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium prausnitzii K |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalibacterium sp003449675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena contorta B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena faecis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena fissicatena |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena glycyrrhizinilyticum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena gnavus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena lactaris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena lactaris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena lactaris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena lactaris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena orotica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp000509105 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp001487105 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp002314255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena sp900066545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicatena torques |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalicoccus pleomorphus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Faecalitalea cylindroides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fannyhessea vaginae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria timonensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fenollaria timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fermentimonas massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
FibrobacterA intestinalis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
FibrobacterA intestinalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
FibrobacterA intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
FibrobacterA intestinalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
FibrobacterA intestinalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Filifactor |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Filifactor |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Filifactor |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Filifactor |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna F |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna F |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna F |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna F |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna H |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna H |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna H |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna H |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Finegoldia magna H |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g Firm-07 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g Firm-10 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f Firm-18 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Firmicutes |
Oxaliplatin |
Therapeutic Substance |
chemotherapy agent |
n.a. |
n.a. |
Reduce the side effects of drugs |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Firmicutes |
Cyclophosphamide |
Therapeutic Substance |
lymphoma and leukemia |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Planococcaceae g FJAT-21963 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Planococcaceae g FJAT-21963 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Planococcaceae g FJAT-21963 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Planococcaceae g FJAT-21963 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flaviflexus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flaviflexus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flaviflexus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flaviflexus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavobacterium lindanitolerans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor plautii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor sp900199495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor sp900199495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor sp900199495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor sp900199495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Flavonifractor sp900199495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fournierella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Franconibacter helveticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
fusarium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusicatenibacter saccharivorans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacteria |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
Drugs for acid related disorders |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium animalis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium animalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium animalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium animalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium animalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium massiliense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium massiliense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum E |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium nucleatum E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum D |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium periodonticum D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium polymorphum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium polymorphum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium polymorphum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium polymorphum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium polymorphum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium sp000235465 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium sp000235465 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium sp000235465 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium vincentii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium vincentii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium vincentii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium vincentii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium vincentii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A mortiferum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A mortiferum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A mortiferum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A mortiferum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A mortiferum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A sp900015295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A ulcerans |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium A varium B |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C gonidiaformans |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C gonidiaformans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C gonidiaformans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C gonidiaformans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C gonidiaformans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Fusobacterium C necrophorum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gabonibacter massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Garciella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Garciella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Garciella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilales |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilus phascolarctosicola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilus phascolarctosicola |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilus phascolarctosicola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gastranaerophilus phascolarctosicola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella haemolysans B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella morbillorum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sanguinis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemella sp002871655 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Hydrocortisone |
Therapeutic substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
20beta-dihydrocortisone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulfapyridine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger formicilis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger sp003476825 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gemmiger variabile |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gleimia europaea A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paenibacillaceae g GM2 s GM2 sp900069005 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter pamelaeae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gordonibacter urolithinfaciens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gorillibacterium timonense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gracilibacillus timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella adiacens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Granulicatella sp001071995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Grimontia hollisae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Prontosil |
Therapeutic Substance |
antibacterial |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Saponins |
Therapeutic substance |
compound |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ethanol |
Therapeutic Substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Flucytosine |
Therapeutic Substance |
antifungals |
n.a. |
5-fluorouracil |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Fluoxetine |
"Therapeutic Substance; Herbal Substance" |
inhibitor |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
L-carnitine |
Therapeutic Substance |
compound |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Indicine N-oxide |
Therapeutic substance |
compound |
n.a. |
N-oxide |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Isosorbide dinitrate |
"Therapeutic Substance; Herbal Substance" |
organic nitrates for the treatment of angina pec-toris |
n.a. |
mononitrates and isosorbide |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
L-tryptophan |
Therapeutic Substance |
amino acid |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Metformin |
"Therapeutic Substance; Herbal Substance" |
Cardiac drugs |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Loperamide oxide |
Therapeutic Substance |
Antiiarrheal medication |
n.a. |
n.a. |
LOPOX reductase |
activation |
n.a. |
Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humansn.a. |
PMID:36467581 |
|
Gut microbes |
Mefenamic Acid |
Therapeutic substance |
NSAID |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Methylmercuric chloride |
Therapeutic substance |
compound |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Metoprolol |
Therapeutic Substance |
beta-blocker |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Phosphatidylcholine |
Therapeutic substance |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Phospholipase A2 |
Therapeutic substance |
unknown |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Rosuvastatin |
Therapeutic Substance |
lipid-lowering drug |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac sulfide |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulfinpyrazone |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac sulfide |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Xylose |
Therapeutic Substance |
nutritional usage |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Omeprazole |
Therapeutic Substance |
gastric acid-related disorders |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ranitidine |
"Therapeutic Substance; Herbal Substance" |
Drugs for acid related disorders |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Baicalin |
Herbal Substance |
anti-inflammatory |
n.a. |
baicalein |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulphinpyrazone |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Misonidazole |
Therapeutic Substance |
Tumor Hypoxia |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Insulin |
Therapeutic Substance |
Blood glucose control |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Calcitonin |
Therapeutic Substance |
calcitonin |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Neoprontosil |
Therapeutic Substance |
antinfective |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
Cardiac drugs |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Zonisamide |
Therapeutic Substance |
anticonvulsant |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
m-tyrosine, m-tyramine, m-hydroxyphenylacetic acid |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Hespesidin |
Therapeutic substance |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Hesperetin |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Glyceryl trinitrate |
Therapeutic Substance |
angina pectoris |
n.a. |
Glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, glyceryl-1-mononitrate |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Metronidazole |
"Therapeutic Substance; Herbal Substance" |
antibiotic |
n.a. |
N-(2-hydroxyethyl)-oxamic acid and acetamide |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nizatidine |
Therapeutic Substance |
antiulcerotics |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Olsalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
5-aminosalicylic-acid |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Chloramphenicol |
"Therapeutic Substance; Herbal Substance" |
bacteriostatic |
n.a. |
p-aminphenyl-2-amino-1, 3-propanediol |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
(E)-5-(2-bromovinyl)uracil |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nitrazepam |
Therapeutic Substance |
anticonvulsant and hypnotic |
n.a. |
7-aminonitrazepam |
teratogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
2-Amino-3-methylimidazo(4,5-f)quinoline(IQ) |
Therapeutic substance |
chemicalcompounds |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Arbutin |
Therapeutic Substance |
anti-infective |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Geniposide |
Herbal Substance |
Geniposide has significant effects on digestive system, cardiovascular system and central nervous system diseases. Geniposide also has certain anti-inflammatory and soft tissue injury effects. |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Butyl paraben |
Therapeutic substance |
compound |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ochratoxin A |
Environmental Chemicals |
compound |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Zearalenone |
Therapeutic substance |
compound |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulfotransferase |
Therapeutic substance |
enzyme |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
5-aminosalicyclic acid and sulfapyridine |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Balsalazide |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulfapyridine and 4-aminobenzoyl-beta-alanine |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Phenacetin |
Therapeutic Substance |
analgesic |
n.a. |
p-phenetidin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Clonazepam |
Therapeutic Substance |
Central nervous system agents |
n.a. |
7-aminoclonazepam |
teratogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
Dihydrodigoxin and dihydrodigoxigenin |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Azetirelin |
Therapeutic Substance |
thyrotropin-releasing hormone (TRH) ana-logue |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Potassium oxonate |
Environmental Chemicals |
unknown |
n.a. |
cyanuric acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Hesperidin |
"Therapeutic Substance; Herbal Substance" |
anti-allergy |
n.a. |
hesperitin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
amphetamine |
no impact |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
Acetylated 5-ASA |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
succinylsulfathiazole |
Therapeutic substance |
antibacterial |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nitroglycerin(glyceryl trinitrate) |
Therapeutic substance |
angina pectoris |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Daidzein |
"Therapeutic Substance; Herbal Substance" |
a weakly estrogenic compound with potential health |
n.a. |
dihydrodaidzein and equol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Bromazepam |
Therapeutic Substance |
anti-anxiety disorders |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Benzodiazepines |
Therapeutic substance |
unknown |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Linoleic acid |
Herbal Substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Caffeic acid |
Herbal Substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Levosimendan |
Therapeutic Substance |
Levosimendan is used to manage acutely decompensated congestive heart failur |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Eltrombopag |
Therapeutic Substance |
Eltrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia or aplastic anemia associated with various etiologies. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Methotrexate |
Therapeutic Substance |
chemotherapeutic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sodium picosulfate |
Therapeutic Substance |
laxative |
n.a. |
4,40-dihydroxydiphenyl-(2-pyridyl)-methane |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Levametabol-I,-II,-and-III |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Deleobuvir |
Therapeutic Substance |
under investigation in clinical trial |
n.a. |
CD6168 |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Epacadostat |
Therapeutic Substance |
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others. |
n.a. |
M11 |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Morphine |
"Therapeutic Substance; Herbal Substance" |
opioid agonist |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Amlodipine |
Therapeutic Substance |
antihypertensive |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Berberine |
Herbal Substance |
antifungal infections and as antidiarrheal |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ellagic acid |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Grape Seed Polyphenol Extract (GPSE) |
Therapeutic substance |
unknown |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Oxaliplatin |
Therapeutic Substance |
chemotherapy agent |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Cycasin |
Therapeutic substance |
compound |
n.a. |
methylazoxymethano |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
2-methoxy esterone |
Therapeutic substance |
Anti-angiogenic |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Chlorogenic acid |
Therapeutic Substance |
Antioxidant |
n.a. |
3-hydroxycinnamic-acid-and3-(3-hydroxyphenyl)propionic-acid |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Soy-derived phytoestrogens |
Therapeutic substance |
Xeno-estrogens |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Heterocyclic aromaticamines (HAAs) |
Therapeutic substance |
Carcinogenic agents |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Aflatoxin B1 |
Environmental Chemicals |
Carcinogenic mycotoxins |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
7-ethyl-10-hydroxycamptothecin(SN-38) |
Therapeutic substance |
antineoplastic |
n.a. |
SN-38-glucuronide |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
PD-1 inhibitors |
Therapeutic substance |
unknown |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Cyclophosphamide |
Therapeutic Substance |
lymphoma and leukemia |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
NaringNnin |
Therapeutic substance |
compound |
n.a. |
n.a. |
inactivation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nifedipine |
"Therapeutic Substance; Herbal Substance" |
calcium channel blocker |
n.a. |
n.a. |
inactivation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ipilimumab |
Therapeutic Substance |
a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Lovastatine |
Therapeutic Substance |
Hypolipidemics |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
n.a. |
Beneficial bacteria increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Cisplatin |
Therapeutic Substance |
Antitumor |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Nitroglycerin |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
"Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate" |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Dihydroxyphenylalanine (DOPA) |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
"m-tyramine; m-hydroxylphenylacetic acid" |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
7-ethyl-10-hydroxycamptothecin |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
"SN-38G;cyanuric acid" |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
NSAIDs |
Therapeutic Substance |
compound |
n.a. |
"SN-38G; ;cyanuric acid" |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Phenoxyethanol |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
"SN-38G ;cyanuric acid" |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
anti-infective |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Daidzin |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
daidzein,calycosin |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Puerarin |
"Therapeutic Substance; Herbal Substance" |
Herbal |
n.a. |
daidzein,calycosin |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sennosides |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
rheinanthrone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Hippuric acid |
Environmental Chemicals |
Environmental Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Azo dyes |
Environmental Chemicals |
Environmental Substance |
n.a. |
mutagenic bis-aniline benzidine |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Methylmercury |
Environmental Chemicals |
compound |
n.a. |
inorganic mercury |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Brivudine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
additional bromovinyluracil |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Ipsalazide |
Therapeutic Substance |
unknown |
n.a. |
local 5-ASA |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Picosulfuric acid |
Therapeutic Substance |
compound |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Sulfadiazine |
Therapeutic Substance |
antibiotic |
n.a. |
local 5-ASA |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Amiodarone |
Therapeutic Substance |
anti-arrhythmic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Codeine |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Metamfetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Estradiol |
"Therapeutic Substance; Herbal Substance" |
Herbal |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Taurine conjugated bile acid |
Environmental Chemicals |
Environmental Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Altretamine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Gut microbes |
Levocarnitine |
"Therapeutic Substance; Herbal Substance" |
Herbal |
n.a. |
trimethylamine-N-oxide(TMAO) |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A parahaemolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A paraphrohaemolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus A sputorum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae J |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae K |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae L |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae M |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D parainfluenzae N |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus D pittmaniae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus influenzae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haemophilus sp002998595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia alvei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hafnia paralvei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Haloferax massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Halorubrum lipolyticum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helcococcaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helcococcaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helcococcaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helcococcaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
m-hydroxyphenylacetic |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori BU |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori BU |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori BU |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori BU |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori C |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter pylori C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter A rappini |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter A rappini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter A rappini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter A rappini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacteraceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter B sp001854545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter B sp001854545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter B sp001854545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter B sp001854545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter B sp001854545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter C cinaedi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter F sp002287135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter F sp002287135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter F sp002287135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Helicobacter F sp002287135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella biformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella biformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella biformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella biformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemanella sp002299315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania filiformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Holdemania sp900120005 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g HUN007 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella effluvii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella hathewayi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella sp000526575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hungatella A hathewayi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hydrogenoanaerobacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hydrogenoanaerobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hydrogenoanaerobacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Hydrogenoanaerobacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinibacter bartlettii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas butyriciproducens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas butyriciproducens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas butyriciproducens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas butyriciproducens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas butyriciproducens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Intestinimonas massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Jonquetella anthropi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Jonquetella anthropi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Jonquetella anthropi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Jonquetella anthropi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001689515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001689515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001689515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001689515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001689515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g K10 s K10 sp001941205 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptoniphilaceae g KA00134 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptoniphilaceae g KA00134 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptoniphilaceae g KA00134 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Fastidiosipilaceae g KA00274 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga gabonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kallipyga massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella |
Phenoxyethanol |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
cyanuric acid |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
Monosaccharides |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella pneumoniae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasipneumoniae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella quasivariicola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella variicola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A grimontii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A michiganensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella A oxytoca |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Klebsiella B aerogenes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kluyvera ascorbata B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kocuria rhizophila B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kocuria rhizophila B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kocuria rhizophila B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kocuria rhizophila B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kocuria rhizophila B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kosakonia cowanii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia senegalensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia sp002418445 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia sp002418445 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia sp002418445 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Kurthia sp002418445 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum saburreum A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum sp000296385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoanaerobaculum umeaense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnobacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium phytofermentans A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium sp900078195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A edouardi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnoclostridium A sp002160755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira eligens B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira rogosae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000436535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp000437735 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp003537285 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospira sp900316325 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Clonazepam |
Therapeutic Substance |
Central nervous system agents |
n.a. |
clonazepam-M1 |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospiraceae |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lachnospirales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillales |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
Amphetamine, norephedrine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B agilis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B animalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B murinus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillu B ruminis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B salivarius |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus B salivarius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C paracasei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C rhamnosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C saniviri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C saniviri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C saniviri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C saniviri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C saniviri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus C zeae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D curvatus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D curvatus |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D curvatus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D sakei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D sakei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D sakei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus D sakei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus E coryniformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus E coryniformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus E coryniformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F pentosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus F plantarum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G brevis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G buchneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G hilgardii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G kefiri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parabuchneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G parafarraginis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G sanfranciscensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G senioris |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G senioris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G senioris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus G senioris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H antri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H fermentum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H fermentum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H fermentum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H mucosae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H oris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H vaginalis A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H vaginalis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H vaginalis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus H vaginalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus J harbinensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus K farciminis A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus L dextrinicus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Methamphetamine |
Therapeutic Substance |
psychostimulant and sympathomimetic |
n.a. |
Amphetamine, norephedrine |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Lactulose |
Therapeutic Substance |
laxative |
n.a. |
lactic and acetic acids |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Simvastatin |
"Therapeutic Substance; Herbal Substance" |
Cardiac drugs |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus |
Acetylsalicylic acid |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri AM 63,DSM 20243,ATCC 33323,NCDO 2233,NCIB 11718 |
Levamisole |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus paracasei LPC-37,ATCC SD5275 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus paracasei LPC-37,ATCC SD5275 |
Rosiglitazone |
Therapeutic substance |
Anti-diabetics |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus plantarum WCFS1,LMG 9211,NCIMB 8826 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Salicin |
Therapeutic Substance |
compound |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus acidophilus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus amylolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus amylolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus amylovorus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus amylovorus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus amylovorus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus apis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus crispatus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus crispatus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus crispatus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus delbrueckii A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gallinarum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gallinarum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus gasseri A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus helveticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus helveticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus hominis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus iners |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus intestinalis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus intestinalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus intestinalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus jenseniis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus jenseniis A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus johnsonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus johnsonii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus johnsonii |
Cyclophosphamide |
Therapeutic Substance |
lymphoma and leukemia |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus kalixensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus murinus |
Cyclophosphamide |
Therapeutic Substance |
lymphoma and leukemia |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactobacillus ultunensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis subsp. lactis IL1403,CIRM BIA 96,CNRZ 1342 |
Roflumilast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus garvieae B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis E |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus lactis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus petauri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus piscium C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactococcus raffinolactis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Secoisolariciresinol |
Therapeutic Substance |
anticancer |
n.a. |
enterodiol and entero lactone |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lactonifactor longoviformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lagierella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lagierella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lagierella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lagierella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lagierella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella parvula |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella rimae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lancefieldella sp000564995 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Laribacter hongkongensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonella clevelandensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter asaccharolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp000177015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp002160305 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066645 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066645 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066645 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066645 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066645 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lawsonibacter sp900066825 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leclercia adecarboxylata C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella grimontii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leminorella richardii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leptotrichia wadei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc citreum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc lactis B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Leuconostoc mesenteroides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Levyella massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Levyella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Levyella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Levyella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Levyella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Libanicoccus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria grayi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria innocua |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria monocytogenes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri |
Cladribine |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri |
Tretazicar |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri |
Daunorubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri |
Fludarabine de phosphate |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri serovar 6B SLCC533410 |
Fludarabine de phosphate |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri serovar 6B SLCC533410 |
Tretazicar |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri serovar 6B SLCC533410 |
Cladribine |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Listeria welshimeri serovar 6B SLCC533410 |
Daunorubicin |
Therapeutic substance |
chemotherapeutic |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Luminal bacteria |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lysinibacillus C |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lysinibacillus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lysinibacillus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Lysinibacillus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella sp003150275 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella sp003150275 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella sp003150275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mailhella sp003150275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marinilabiliaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P3106 sp900169975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marseille-P4683 sp900232885 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia formatexigens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Marvinbryantia sp900066075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacillaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacillaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacillaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacillaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacillaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacterium senegalense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacterium senegalense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacterium senegalense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacterium senegalense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilibacterium senegalense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilimaliae timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium coli |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massilioclostridium methylpentosum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota sp002160815 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Massiliomicrobiota timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas funiformis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas funiformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas funiformis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas funiformis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megamonas hypermegale |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera elsdenii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera elsdenii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera elsdenii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera elsdenii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp000417505 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp000417505 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp000417505 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp000417505 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp001546855 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp001546855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp001546855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp001546855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp001546855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp002319965 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp002319965 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp002319965 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp002319965 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp900066485 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp900066485 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp900066485 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp900066485 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Megasphaera sp900066485 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Merdibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intermedia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia intestini |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metakosakonia sp002377245 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metamycoplasma hominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Metamycoplasma hominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobacterium sp000499765 |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobacterium sp000499765 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobacterium sp000499765 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobacterium sp000499765 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A oralis |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A oralis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A oralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A oralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii A |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A smithii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A woesei |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A woesei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanobrevibacter A woesei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanocorpusculum |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanocorpusculum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanocorpusculum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomassiliicoccus A intestinalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanomethylophilaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera cuniculi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera cuniculi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera sp900322125 |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera sp900322125 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera sp900322125 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera stadtmanae |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera stadtmanae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methanosphaera stadtmanae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Methylobacterium sp002778835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Micrococcus luteus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Micrococcus luteus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Micrococcus luteus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Micrococcus luteus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Microvirga massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella jalaludinii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella multacida |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella multacida |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella multacida |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella multacida |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mitsuokella multacida |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobilicoccus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mobiluncus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Moellerella wisconsensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp002299625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp002299625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp002299625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp900315625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp900315625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp900315625 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp900315625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium sp900315625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium timonense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium timonense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium timonense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mogibacterium timonense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobaceae |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobales |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Monoglobus pectinilyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Morganella morganii B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g MS4 s MS4 sp000752215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murdochiella vaginalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum intestinale |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp001701195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002358615 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002473395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp002492595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Muribaculum sp003150235 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Murimonas intestini |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium avium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycobacterium tuberculosis |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasma |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasma |
Floxuridine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasma |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasma hyorhinis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasmoidaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Mycoplasmoidaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NC2004 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus sp000435195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus sp000435195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus sp000435195 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus sp000435195 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativibacillus sp000435195 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativicoccaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativicoccus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativicoccus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativicoccus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Negativicoccus succinicivorans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria gonorrhoeae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria macacae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria sp000186165 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria subflava B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neisseria D elongata |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neobitarella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Neofamilia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nesterenkonia massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nesterenkonia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nesterenkonia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nesterenkonia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Niameybacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nigerium massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter archeti |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nissabacter sp002858715 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g NK3B98 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nosocomiicoccus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nosocomiicoccus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nosocomiicoccus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Nosocomiicoccus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Noviherbaspirillum massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Numidum massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus caeni |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus caeni |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus caeni |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus caeni |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus caeni |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus jeddahense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oceanobacillus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter laneus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Odoribacter splanchnicus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olegusella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella sp001457795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella B sp000752675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E provencensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002159735 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp002160255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp003150175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Olsenella E sp900119915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oribacterium sinus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter ruminantium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp000436875 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp000436875 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp000436875 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp000436875 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp000436875 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp001916835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp001916835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp001916835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp001916835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp001916835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillibacter sp900066435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospiraceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oscillospirales |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Oxalobacter formigenes B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A phocaensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus A senegalimassiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus B thiaminolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus F sp000411255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus L senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus P antibioticophila |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus Q ihumii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus amylolyticus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus ihuae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lactis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus lautus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus odorifer |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenibacillus polymyxa |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
PaenibacilluU tuaregi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paeniclostridium sordellii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paenisporosarcina A sp000411295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paludibacteraceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea agglomerans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea ananatis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea anthophila |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea brenneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea conspicua |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea septica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea sp002920175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea vagans A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pantoea B calida |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides bouchesdurhonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides chinchillae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulfapyridine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Tolcapone |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides distasonis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides goldsteinii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides gordonii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides johnsonii |
Imatinib |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides merdae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp000436495 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides sp900155425 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroides timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parabacteroidesdistasonis |
Hydrocortisone acetate |
Therapeutic Substance |
immune, inflammatory, and neoplastic conditions |
n.a. |
hydrocortisone |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraclostridium massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp000431155 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp000431155 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp000431155 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp000431155 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp000431155 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paramuribaculum sp001689535 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella clara |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Paraprevotella xylaniphila |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parascardovia denticolens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella excrementihominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parasutterella sp000980495 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas micra |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas micra |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas micra |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas micra |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas sp001553085 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas sp001553085 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas sp001553085 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Parvimonas sp001553085 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia bouchesdurhonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia bouchesdurhonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia bouchesdurhonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia cardiffensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia keddieii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia polynesiensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia radingae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000278725 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000308055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000411415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000758755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000758755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000758755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp000758755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia sp001838165 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia turicensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia turicensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia turicensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pauljensenia turicensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus acidilactici |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pediococcus pentosaceus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pelistega indica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptococcus niger |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A grossensis B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A grossensis B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A grossensis B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A grossensis B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A harei A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A lacrimalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A phoceensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A phoceensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A phoceensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A phoceensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A rhinitidis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A rhinitidis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A rhinitidis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A rhinitidis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A senegalensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A sp900099555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A sp900099555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus A sp900099555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B duerdenii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B duerdenii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B duerdenii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B sp000478985 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B sp000478985 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B sp000478985 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus B sp000478985 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C urinimassiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C urinimassiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus C urinimassiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus E obesi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus E obesi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptoniphilus E obesi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus anaerobius |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus russellii A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus sp000758885 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus sp000758885 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus sp000758885 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus sp000758885 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Peptostreptococcus stomatis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium faecium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium faecium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium sp000436095 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium sp000436095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium sp000436095 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium sp000436095 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens A |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phascolarctobacterium A succinatutens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phocea massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phocea massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phocea massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phocea massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phoenicibacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Phyllobacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pigmentiphaga sp002188635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Planomicrobium massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Planomicrobium massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Planomicrobium massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Planomicrobium massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Plesiomonas shigelloides |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pluralibacter gergoviae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas asaccharolytica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas bennonis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas endodontalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas endodontalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas endodontalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas endodontalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas gingivalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas somerae A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas sp001808555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Porphyromonas uenonis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella amnii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella amnii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella amnii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella amnii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella amnii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bergensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bivia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bivia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bivia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bivia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella bivia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella buccalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella colorans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Nivolumab |
Therapeutic Substance |
Anticancer |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Carboplatin |
Therapeutic Substance |
antineoplastic alkylating |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Levonorgestrel |
Therapeutic Substance |
contraception and hormone |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Spironolactone |
Therapeutic substance |
diuretic and also antihypertensive effects |
n.a. |
7thiospironolactone |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Torsemide |
Therapeutic substance |
loop diuretic |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella copri A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella corporis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella corporis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella corporis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella corporis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella denticola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella disiens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella disiens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella disiens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella intermedia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella jejuni |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella lascolaii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella melaninogenica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella melaninogenica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella melaninogenica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella melaninogenica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella melaninogenica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella multisaccharivorax |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella nigrescens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella oris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella salivae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000431975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000433175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000434975 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000435635 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436695 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000436915 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp000834015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp001275135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251365 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002251385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002265625 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002299635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002300055 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002300055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002300055 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002300055 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002300055 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002350355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002480935 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp002481295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp003447235 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900290275 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900313215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900315955 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900316565 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella sp900317685 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella stercorea |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotella veroralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia sp000437675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia sp000437675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia sp000437675 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia sp000437675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia sp000437675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Prevotellamassilia timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacteriaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Propionibacterium freudenreichii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus mirabilis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus penneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus sp001722135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus terrae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Proteus vulgaris A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Provencibacterium massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia alcalifaciens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rettgeri D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia rustigianii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Providencia stuartii B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia sp002298805 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudescherichia vulneris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudobutyrivibrio fibrisolvens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudoflavonifractor capillosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas B luteola |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonadaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E aeruginosa |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E extremaustralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fragi B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E fulva |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas E putida P |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
2,8-DHQ (including 2,4-DHQ) |
Environmental Chemicals |
Environmental Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas aeruginosa |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas citronellolis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pseudomonas putida |
Altretamine |
Therapeutic Substance |
Therapeutic Substance |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pygmaiobacter massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter piscolens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter piscolens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter piscolens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter piscolens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Pyramidobacter piscolens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g QALR01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QAMI01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Christensenellaceae g QANA01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f QAND01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QANG01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QANG01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g QANG01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Neisseriaceae g QFNR01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rahnella sp003263545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ralstonia pickettii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella ornithinolytica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Raoultella planticola |
Doxorubicin |
"Therapeutic Substance; Herbal Substance" |
chemotherapeutic |
n.a. |
n.a. |
inactivation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g RF16 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rhodocyclaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenella microfusus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) |
Therapeutic substance |
negative regulators of T cell proliferation and functions |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rikenellaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Risungbinella massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Enterobacteriaceae g RIT-PI-d |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Robinsoniella peoriensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia dakarense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Romboutsia timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Digoxin |
"Therapeutic Substance; Herbal Substance" |
cardiac glycoside |
n.a. |
dihydrodigoxin |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Clofazimine |
"Therapeutic Substance; Herbal Substance" |
antimicrobial |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Risperidone |
Therapeutic Substance |
second-generation antipsychotic (SGA) |
n.a. |
risperidone-M1 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia faecis |
Sulindac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
sulindac-M2 |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia hominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia intestinalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia inulinivorans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Roseburia sp003483745 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia aeria |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia aeria |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia aeria |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia dentocariosa |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia mucilaginosa B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia sp001808955 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rothia sp001808955 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubeoparvulum massiliense |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubeoparvulum massiliense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubeoparvulum massiliense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubeoparvulum massiliense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubneribacter badeniensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubneribacter badeniensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Rubneribacter badeniensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Eggerthellaceae g RUG013 s RUG013 sp001486445 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG420 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g RUG472 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g RUG472 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g RUG472 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g RUG472 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g RUG563 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g RUG705 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g RUG806 s RUG806 sp900313475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g RUG832 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g RUG832 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g RUG832 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium C sp000435295 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E siraeum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminiclostridium E sp003512525 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminobacter A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminobacter A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcaceae |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000432335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp000437095 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus A sp003011855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C callidus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000433635 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000437255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus C sp000980705 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D bicirculans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D bicirculans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus D sp000434695 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E bromii B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp002493635 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp003521625 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp003521625 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp003526955 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus E sp900314705 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus F champanellensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus G gauvreauii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus gnavus VPI C7-9,ATCC 29149 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus gnavus VPI C7-9,ATCC 29149 |
Roflumilast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Dolasetron |
Therapeutic substance |
antinauseant and antiemetic |
n.a. |
duloxetine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Ketoconazole |
"Therapeutic Substance; Herbal Substance" |
fungal infections |
n.a. |
ketoprofen |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Lovastatin |
"Therapeutic Substance; Herbal Substance" |
lower the risk of cardiovascular disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Misoprostol |
Therapeutic substance |
reduce the risk of NSAID induced gastric ulcers |
n.a. |
misoprostol-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Mycophenolate mofetil |
Therapeutic Substance |
inosine monophosphate dehydrogenase inhibitor |
n.a. |
mycophenolic-acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Nicardipine |
Therapeutic substance |
effective in the treatment of angina and coronary spasms without showing cardiodepressant effects |
n.a. |
aminonicardipine |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Praziquantel |
Therapeutic substance |
Anti-infection |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus bromii |
Ropinirole |
Therapeutic substance |
Parkinson's |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus gnavus |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruminococcus sp002438605 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium lactatiformans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ruthenibacterium sp003149955 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Saccharimonadaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salinicola tamaricis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella bongori |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella enterica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Salmonella typhimurium |
Sulfasalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
"sulfapyridine; 5-aminosalicylate" |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Scardovia wiggsiae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sedimentibacter sp003457065 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C bovis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C sp002351185 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C sp002351185 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C sp002351185 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C sp002351185 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonas C sp002351185 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Selenomonadaceae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas intestinalis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sellimonas sp002161525 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Senegalimassilia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Senegalimassilia anaerobia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia liquefaciens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia marcescens I |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia sp001642805 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Serratia ureilytica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia exigua |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Slackia A piriformis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia amnii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sneathia sanguinegens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium moorei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium moorei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium moorei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium moorei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium moorei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium sp900290205 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium sp900290205 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium sp900290205 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium sp900290205 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Solobacterium sp900290205 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sphingomonas ginsenosidimutans |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-01 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g Spiro-02 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporanaerobacter acetigenes |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporanaerobacter acetigenes |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporanaerobacter acetigenes |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporolactobacillus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporolactobacillus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporolactobacillus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporolactobacillus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sporolactobacillus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus A lentus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus argenteus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus argenteus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus argenteus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus argenteus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus aureus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus aureus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus aureus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus aureus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus capitis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus capitis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus capitis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus capitis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus epidermidis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus epidermidis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus epidermidis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus epidermidis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Levodopa |
"Therapeutic Substance; Herbal Substance" |
Parkinson's |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus haemolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus hominis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus hominis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus hominis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus hominis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus lugdunensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus lugdunensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus lugdunensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus lugdunensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus nepalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus schleiferi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus schleiferi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus schleiferi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus schleiferi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus warneri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Staphylococcus xylosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas bentonitica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AK |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia AM |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia F |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas maltophilia S |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stenotrophomonas sp003028475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum longum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum naviforme |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum sp002892395 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum sp002892395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum sp002892395 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stomatobaculum sp002892395 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Stoquefichus sp001244545 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 |
Duloxetine |
Therapeutic Substance |
Major Depressive Disorder. |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 |
Montelukast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 |
Roflumilast |
Therapeutic Substance |
Drugs for obstructive airway disease |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus agalactiae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus anginosus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus constellatus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus constellatus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus constellatus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus constellatus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus constellatus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus equinus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus gordonii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus gordonii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus gordonii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus gordonii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus gordonii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantarius |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantiI |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantiI |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantiI |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantiI |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus infantiI |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus lutetiensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis AC |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis AC |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis AC |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis AC |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis AC |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mitis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mutans |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mutans |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mutans |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mutans |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus mutans |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis AE |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis AE |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis AE |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis AE |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis E |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis E |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis E |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis E |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis E |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis S |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis S |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis S |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis S |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis S |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis V |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis V |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis V |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis V |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus oralis V |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus parasanguinis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pasteurianus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus peroris |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus peroris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus peroris |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus peroris |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus peroris |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pseudopneumoniae O |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pseudopneumoniae O |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pseudopneumoniae O |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pseudopneumoniae O |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pseudopneumoniae O |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus pyogenes |
Sulfanilamide |
"Therapeutic Substance; Herbal Substance" |
anti-infective |
n.a. |
sulfanilamide |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus salivarius |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000187445 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000187445 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000187445 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000187445 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000187445 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000411475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000411475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000411475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000411475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000411475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000479315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000479315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000479315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000479315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp000479315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp001556435 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp001556435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp001556435 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp001556435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp001556435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus sp002300045 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus thermophilus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus thermophilus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus thermophilus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus thermophilus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus thermophilus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus timonensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus timonensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus timonensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus vestibularis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus vestibularis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus vestibularis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus vestibularis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptococcus vestibularis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Streptomyces albus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas hippei |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas hippei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas hippei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas hippei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinatimonas hippei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900314855 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900314855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900314855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900314855 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900315805 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900315805 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900315805 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900315805 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900316935 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900316935 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900316935 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succiniclasticum sp900316935 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp000431835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp000431835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Succinivibrio sp003456415 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella |
Ginsenoside Rb1 |
"Therapeutic Substance; Herbal Substance" |
"Therapeutic Substance; Herbal Substance" |
n.a. |
Compound K |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella parvirubra |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Sutterella wadsworthensis B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g SZUA-378 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tenericutes |
Oxaliplatin |
Therapeutic Substance |
chemotherapy agent |
n.a. |
n.a. |
Reduce the side effects of drugs |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter glycolicus A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Terrisporobacter othiniensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tessaracoccus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Thalassobacillus sp001368835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tidjanibacter inops |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tidjanibacter inops |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tidjanibacter inops |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tidjanibacter inops |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tidjanibacter inops |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Timonella senegalensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tissierella sp002266425 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Saccharimonadaceae g TM7x |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Saccharimonadaceae g TM7x |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Traorella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D berlinense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D berlinense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D berlinense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D berlinense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D berlinense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002449305 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D sp002478955 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Treponema D succinifaciens |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sanguinis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicibacter sp001543345 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Turicimonas muris |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g TWA4 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella nexilis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000209385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Tyzzerella sp000411335 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1081 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Saccharimonadaceae g UBA1103 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA11517 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1174 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Paludibacteraceae g UBA1181 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA11940 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g UBA11963 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g UBA11963 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-1000 g UBA11963 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1219 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1219 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1219 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1219 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1219 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1227 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f UBA1234 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f UBA1234 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f UBA1234 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f UBA1234 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f UBA1234 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o UBA1212 f UBA1255 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Negativicutes o UBA1444 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Negativicutes o UBA1444 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Negativicutes o UBA1444 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Negativicutes o UBA1444 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Negativicutes o UBA1444 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA1711 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA1712 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1732 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o ML615J-28 f CAG-313 g UBA1737 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-272 g UBA1740 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA1786 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Dialisteraceae g UBA1822 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Dialisteraceae g UBA1822 s UBA1822 sp002314995 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2727 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Succinivibrionaceae g UBA2804 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2821 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Saccharimonadaceae g UBA2834 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2856 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Selenomonadaceae g UBA2913 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA3263 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Mycoplasmatales f UBA3375 g UBA3375 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Mycoplasmatales f UBA3375 g UBA3375 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Mycoplasmatales f UBA3375 g UBA3375 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g UBA3631 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g UBA3631 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA3700 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA3789 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA3818 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Dehalobacteriia o UBA4068 f UBA4068 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bradymonadales f UBA4248 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bradymonadales f UBA4248 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bradymonadales f UBA4248 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bradymonadales f UBA4248 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bradymonadales f UBA4248 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4334 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA4372 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA4626 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Butyricicoccaceae g UBA4644 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA4675 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA1381 g UBA4716 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4855 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA4871 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Caldanaerobiales f UBA4877 g UBA4877 s UBA4877 sp002399345 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA4951 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g UBA5026 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-822 g UBA5026 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA5416 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA5446 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA5489 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA5489 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA5489 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Dialisteraceae g UBA5809 s UBA5809 sp002417965 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA5884 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA5920 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA6345 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Erysipelotrichaceae g UBA636 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6382 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g UBA6414 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g UBA6414 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-302 g UBA6414 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f UBA644 A |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA6857 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o TANB77 f CAG-508 g UBA7001 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Acholeplasmatales f CAG-307 g UBA7004 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA7057 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RF39 f CAG-611 g UBA7057 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Christensenellales f UBA1750 g UBA7102 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7160 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 s UBA7173 sp001701135 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA7182 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptococcaceae g UBA7185 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptococcaceae g UBA7185 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptococcaceae g UBA7185 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Peptococcaceae g UBA7185 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-826 g UBA733 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA737 s UBA737 sp002431945 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA738 s UBA738 sp003522945 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Bacilli o RFN20 f CAG-288 g UBA7642 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Atopobiaceae g UBA7748 s UBA7748 sp900314535 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA7862 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA7862 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA791 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA791 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA791 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g UBA791 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA866 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Bacteroidales f UBA932 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9414 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Acutalibacteraceae g UBA945 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Ruminococcaceae g UBA946 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Oscillospiraceae g UBA9475 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Amphetamine |
Therapeutic Substance |
attention-deficit/hyperactivity disorders (ADHD) |
n.a. |
n.a. |
activity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA953 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA9783 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Opitutales f UBA9783 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA9845 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
c Clostridia o 4C28d-15 f UBA1242 g UBA9845 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ureaplasma parvum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ureaplasma parvum |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Ureaplasma parvum |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Urmitella timonensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Urmitella timonensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vagococcus teuberi |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum cambriense B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum sp900106855 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum sp900106855 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Varibaculum A timonense |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella atypica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella dispar |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella dispar A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella infantium |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella parvula |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella parvula A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella rogosae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella sp. 32 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella sp002959755 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella tobetsuensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A magna |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A seminalis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonella A sp000431435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonellales |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Veillonellales |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio cholerae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio fluvialis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio furnissii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio metoecus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio parahaemolyticus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vibrio vulnificus |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallaceae |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis |
Acetaminophen |
"Therapeutic Substance; Herbal Substance" |
analgesics |
n.a. |
n.a. |
toxicity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis sp002998355 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Poncirin |
Therapeutic substance |
unknown |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Victivallis vadensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Virgibacillus picturae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Vitreoscilla massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella cibaria |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella confusa |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella paramesenteroides |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Weissella viridescens |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia neuii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Winkia sp002849225 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Xanthomonas B massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia aleksiciae |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia bercovieri |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia enterocolitica |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia frederiksenii C |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia intermedia |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Indomethacin |
Therapeutic Substance |
NSAID |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Diclofenac |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Irinotecan |
Therapeutic Substance |
antineoplastic enzyme inhibitor |
n.a. |
7-ethyl-10-hydroxycamptothecin |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Serotonin dopamine |
Therapeutic substance |
compound |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Nitrotoluene |
Therapeutic substance |
compound |
n.a. |
n.a. |
carcinogenic |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Ketoprofen |
"Therapeutic Substance; Herbal Substance" |
anti-inflammatory |
n.a. |
n.a. |
toxicity increased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia kristensenii B |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Tryptophan |
"Therapeutic Substance; Herbal Substance" |
amino acid commonly found |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia massiliensis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia mollaretii |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yersinia pestis |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Amygdalin |
"Herbal Substance; Dietary Substance" |
Herbal Substance |
n.a. |
n.a. |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Aspirin |
Therapeutic substance |
pain and fever due to various causes |
n.a. |
n.a. |
side effect |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Ginsenoside |
Therapeutic substance |
reproductive system in animal testicles |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Rutin |
"Therapeutic Substance; Herbal Substance" |
decrease capillary fragility |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Steviol glycosides |
Therapeutic Substance |
unknown |
n.a. |
Steviol glycosides |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Rebaudioside A |
Therapeutic Substance |
compound |
n.a. |
rebaudioside A |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Stevioside |
Therapeutic Substance |
compound |
n.a. |
steviol |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Isoquercetin(uercitin-3-glucoside) |
Therapeutic substance |
n.a. |
n.a. |
Butyrate, acetate, 3,4-dihydroxyphenylacetic acid |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Choline |
"Therapeutic Substance; Herbal Substance" |
compound |
n.a. |
n.a. |
Induced disease |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Mesalazine |
Therapeutic Substance |
anti-inflammatory |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Anthocyanins |
Therapeutic substance |
Potential anticancer, anti-oxidant and anti-inflammatory |
n.a. |
n.a. |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Naringin |
Herbal Substance |
Anti-oxidant, anti-cancer and blood cholesterol lowering effect |
n.a. |
naringenin |
activation |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
Yokenella regensburgei |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002103105 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp002103105 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 |
Sorivudine |
Therapeutic Substance |
antiviral |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 |
5-Fluorouracil |
Therapeutic Substance |
antineoplastic antimetabolite |
n.a. |
n.a. |
involved in substrate metabolism |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 |
Capecitabine |
Therapeutic Substance |
chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. |
n.a. |
degylcocapecitabine |
toxicity |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 |
Trifluridine |
Therapeutic Substance |
deglycosylation |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 |
Gemcitabine |
Therapeutic Substance |
chemotherapy |
n.a. |
n.a. |
activity decreased |
n.a. |
n.a. |
n.a. |
PMID:36467581 |
|
fecal microbiota |
Progesterone |
Therapeutic substance |
hormone |
Reduction and dehydoxylation |
5 and 5pregnanolone |
inactivation |
human faecal slurry |
n.a. |
Metabolism significantly decreased the concentration by a 28-minute half-life period |
PMID:32806503 |
|
fecal microbiota |
LevonorGestrel |
Therapeutic Substance |
contraception and hormone |
Reduction and dehydoxylation |
tetrahydro- and hydroxy- derivatives, sulfate and glucuronide conjugations |
inactivation |
human faecal slurry |
n.a. |
Metabolism significantly decreased the concentration by a 240-minute half-life period |
PMID:32806503 |
|
fecal microbiota |
Medroxyprogesterone Acetate |
Therapeutic substance |
hormone |
Reduction and dehydoxylation |
5dihydro MPA and tetrahydro MPA |
inactivation |
human faecal slurry |
n.a. |
Metabolism significantly decreased the concentration by a 644-minute half-life period |
PMID:32806503 |
|
Bacteroides thetaiotaomicron |
Alternariaspp. toxins |
Environmental Chemicals |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Mycotoxins may be metabolized and used as carbon source by specific bacteriaa |
PMID:33847775 |
|
Escherichia coli |
carboxymethylcellulose |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
nduction of virulence factors such as flagella, type 1 pili and long polar fimbriae |
PMID:33027647 |
|
Escherichia coli |
polysorbate-80 |
Environmental Chemicals |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
nduction of virulence factors such as flagella, type 1 pili and long polar fimbriae |
PMID:33027647 |
|
B. thetaiotaomicron |
diltiazem |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
Deacetylation of both diltiazem and diltiazem metabolites in the gut isbt4096dependent |
PMID:31158845 |
|
F. prausnitzii |
As toxicity |
Environmental Chemicals |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
These bacteria can biotransform arsenical compounds and build up this toxin for excretion via feces and urine |
https://link.springer.com/doi/10.1186/2050-6511-14-62
|
|
Intestinal microflora |
Loperamide |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
loperamide |
Activation of prodrug |
In vivo |
n.a. |
n.a. |
PMID:7628301 |
|
Unclassified gut microbiota |
Olsalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
Activation of prodrug |
In vitro |
n.a. |
n.a. |
"PMID:32652007 |
|
Clostridium |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
Health |
n.a. |
"PMID:30158249 |
|
Clostridium |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
n.a. |
Inflammatory bowel disease (IBD) |
Sulfasalazine is prodrug converted to the active agent 2-ASA by gut microbes |
PMID:31675176 |
|
Escherichia coli |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes |
PMID:31675176 |
|
Eubacterium |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 4-ASA by gut microbes |
PMID:31675176 |
|
Prevotella |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes |
PMID:31675176 |
|
Ruminococcus gnavus |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 3-ASA by gut microbes |
PMID:31675176 |
|
Salmonella typhimurium |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes |
PMID:31675176 |
|
Alistipes |
Sulfasalazine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Azo bond reduction |
"sulfapyridine; 5-aminosalicylate" |
Activation of prodrug |
In vitro |
n.a. |
Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes |
PMID:31675176 |
|
Unclassified gut microbiota |
Balsalazide |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
Activation of prodrug |
In vitro |
n.a. |
n.a. |
"PMID:32652007 |
|
Escherichia coli |
Paclitaxel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vivo |
n.a. |
developmental delay |
"PMID:30890566 |
|
Comamonas |
Paclitaxel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vivo |
n.a. |
developmental delay |
"PMID:30890566 |
|
Escherichia coli |
5-fluorouracil |
Therapeutic Substance |
Approved Drug |
Phosphorylation |
5-fluorouridine monophospate |
Increase activity |
In vivo |
n.a. |
Lead to sterility |
"PMID:30890566 |
|
Comamonas |
5-fluorouracil |
Therapeutic Substance |
Approved Drug |
Phosphorylation |
5-fluorouridine monophospate |
Increase activity |
In vivo |
n.a. |
Lead to sterility |
"PMID:30890566 |
|
Escherichia coli |
5-fluoro-2'-deoxyuridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vivo |
n.a. |
completely sterile |
"PMID:30890566 |
|
Escherichia coli |
Camptothecin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vivo |
n.a. |
production of few dead embryos |
"PMID:30890566 |
|
Comamonas |
Camptothecin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vivo |
n.a. |
production of few dead embryos |
"PMID:30890566 |
|
Escherichia coli |
Capecitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Capecitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Cladribine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Cladribine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Etoposide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Etoposide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
5-fluorouracil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
5-fluorouracil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
5-fluorocytosine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase chemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
5-fluorocytosine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
6-Mercaptopurine-2?deoxyriboside |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Actinomycin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
AQ4N |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase cemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Ara G hydrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Ara G hydrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
CB1954 |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
CB1954 |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Clofarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Clofarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Cytarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Cytarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Daunorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Daunorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Estramustine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Fludarabine de phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Fludarabine de phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Idarubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Menadione |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Mitomycin C |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Mitoxantrone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Escherichia coli |
Nelarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Nelarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Pentostatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Listeria welshimeri |
Pentostatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Streptonegrin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Tegafur |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Increase activity |
In vitro |
n.a. |
Increase hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Tegafur |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Valacyclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Vidarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Listeria welshimeri |
Vidarabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
Vinblastine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
No change of activity |
In vitro |
n.a. |
n.a. |
"PMID:26416623 |
|
Escherichia coli |
betaLapachone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Decrease activity |
In vitro |
n.a. |
Decrease hemotherapeutic drug cytotoxicity in vitro. |
"PMID:26416623 |
|
Eggerthella lenta |
Digoxin |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Reduction |
dihydrodigoxin |
"Reduce bioavailability; Decrease activity" |
In vivo |
n.a. |
Digoxin is converted to the inactive metabolite dihydrodigoxin by Eggerthella lenta, limiting the amount of active drug that is absorbed into the systemic circulation. |
PMID:23869020 |
|
Klebsiella pneumoniae |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug inactivation |
In vivo |
n.a. |
n.a. |
PMID:31675176 |
|
Unclassified gut microbiota |
Bromazepam |
Therapeutic Substance |
Approved Drug |
Nitro reduction |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Unclassified gut microbiota |
Caffeic acid |
Therapeutic Substance |
Dietary Compounds |
Reduction and dehydoxylation |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Unclassified gut microbiota |
Choline |
Therapeutic Substance |
Dietary Compounds |
C-N bond cleavage elimination/oxidation |
Trimethylamine |
Drug metabolism |
In vitro |
n.a. |
Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO |
PMID:30890566 |
|
Unclassified gut microbiota |
Clonazepam |
Therapeutic Substance |
Approved Drug |
Nitro reduction |
7-aminoclonazapam |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Alistipes indistinctus |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Clostridium bolteae |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
Microbiota species involved in ALL chemotherapeutics metabolism |
PMID:31675176 |
|
Bacteroides fragilis |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Bifidobacterium ruminantium |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Clostridium scindens |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
Dexamethasone side chain cleavage |
n.a. |
Drug metabolism |
In vitro |
n.a. |
Microbiota species involved in ALL chemotherapeutics metabolism |
PMID:31675176 |
|
Unclassified gut microbiota |
Diclofenac |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Escherichia coli |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug inactivation |
In vivo |
n.a. |
n.a. |
PMID:31675176 |
|
Escherichia coli BW25113 |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
"7-deoxydoxorubicinol; 7-deoxydoxorubicinolone" |
Reduced toxicity |
In vitro |
n.a. |
n.a. |
"PMID:30890566 |
|
Klebsiella pneumoniae |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:30890566 |
|
Raoultella planticola |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug inactivation |
In vivo |
n.a. |
n.a. |
PMID:31675176 |
|
Raoultella planticola |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
reductive deglycosylation |
"7-deoxydoxorubicinol; 7-deoxydoxorubicinolone" |
reduced toxicity |
In vitro |
n.a. |
For cancer patients, inactivation of doxorubicin by gut microbes could result in a decrease in active doxorubicin levels, potentially altering the efficacy of chemotherapeutic treatment and the severity of side effects. |
"PMID:30890566 |
|
Escherichia coli |
Gemcitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug inactivation |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Bacteroides eggerthii |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Bacteroides vulgatus |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Bacteroides stercoris |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Parabacteroides johnsonii |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug activation |
In vitro |
n.a. |
Microbiota as ALL chemotherapy response biomarker |
PMID:31675176 |
|
Unclassified gut microbiota |
Indomethacin |
Therapeutic Substance |
Approved Drug |
Glucuronide hydrolysis |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Unclassified gut microbiota |
Ipsalazide |
Therapeutic Substance |
"Approved Drug; Prodrug" |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32466672 |
|
Eggerthella lenta |
Levodopa |
Therapeutic Substance |
Approved Drug |
n.a. |
m-tyramine |
"Decreases bioavailability; Increase toxicity" |
In vitro |
n.a. |
n.a. |
"PMID:31196984 |
|
Enterococcus faecalis |
Levodopa |
Therapeutic Substance |
Approved Drug |
decarboxylation |
dopamine |
Decreases bioavailability |
In vitro |
n.a. |
n.a. |
"PMID:31196984 |
|
Enterococcus faecium |
Levodopa |
Therapeutic Substance |
Approved Drug |
decarboxylation |
dopamine |
Decreases bioavailability |
In vitro |
n.a. |
n.a. |
"PMID:31196984 |
|
Lactobacillus spp. |
Levodopa |
Therapeutic Substance |
Approved Drug |
decarboxylation |
dopamine |
Decreases bioavailability |
In vitro |
n.a. |
n.a. |
"PMID:32409589 |
|
Unclassified gut microbiota |
Lovastatin |
Therapeutic Substance |
Approved Drug |
Hydroxylation |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:30890566 |
|
Unclassified gut microbiota |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32652007 |
|
Unclassified gut microbiota |
Nitrazepam |
Therapeutic Substance |
Approved Drug |
Nitro reduction |
7-amino-nitrazepam |
Drug metabolism |
In vitro |
n.a. |
Nitrazepam is metabolized into 7-aminonitrazepam, which undergoes host hepatic metabolism into a teratogen |
PMID:30890566 |
|
Unclassified gut microbiota |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
nitroso-deoxygenated metabolite |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Bifidobacterium longum subsp. Infantis |
Resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
piceid |
Does not change activity |
n.a. |
n.a. |
n.a. |
"PMID:9784180 |
|
Lactobacillus acidophilus |
Resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
piceid |
Does not change activity |
In vitro |
n.a. |
n.a. |
"PMID:9784180 |
|
Bacillus cereus |
Resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
piceid |
Does not change activity |
In vitro |
n.a. |
n.a. |
"PMID:9784180 |
|
Unclassified gut microbiota |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
ketone |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Enterobacteriaceae |
Sorivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
(e)-5-(2-bromovinyl) uracil |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31885474 |
|
Bacteroidetes sp. |
Sorivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
(e)-5-(2-bromovinyl) uracil |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31885474 |
|
Unclassified gut microbiota |
Sorivudine |
Therapeutic Substance |
Approved Drug |
Hydrolysis |
n.a. |
Drug metabolism |
In vitro |
n.a. |
Reduction and dehydoxylation Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) |
PMID:30890566 |
|
Unclassified gut microbiota |
Sulfinpyrazone |
Therapeutic Substance |
Approved Drug |
sulfoxide reduction |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Sulindac |
Therapeutic Substance |
Approved Drug |
sulfoxide reduction |
deoxysulindac |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Faecalibacterium prausnitzii |
Tacrolimus |
Therapeutic Substance |
Approved Drug |
n.a. |
M1 |
Decrease activity |
In vitro |
n.a. |
Faecalibacterium prausnitzii metabolizes tacrolimus into less potent metabolites M1, which is 15-fold less potent than tacrolimus as an immunosuppressant. |
PMID:30598508 |
|
Intestinal microflora |
5-fluorocytosine |
Therapeutic Substance |
"Approved Drug; Prodrug" |
deamination |
5-fluorouracil |
Increase toxicity |
In vitro |
n.a. |
n.a. |
PMID:3729334 |
|
Mycoplasma |
5-fluorodeoxyuridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug inactivation |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Unclassified gut microbiota |
Carnitine |
Therapeutic Substance |
Dietary Compounds |
Oxidation/Reduction |
Trimethylamine |
Drug metabolism |
In vitro |
n.a. |
Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO |
PMID:30890566 |
|
Bacteroides dorei |
Corticosteroids |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Unclassified gut microbiota |
Glucocorticoids |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32652007 |
|
Unclassified gut microbiota |
Indigestible polysaccharides |
Therapeutic Substance |
Dietary Compounds |
Fermentation |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:30890566 |
|
Unclassified gut microbiota |
L-tyrosine |
Therapeutic Substance |
Dietary Compounds |
Removal of carboxyl group |
n.a. |
Drug metabolism |
In vitro |
n.a. |
Bacterial production of p-cresol, which is sulfated by the host. P-cresol competes with acetaminophen for sulfation. |
PMID:30890566 |
|
Unclassified gut microbiota |
Mesalazines |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32652007 |
|
Proteobacteria |
Polychemotherapy |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Increased chemotherapy induced HEM toxicity |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Unclassified gut microbiota |
Thioguanine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32652007 |
|
Enterococcus faecalis |
Thiopurines |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Drug activation |
In vitro |
n.a. |
Microbiota as IBD therapy response biomarker |
PMID:31675176 |
|
Escherichia coli |
Thiopurines |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Drug activation |
In vitro |
n.a. |
n.a. |
PMID:31675176 |
|
Bacteroides thetaiotaomicron |
Thiopurines |
Therapeutic Substance |
Drug Class |
n.a. |
n.a. |
Drug activation |
In vitro |
n.a. |
Microbiota as IBD therapy response biomarker |
PMID:31675176 |
|
Slackia equolifaciens |
Trans-resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
dihydroresveratrol |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:23283496 |
|
Adlercreutzia equolifaciens |
Trans-resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
dihydroresveratrol |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:23283496 |
|
Unclassified gut microbiota |
Trans-resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
3,4'-dihydroxy-trans-stilbene |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:23283496 |
|
Unclassified gut microbiota |
Trans-resveratrol |
Therapeutic Substance |
Approved Drug |
n.a. |
3,4'-dihydroxybibenzyl |
Drug metabolism |
In vitro |
n.a. |
n.a. |
"PMID:23283496 |
|
Clostridium ramosum |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Glucuronide hydrolysis |
SN-38 |
"Metabolize prodrug to active form; Increase toxicity" |
In vitro |
n.a. |
Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. |
"PMID:21789126 |
|
Escherichia coli |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Glucuronide hydrolysis |
SN-38 |
"Metabolize prodrug to active form; Increase toxicity" |
In vitro |
n.a. |
Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. |
"PMID:21789126 |
|
Bacteroides vulgatus |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Glucuronide hydrolysis |
SN-38 |
"Metabolize prodrug to active form; Increase toxicity" |
In vitro |
n.a. |
Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. |
"PMID:21789126 |
|
Beta-glucuronidase encoding species |
Irinotecan |
Therapeutic Substance |
"Approved Drug; Prodrug" |
Glucuronide hydrolysis |
SN-38 |
"Metabolize prodrug to active form; Increase toxicity" |
In vitro |
n.a. |
Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. |
"PMID:21789126 |
|
Unclassified gut microbiota |
Abacavir Sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bicalutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Biperiden |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bosentan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Budesonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bupropion |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Carvedilol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acetaminophen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cetirizine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cimetidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clarithromycin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clonidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Albendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Colchicine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cyclobenzaprine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cyclophosphamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dasatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Alfuzosin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Diclofenac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dicyclomine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Digoxin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dipyridamole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Drospirenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Efavirenz |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Altretamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Erlotinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Estropipate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Eszopiclone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Amantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Etodolac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Etoposide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ezetimibe |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Famotidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Febuxostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Felodipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Finasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fluconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fluphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Galantamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Gatifloxacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Gefitinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Amlodipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Glipizide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Amoxapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Griseofulvin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Haloperidol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Imatinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Indomethacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Anagrelide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Irbesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Anastrozole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Itraconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ketoconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ketoprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lansoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Leflunomide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Levonorgestrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Linezolid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Loperamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Loratadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lovastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mebendazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mefloquine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Memantine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metaxalone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metformin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methoxsalen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Miconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mifepristone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mitotane |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Montelukast |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Moxifloxacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nateglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nevirapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nizatidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ofloxacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Olanzapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxaprozin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxcarbazepine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Aprepitant |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Paroxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Perphenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pimozide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pioglitazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Aripiprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pyrimethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Quinapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ramelteon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ramipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Repaglinide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Reserpine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rifapentine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rifaximin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Riluzole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ritonavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sertraline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Simvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sotalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Atovaquone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sulfadiazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tadalafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Telmisartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolazamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trandolapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trihexyphenidyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trimethoprim |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Azithromycin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Vardenafil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Verapamil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Voriconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Warfarin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Zafirlukast |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Zaleplon |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Zileuton |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Benazepril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
4-Aminosalicylic Acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acebutolol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acetohexamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acitretin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acrivastine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acyclovir Zovirax |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Adefovir Dipivoxil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Alosetron |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ambrisentan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Amiloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Aminophylline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Amitriptyline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Apomorphine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Artemether |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Asenapine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Aspirin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Atazanavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Atorvastatin Calcium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Benztropine Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bexarotene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bisoprolol Fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bromocriptine Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Brompheniramine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bumetanide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Buspirone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Butorphanol-(+)-Tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cabergoline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Caffeine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Calcitriol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Candesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Carbamazepine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Carbidopa |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Carbinoxamine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cefditoren Pivoxil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cefpodoxime Proxetil |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chloroquine Diphosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chlorothiazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chlorpheniramine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chlorpropamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chlorthalidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chlorzoxazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cilostazol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cinacalcet |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ciprofloxacin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Citalopram |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clindamycin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clindamycin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clobazam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clomiphene Citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clomipramine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clopidogrel Hydrogen Sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clozapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cromolyn |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cyclosporine A |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cyproheptadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dapsone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Darifenacin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Darunavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Deferasirox |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Delavirdine Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Demeclocycline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Desipramine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Desloratadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Desvenlafaxine Succinate Hydrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dexchlorpheniramine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dextromethorphan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Diazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Diazoxide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dienogest |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Diflunisal |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dimenhydrinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Diphenhydramine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Disopyramide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dofetilide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Donepezil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Doxazosin Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Doxepin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Doxycycline |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dutasteride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Emtricitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Enalapril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Enalaprilat Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Eprosartan Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ergotamine Tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Escitalopram |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Esomeprazole Potassium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Estrone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ethinyl Estradiol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ethionamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Everolimus |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Felbamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fenoprofen Calcium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fexofenadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fingolimod |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Flavoxate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Flecainide Acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Flurbiprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fluvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fluvoxamine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Formoterol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fosinopril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Furosemide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Gabapentin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Gemfibrozil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Gemifloxacin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Glimepiride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Glyburide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Granisetron |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Guanabenz Acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Guanfacine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydralazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydrochlorothiazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydroflumethiazide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydroxychloroquine Sulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydroxyzine Dihydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ibuprofen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Imipramine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Indapamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Indinavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Isocarboxazid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Isradipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ketorolac Tromethamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ketotifen Fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Labetalol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lacosamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lamivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lamotrigine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lapatinib Ditosylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lenalidomide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Letrozole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Levocetirizine Dihydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Levofloxacin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lincomycin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lopinavir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Losartan Potassium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Loxapine Succinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Maprotiline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Maraviroc |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Meclizine Dihydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Meclofenamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mefenamic Acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Meloxicam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mepenzolate Bromide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Meprobamate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mestranol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metaproterenol Hemisulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methazolamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methenamine Hippurate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methimazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methocarbamol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methylergonovine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metoclopramide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metolazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metoprolol Tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metyrapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mexiletine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Milnacipran |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Minocycline |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mirtazapine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Modafinil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Moexipril |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mycophenolic Acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nadolol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Naltrexone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Naproxen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Naratriptan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nebivolol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nefazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nelfinavir Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nisoldipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nortriptyline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nystatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Olmesartan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Olopatadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ondansetron |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oseltamivir Phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxtriphylline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxybutynin Chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxytetracycline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Palonosetron |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pazopanib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pemirolast Potassium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pentoxifylline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Perindopril Erbumine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Phenoxybenzamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Phenylephrine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Phenytoin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pilocarpine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Piroxicam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pitavastatin Calcium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Posaconazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pramipexole Dihydrochloride Monohydrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pravastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Praziquantel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Prazosin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Primaquine Phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Primidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Procainamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Promethazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Propafenone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Propranolol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Propylthiouracil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Protriptyline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pyrazinamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Quetiapine Fumarate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Quinidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Quinine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rabeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Raloxifene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Raltegravir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ranolazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rasagiline Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rimantadine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rivastigmine Tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ropinirole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rosiglitazone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rosuvastatin Calcium |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rufinamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Saquinavir Mesylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Scopolamine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Selegiline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sildenafil Citrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sitagliptin Phosphate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sorafenib Tosylate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sumatriptan Succinate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sunitinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tacrine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tamoxifen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tamsulosin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Telbivudine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Telithromycin |
Therapeutic Substance |
"Approved Drug; Antibiotics" |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Temazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Terazosin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Terbinafine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Terbutaline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tetrabenazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Thalidomide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Theophylline |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Thioguanine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Thioridazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tiagabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ticlopidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tizanidine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolbutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolmetin sodium dihydrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolterodine Tartrate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolvaptan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Topiramate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Topotecan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Toremifene Base |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Torsemide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tramadol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tranylcypromine Hemisulfate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trazodone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Triamcinolone Acetonide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Triamterene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Triazolam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trifluoperazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trimethobenzamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trimipramine Maleate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Trospium Chloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Venlafaxine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Vinorelbine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ziprasidone hydrochloride |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Zolmitriptan |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Bisacodyl |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Capecitabine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Capsaicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clofazimine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Clonazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dexamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Duloxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Entacapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Estradiol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Famciclovir |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fluoxetine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Metronidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nabumetone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nilutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nimodipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nitrofurantoin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Paliperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Pantoprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rifabutin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Risperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sulfasalazine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sulindac |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tinidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Azathioprine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Zidovudine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Allopurinol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Betamethasone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Chenodiol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Cortisone Acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dantrolene |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Dolasetron |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ethacrynic Acid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Exemestane |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Fludrocortisone Acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Flutamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydrocortisone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Hydrocortisone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Iloperidone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Lorazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Megestrol Acetate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Methylprednisolone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Misoprostol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Mycophenolate Mofetil |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nicardipine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Nitisinone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Oxazepam |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Prasugrel |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Prednisolone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Prednisone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Probenecid |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Progesterone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Rifampin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Spironolactone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Sulfamethoxazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Tolcapone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Ursodiol |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Vorinostat |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Drug metabolism |
In vitro |
n.a. |
n.a. |
PMID:32526207 |
|
Unclassified gut microbiota |
Acetaminophen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Levodopa |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Metronidazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Omeprazole |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Simvastatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Zonisamide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Unclassified gut microbiota |
Dapsone |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
PMID:30158249 |
|
Escherichia coli |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Etoposide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Etoposide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Methotrexate |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Temozolomide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Temozolomide |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
5-fluoro-2'-deoxyuridine |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Neocarzinostatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Neocarzinostatin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Sunitinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Sunitinib |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli |
Tamoxifen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Comamonas |
Tamoxifen |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vivo |
n.a. |
No effect on Caenorhabditis elegans |
"PMID:30890566 |
|
Escherichia coli BL21(DE3) |
Doxorubicin |
Therapeutic Substance |
Approved Drug |
n.a. |
n.a. |
Microbe does not metabolize drug |
In vitro |
n.a. |
n.a. |
"PMID:30890566 |
|
Unclassified gut microbiota |
Indole |
Environmental Substance |
Metabolite |
n.a. |
"indoxyl sulfate; indole-3-propionic acid; isatin; 5-hydroxyindole" |
Metabolism |
In vitro |
n.a. |
n.a. |
PMID:26439294 |